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Summary
The objective of this PhD project is to experimentally and theoretically investigate
the separation performance and to improve the process understanding of a newly
developed continuous preferential crystallization (PC) process for the separation of
enantiomers forming conglomerates. This PC process is regarded as a first step to-
wards a fully continuous PC process. The current knowledge of the importance of
crystallization processes in the pharmaceutical industry and the complex thermody-
namic and kinetic phenomena accompanied with the separation of chiral compounds
are addressed. The experimental work covers laboratory studies and the theoretical
work is based on the experimental data and observations.
A large fraction of active pharmaceutical ingredients (APIs) are enantiomers and the
desired biological activity is provided only by one of the enantiomers. Strict regula-
tory requirements, increasing public demand, and fierce competition have forced the
pharmaceutical industry to redevelop existing methods or develop completely new
methods to produce pharmaceuticals consisting of APIs of the desired enantiomer.
PC is one of several methods used industrially to obtain pure enantiomers by sepa-
ration of a racemic mixture. The potential application of PC is strongly dependent
on requirements to the thermodynamics and crystallization kinetics of the considered
solute-solvent(s) system, and the desired operating conditions. Meeting these require-
ments are essential to achieve predefined physical attributes of the final product and
process economical targets. In this respect, an increasing interest in converting from
the conventional batch to continuous PC has initiated the search for new process
development opportunities of PC processes. The reason is the many advantages of
continuous operation, especially in the case of separation of enantiomers.
A newly developed lab-scale continuous PC process, so-called continuous coupled
preferential crystallization (CC-PC) process, consisting of two mixed flow crystalliz-
ers coupled via crystal-free mother liquor exchange streams and with only the liquid
phases operated continuously, was built as the main part of this PhD project. Exper-
iments in triplicate were conducted for the experimental investigation to assess the
robustness of the CC-PC process and to investigate the achievement of simultane-
ous separation of the enantiomers of the conglomerate forming system of the amino
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acid asparagine monohydrate by crystal growth of seed crystals. The achievement of
a racemic liquid phase composition consisting of nearly equal distribution of enan-
tiomers in solution was also investigated. Finally, the performance of the CC-PC
process and its potential for further development to a fully continuous PC process
was discussed. A nearly racemic composition of the liquid phase in the crystallizers
was obtained. Successfull enantioseparation by crystal growth was verified, with the
repeatability being within ±10% deviation. Productivities, yields, and purities of
solid products were influenced by the morphological differences in the seed crystals.
Due to irregularly shaped seed crystals of l-asparagine mnohydrate (l-AsnH2O), in-
crease in the productivities and yields were achieved in the l-Tank, i.e. the crystallizer
in which l-AsnH2O crystals grow. Lower purities of solid products from the l-Tank
compared to solid products from the d-Tank, in which seeds of d-asparagine monohy-
drate (d-AsnH2O) were used, were obtained. This could be due to surface nucleation
of d-AsnH2O, ascribed to the surface structure of the seeds of l-AsnH2O supplied.
An additional experiment was also carried out using seed crystals of a smaller average
particle size having a smoother surface structure than used in the reference experi-
ments. Productivity, yield, and purity were slightly improved in the l-Tank, for the
same process duration. It should be emphasized, however, that it was found that the
growth rate of the desired enantiomer was very low at the given experimental condi-
tions and therefore practically no consumption of the enantiomer in the feed occurred
in the crystallizer. This was ascribed to the nature of the controlling mechanism for
crystal growth comprising slow surface integration of the asparagine monohydrate
molecules onto the surfaces of the supplied seed crystals. The main advantages of
the CC-PC process compared to other separation processes are low capital cost, high
crystal purity and yield, ease of upscaling, increased safety, and reduced environmen-
tal impact due to reduction in amount of solvent used. Currently, the application
is, however, limited to conglomerate forming systems. Nevertheless, the separation
concept may open new possibilities for process improvements for enantioseparation
of racemic compound forming systems as well.
The theoretical investigation of the CC-PC process consisted of the establishment of a
dynamic one-dimensional model describing the continuous separation of enantiomers
by simultaneous preferential crystallization. The evolution in the moments of the
crystal population balances in combination with the liquid phase mass balances for
the enantiomers were presented. The model was validated against experimental data
for the conglomerate forming system of asparagine monohydrate in aqueous solution.
The kinetic parameters required were taken from available literature sources and sim-
ulations compared to experimental data. The simulations were found to be in good
agreement with the experimental data. The sensitivity analysis conducted suggests
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that the separation process can be improved by increasing the mean residence time
of the liquid phase in the crystallizers, the crystallization temperature, and the mass
of seeds supplied. Reducing the size of seed crystals will also lead to an improved
separation. The model can be used to simulate the performance of the continuous
crystallization process for a racemic compound forming system. The racemic com-
pound and the pure enantiomer can be separated simultaneously in each crystallizer
having sufficient enrichment of the pure enantiomer in the feed solution. The model
can also be extended to represent a fully continuous separation process taking into
account the continuous supply of enantiopure seed crystals and liquid feed solution
and the continuous removal of solid product and mother liquor.
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Resumé
Formålet med dette phd-projekt er, at eksperimentelt og teoretiskt undersøge separa-
tionens ydeevne, og at forbedre procesforståelsen af et nyudviklet kontinuert proces
for selektiv krystallisation (SK) til separation af enantiomere, som danner et kon-
glomerat system. Denne SK proces betragtes som det første trin mod et fuldt kon-
tinuert SK proces. Et litteraturstudie over vigtigheden af krystallisationsprocesser i
den farmaceutiske industri og de kompleske termodynamiske og kinetiske fænomener
tilknyttet separationen af chirale komponenter er udarbejdet. Det eksperimentelle
arbejde dækker laboratoriestudier, og det teoretiske arbejde er baseret på eksperi-
mentelle data og observationer.
En stor del af aktive farmaceutiske ingredienser (AFI’er) er enantiomere, og den øns-
ket biologiske aktivitet tildeles kun én af enantiomererne. Strenge myndighedskrav,
forøget efterspørgsel, og hård konkurrence har tvunget den farmaceutiske industri at
genudvikle eksisterende metoder eller udvikle helt nye metoder til produktionen af
lægemidler bestående af AFI’er af den ønsket enantiomer. SK er en af et antal indus-
trielt anvendte metoder at opnå rene enantiomere på ved separation af en racemisk
blanding. Anvendelsespotentialet af SK er stærkt afhængigt af krav til termody-
namikken og krystallisationskinetikken af det betragtet solut-solvent system, og de
ønskede driftsbetingelser. At opfylde disse krav er afgørende for at opnå forudde-
finerede fysiske egenskaber af det endelige produkt og procesekonomiske mål. I denne
sammenhæng, en forøget interesse i omdannelsen fra konventionel batch til kontin-
uert SK har indledt søgningen efter nye procesudviklingsmuligheder af SK processer.
Årsagen er de mange fordele ved kontinuert drift, særligt når det gælder separation
af enantiomere.
En nyudviklet lab-skala kontinuert SK proces, såkaldt kontinuert koblet selektiv
krystallisation (KK-SK), bestående af to strømningsreaktorer (krystallisationstanke)
koblede via vekslingsstrømme af krystalfri moderlud, og kun med væskefasen i kon-
tinuert drift, blev bygget som hovedparten af dette phd-projekt. Eksperimenter i
triplikater blev udført for den eksperimentelle undersøgelse for at vurdere robusthe-
den af KK-SK processen, og at undersøge opnåelsen af samtidig separation of enan-
tiomererne af det konglomeratdannende system af aminosyren asparagin monohydrat
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via krystalvækst af podekrystaller. Opnåelsen af en næsten racemisk væskefasesam-
mensætning bestående af næsten ligelig fordeling af enantiomere i opløsning blev
også undersøgt. Endeligt blev ydeevnen af KK-SK processen og dets potentiale for
videre udvikling til en fuld kontinert SK proces diskuteret. En næsten racemisk
sammensætning af væskefasen blev opnået. Succéfuld separation af enantiomere via
krystalvækst blev verificeret med en repetérbarhed indenfor ±10% afvigelse. Pro-
duktiviteter, udbytter, og renhedsgrader af krystallint produkt var påvirkede af de
morfologiske forskelle i de tilførte podekrystallerne. Forøgelse i produktiviteter og
udbytter var opnåelige i l-Tanken på grund af den irregulær form af podekrystaller
af l-asparagin monohydrat (l-AsnH2O). Lavere renhedsgrader af krystallint produkt
fra l-Tanken blev opnået sammenlignet med produkt fra d-Tanken, hvori podekrys-
taller af d-asparagin monohydrat (d-AsnH2O) blev tilført. Dette kan skyldes over-
fladenuklering af d-AsnH2O tilskrevet overfladestrukturen af tilførte podekrystaller
af l-AsnH2O. Et yderligere eksperiment, hvori podekrystaller af l-AsnH2O af mindre
gennemsnitlig partikelstørrelse med en mere fin overfladestruktur blev anvendt, re-
sulterede i en anelse forbedring af produktivitet, udbytte, og renhedsgrad i l-Tanken
for samme procesvarighed. Det skal dog understreges at væksthastigheden af den
ønsket enantiomer var meget lav under de givne driftsbetingelser. Derfor opstod der
praktisk set inget forbrug af enantiomere fra fødeblandingen i krystallisationstankene.
Dette var tildelt den kontrollerende mekanisme for krystalvækst som udgjorde lang-
som overfladeintegration af asparagin monohydrat molekylerne på overfladen af de
tilførte rene podekrystaller. Hovedfordelene ved KK-SK processen sammenlignet med
andre separationsprocesser er lave kapitalomkostninger, høj krystalrenhed og udbytte,
let at opskalere, forbedret sikkerhed, og reduceret miljøpåvirkning på grund af reduk-
tion i mængde af opløsningsmiddel anvendt. Anvendelsen af KK-SK processen er på
nuværende tidspunkt dog begrænset til konglomeratdannende systemer. Ikke desto
mindre kan separationskonceptet åbne nye muligheder for procesforbedringer inden-
for selektiv separation af enantiomere i systemer som danner racemisk stof såvel som
i konglomeratdannende systemer.
Den teoretiske undersøgelse af KK-SK processen bestod af etableringen af en dy-
namisk én-dimensionel model, som beskriver den kontinuerte separation af enan-
tiomere via samtidig SK. Udviklingen i krystalpopulationsbalancens momenter i kom-
bination med massebalancerne for enantimererne i væskefasen blev præsenteret. Mod-
ellen blev valideret imod eksperimentelle data for det konglomeratdannende system
af asparagin monohydrat i vandig opløsning. De påkrævede kinetiske parametre blev
taget fra tilgængelig litteratur, og simuleringer sammenlignet med eksperimentelle
data. Simuleringerne var i overensstemmelse med de eksperimentelle data. Den ud-
førte sensitivitetsanalyse foreslår, at separationsprocessen kan forbedres ved at forøge
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den gennemsnitlig opholdstid af væskefasen i krystallisationstankene, krystallisation-
stemperaturen, og massen af tilført podemateriale. Formindskning i størrelsen af
podekrystaller vil også medføre en forbedret separation. Modellen kan anvendes til at
simulere ydeevnen af den kontinuerte krystallisationsproces for et system som danner
et racemisk stof. Det racemiske stof og den rene enantiomer kan separeres samtidigt
i hver sin krystallisationstank, når en tilstrækkelig berigelse af den rene enantiomer i
fødeblandingen er mulig. Modellen kan også udvides til at beskrive en fuld kontinuert
separationsproces, hvori kontinuert tilførsel af podemateriale af den rene enantiomer
og fødeblanding, og kontinuert udtag af fast produkt og moderlud er taget i betragt-
ning.
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Chapter 1
Introduction
This chapter provides a concise introduction to the underlying motivations for the
production of pure chiral active pharmaceutical ingredients (APIs) and outlines the
potential and challenges of continuous processing in the pharmaceutical industry.
Finally, the objectives of this thesis are outlined.
1.1 Background and motivation
Activity in biological systems, in terms of the specific interaction with a biological
molecule, such as a receptor or enzyme, and the resulting physiological effects of
chiral pharmaceuticals, depends strongly on the stereochemical configurations17,58.
The term chiral is used to describe the three-dimensional property of a molecule
which is nonsuperimposable with its mirror image, i.e. a molecule which lacks a
plane of symmetry (Figure 1.1)48,58.
Figure 1.1: Amino acid molecules representing chirality, i.e. they are nonsuperimposable
with their mirror images64. Only the backbone of the chemical structure of amino acids
is shown. The C-atom in the backbone structure is regarded here as chirality center or
stereocenter. R refers to the side groups of the amino acids and can also include chiral
moieties.
A pair of chiral molecules are called enantiomers (from Greek ’enantios ’ meaning
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’opposite’ and ’méros ’ meaning ’part ’)48,58. Optical isomers also refer to enantiomers
due to the ability of rotation of the plane of polarized light according to the in-
vestigations of the French physicist Jean-Baptiste Biot in the early 19th century.
Counterclockwise rotation of the plane of light is said to be levorotatory, denoted
by l, and is by convention given a minus (–) sign. Clockwise rotation is said to be
dexorotatory, denoted d, and is given a plus sign (+). Another notation based on
the three-dimensional arrangement of substituents at a stereocenter is also commonly
used. The stereocenter can either have either the (R) configuration (from Latin ’rec-
tus ’ meaning ’right ’) or the (S ) configuration (from Latin ’sinister ’ meaning ’left ’)
depending on the priority of substituents58.
A large number of chiral APIs are commercialized as mixtures of the enantiomers,
so-called racemic mixtures. Side effects caused by different therapeutic, toxicological,
and pharmacological properties of the enantiomers are in many cases attributed to
the presence of the undesired enantiomer in the final pharmaceutical48,71,79. Table
1.1 lists examples of chiral substances in pharmaceuticals and their biological activ-
ity25,48.
Table 1.1: Examples of APIs in pharmaceuticals and their biological activity. Trade names
of pharmaceuticals approved by the Food and Drug Administration (FDA) in 2012 are given
in parenthesis25,48.
Chiral substance Biological activity
Ethambutol
(Myambutol)
Tuberculostatic effect is provided by the (S,S )-isomer; Op-
tical neuritis, which can lead to blindness, is caused by the
(R,R)-isomer
Penicillamine
(Cuprimine, Depen)
Antiarthritic activity against joint disorder is provided by
the (S )-isomer; Extreme toxicity is ascribed to the (R)-
isomer
Thalidomide
(Thalomid)
The desired antinausea effect (sedative) is provided by the
(R)-isomer to treat morning sickness; Teratogenic effect
causing fetal abnormalities, such as severely underdevel-
oped limbs, is ascribed to the (S )-isomer
The evident and dramatic consequence of administering thalidomide as racemic mix-
ture in the 1960s has attracted great attention to the development of chiral phar-
maceuticals9. This resulted in issuing guidelines in 1992 by the Food and Drug
Administration (FDA) followed by the Japanese and Chinese authorities and the Eu-
ropean Medicine Agency (EMA). The guidelines can be summarized in two main
points24:
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1. Specifications for the final chiral pharmaceutical should assure stereoisomeric
composition regarding chemical identity, quality, and purity. This should be
performed by the use of appropriate manufacturing and control procedures
2. Methods to quantify single enantiomers or mixture of enantiomers and eval-
uation of the pharmacokinetics of these should be available early in product
development
Strict regulatory requirements, increasing public demand, and nevertheless, the fierce
competition between pharmaceutical companies have initiated the intensive research
devoted to the development of reliable and cost-efficient production processes to pro-
duce pure chiral APIs. These appreciated efforts can result in the following merits of
producing pure enantiomers48:
• The pure enantiomer may have more than double the biological activity as the
racemic mixture. Thus, the dosage for a patient is automatically halved and
the side effects become less or diminish completely
• The unwanted enantiomer can be considered as waste in manufacturing com-
prising 50% of the mixture. Through chiroselective technologies, the yield of
the production process can be doubled and the generation of waste reduced
• The physical properties, e.g. morphology, of pure enantiomer can improve down-
stream processing and formulation
• The opportunity of ’Racemic switching’, i.e. the introduction of a pharmaceuti-
cal of pure enantiomer to market by redevelopment of existing pharmaceutical
commercialized as racemic mixture, can be useful for extending patents
The above mentioned guidelines and the economic, environmental, and health con-
cerns regarding the production and administration of pure enantiomers have to be
strongly considered in the early stages of pharmaceutical discovery and process de-
velopment. The reason is the possibility to reduce the time for product release to the
competitive and new emerging markets by having a more biologically effective and
safe pharmaceutical which reduces the risk of rejection during clinical trials and the
approval process48.
In 2000, about one-third of pharmaceutical sales were single-enantiomer pharmaceuti-
cals comprising 133 billion US$ and expected to hit 200 billion US$ in 200881. About
40% of the pharmaceuticals in use in 2006 were chiral. In 2011, small-molecule chi-
ral pharmaceuticals comprised about 43% (57.2 billion US$) of the sales of top 20
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global pharmaceutical products (Figure 1.2)59. Table 1.2 lists the sales of chiral small-
molecule APIs in 201159. Geographically, the consumption in the United States of
chiral fine chemicals, including pharmaceuticals, comprises 60% of the worldwide
total consumption. This makes USA the World’s largest market for chiral fine chem-
icals48.
Table 1.2: Sales of small-molecule chiral APIs in 2011. Sales are given in billion US$59.
Rank Brand API Manufacturer Sale
1 Lipitor Atorvastatin Pfizer 12.5
2 Plavix Clopidogrel Bristol-Myers Squibb 9.3
3 Seretide Fluticasone GlaxoSmithKline 8.7
4 Crestor Rosuvastatin AstraZeneca 8.0
5 Nexium Esomeprazole AstraZeneca 7.9
11 Singulair Montelukast Merck & Co. 6.1
17 Cymbalta Duloxetin Eli Lilly & Co. 4.7
Figure 1.2: Distribution in percentage of 2011 sales of chiral and nonchiral small-molecule
APIs and protein APIs of the top 20 global pharmaceutical products59. Racemic APIs are
included in chiral small-molecule APIs segment. Note that protein APIs are often chiral in
nature and consist of amino acids of the naturally occurring l-form. Total sales of top 20
pharmaceuticals in 2011 was 132.1 billion US$.
In this respect, strategic decisions have to be made in order not to lose market while
implementing Lean manufacturing principles to ensure sustainability and long-term
viability. An important issue to consider in the decision-making process is the full
or partial conversion from batch to continuous production of APIs, chiral as well as
nonchiral. It is essential to consider the fact that existing batch processes have already
been approved by the demanding authorities, and converting to continuous operation,
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either by retrofitting or new establishments, has to be documented and approved once
again65. Additionally, the existing infrastructure in the pharmaceutical industry is
designed for batch processing and needs to be fitted for continuous manufacturing.
Nevertheless, increasing demand, strict regulatory requirements, and the strong com-
petition have forced the pharmaceutical industry to strongly consider the continuous
alternative in product and process development as a mean for the reduction of man-
ufacturing cost, environmental impact, and social responsibility3,12,65.
1.2 Batch vs. Continuous
Continuous operation provides many advantages and is highly attractive from an en-
vironmental, economical, and regulatory point of view compared to batch processes.
For instance, in theory, a continuously stirred tank reactor (CSTR) ensures ideal
mixing in the reactor. This means that all molecules in the reactor experience the
same reaction conditions. In practice, there exist differences due to residence time
distribution effects, which have to be taken into account in the design stage of a
CSTR23. Critical process parameters are easily controlled in time-invariant, steady-
state operation compared to the time-dependent batch operation87. Higher yields
and reproducible product quality are achievable due to the reduction of batch-to-
batch variations by the implementation of online measurement techniques, as part of
Process Analytical Technology (PAT) tools, to reduce the time delay between oﬄine
measurements and corrective actions. Continuous operation also allows for reduction
of large processing volumes of potentially volatile and flammable or toxic compounds.
Thus, the costs associated with adopting expensive risk management tools and pro-
tection measures can be significantly reduced. Finally, as part of Lean manufacturing
principles, continuous operation can significantly reduce the environmental footprint
and manufacturing costs or cost of goods (COGs). Figure 1.3 shows the distribution
of the costs and revenue as percentage of sales in 2008 averaged over 17 major phar-
maceutical companies3. As shown in Figure 1.3, the COGs comprises 27% of sales3.
The application of continuous processing in API manufacturing can potentially re-
duce the COGs. All in all, the results are a cheaper and a more safe manufacturing
process. Because of the mentioned, and other equally important reasons, research
in continuous processing in general has been ranked as first in key green research
areas44.
Nevertheless, there are some pronounced disadvantages of continuous manufacturing.
Processes run in batch mode are often less complex and process understanding level of
batch processes are typically high. Continuous processing therefore requires a higher
level of process understanding, especially when complex hazardous reactions are in-
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Figure 1.3: Distribution of the average costs as percentage of sales in 2008 for 17 major
pharmaceutical companies3.
volved. Batch processes provide higher level of flexibility and versatility compared to
continuous processes. A continuous process, once developed and implemented, is ded-
icated for a certain reaction or separation and therefore changes in equipment setup,
inventory, and operation protocols are necessary when considering another reaction
or separation. In this respect, flexibility of the continuous process should be strongly
considered in the early stages of process development. For these reasons, and the fact
that in the pharmaceutical industry, where often a very small amount of product is
required, it is difficult to justify the effort connected to startup and shutdown, and
the amount of material required for the establishment of steady-state conditions, the
above mentioned advantages of continuous operation can often be lost. Furthermore,
collection of the product at equilibrium conditions is permitted in batch operation
and not in a continuously operated process. Finally, frequent cleaning of the equip-
ment without disturbing the system is allowed in batch operation, which adds to the
advantages of interest in the pharmaceutical industry3,87.
Having in mind the mentioned advantages and disadvantages of batch and continuous
operation, it should be noted that even when batch operation is considered the most
attractive choice in the fine chemicals industry, including the pharmaceutical industry,
there are some reactions and separations for which batch operation is impractical.
Reactions involving hazardous chemicals at exceptionally high or low temperatures
and pressures and separation of chiral compounds are examples for which continuous
operation is the only suitable choice3,87.
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1.3 Project objectives
The strict regulatory requirements and the increased public demand for the develop-
ment and production of pharmaceuticals consisting of pure enantiomers have resulted
in extensive research to find potential sustainable alternatives to existing production
processes. The current production processes in the fine chemical industries, includ-
ing the pharmaceutical industry, are mainly dominated by batch mode operation.
An increased understanding of process complexity regarding chemical reactions and
transport phenomena in continuous operation, and the change in the infrastructure
of manufacturing are essential in order to convert to the potentially more sustainable
continuous operation. The objectives of the work presented in the subsequent chap-
ters are to gain insight into the separation of enantiomers from racemic mixtures by
preferential crystallization (PC), and to investigate the performance of a newly devel-
oped continuous preferential crystallization process for the separation of enantiomers
from a racemic mixture. It is furthermore the objective of this project to develop
a model of the continuous PC process to increase the understanding of the complex
behavior of preferential crystallization in the continuous PC process.
1.4 Outline of thesis
In chapter 2, a literature survey concerning the methods currently available for the
production of pure enantiomers, crystallization process objectives and constraints
in the pharmaceutical industry, the underlying fundamentals of crystallization and
thermodynamics of racemic mixtures are presented. The insight into the fundamental
aspects of preferential crystallization as a chiroselective separation method for the
separation of enantiomers from racemic mixtures provides the theoretical foundation
for the subsequent investigation of the continuous PC process.
The experimental realization of the separation of enantiomers by preferential crysta-
llization in the newly developed continuous PC process is presented and discussed in
chapter 3. In this respect, special attention is paid to the achievement of simulta-
neous separation of enantiomers by crystal growth and the maintenance of racemic
composition in the liquid phase. The process is evaluated in terms of productivity,
yield, purity, and the fraction of unutilized enantiomer in the purge. The robustness
of the process is also assessed.
In chapter 4, the development of a transient one-dimensional model describing the
continuous PC process is provided. Furthermore, the validation of the model against
experimental data is presented and an investigation of the influence of the different
process parameters on the predictability of the model and performance of the process
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is provided.
Finally, in chapter 5 conclusions and suggestions for future work are presented.
1.5 Conclusions
In this chapter, the background and motivations for the production of pure chiral
APIs were highlighted. Additionally, the potential and challenges of the conversion
from conventional batch processing to continuous processing in the pharmaceutical
industry were outlined and discussed. Finally, the objectives of the work, presented
in the thesis, were outlined.
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Chapter 2
Literature survey
In this chapter, a concise overview of the current methods for the production of pure
enantiomers is provided. Emphasis is placed on the design criteria and constraints
of crystallization processes in the pharmaceutical industry. The underlying thermo-
dynamic aspects of solid-liquid phase equilibria of chiral systems and crystallization
theory are also presented. The content of this chapter provides the basis for the work
presented in the remaining part of the thesis.
2.1 Methods for the production of pure enantiomers
Currently, several methods exist for the production of pure enantiomers depending
on the chemical and physical nature of the raw material used (Figure 2.1). It should
be emphasized that enantiomers are considered pure at an enantiomeric excess above
90%78,79.
Figure 2.1: Current methods for obtaining pure enantiomers78,79.Racemates refer to
racemic mixtures consisting of equal quantity of enantiomers.
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As shown there are three main routes for obtaining pure enantiomers. The first op-
tion is the conversion of a prochiral substrate by asymmetric synthesis. The synthesis
can be performed either chemocatalytically, enzymatically, or by chiral auxiliary, e.g.
chiral additive. The reactions involved are often complex and most commonly divided
into four types depending on the controlling mechanism: 1) Auxiliary-controlled, 2)
catalyst-controlled, 3) reagent-controlled, and 4) substrate-controlled51. A strong
constraint to the commercial application remains in the economical aspect of such
selective synthesis processes due to difficulties in fulfilling required success criteria
in terms of time-to-process (labor), cost-to-process (development), and production
costs3,71. In this respect, the use of expensive chiral auxiliaries as well as catalysts
or enzymes requires efficient recovery systems to essentially improve process econ-
omy78.
The second option is the utilization of a chiral substrate from a chiral pool followed by
synthesis. The substrate is obtained from either de novo fermentation of e.g. sucrose
or extraction of naturally occurring chiral compounds, e.g. amino acids, where one
single enantiomer often exists in nature. This is probably the easiest and cheapest
method because of two reasons: 1) Chiral substrates from the chiral pool are most
often present in large amount, and 2) process and production costs are low79.
The chiroselective separation of enantiomers from racemates, i.e. mixture of equal
quantity of enantiomers, comprises an attractive option for the production of pure
enantiomers. The reason is that the yields of asymmetric synthesis are often low, while
chiral separation techniques can provide higher yields of each enantiomer. However,
chiral separation techniques are considered expensive and inefficient in case the un-
wanted enantiomer is not utilized71. The most commercially utilized technique is
chiral chromatography with its wide selection of chiral stationary phases. This al-
lows the separation of a wide range of racemic mixtures26,27,82. A version of chiral
chromatography successfully applied in industrial scale is continuous countercurrent
Simulated Moving-Bed (SMB) Chromatography realizing the goal of achieving op-
tically pure enantiomers26,27. However, highly expensive chiral stationary phases,
high pressure equipment, and use of substantial amount of solvent have initiated the
search for relatively cheaper alternatives, e.g. PC technology14,21,28,41,54,66,67,91. In
this respect, process economical considerations and regulatory requirements concern-
ing optical purity and operation safety have to be taken into account in order to assess
the economical and technical feasibility of each alternative or a combination thereof,
e.g. PC combined with chiral membrane technology83.
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2.2 Crystallization in the pharmaceutical industry:
Objectives and constraints
In the fine chemical industries, including the pharmaceutical industry, crystalliza-
tion is used to accomplish two main objectives: 1) Separation and purification of
the API, and 2) the achievement of physical attributes of the produced crystals suit-
able for subsequent downstream processing, formulation, and bioavailability. The
constraints underlying the design of the crystallization process to achieve these ob-
jectives comprises economic and manufacturing considerations, such as throughput,
yield, scaleability, and environmental impact3,87.
2.2.1 Separation and purification
The initial point in the design of the overall API production process is the understand-
ing of where in the production process it is necessary to meet purification requirements
for the isolated intermediates. Normally, the production of an API involves a mul-
tistep synthesis procedure to convert raw materials to the desired API compound
in high purity (typically above 99%)3,4. In this multistep procedure, a number of
intermediate crystallization processes is usually used to achieve the desired purity of
the separated intermediates, whereas the final crystallization step is mainly focusing
on the control of the final physical attributes of the API crystals3. In this respect,
it should be addressed that thermodynamics is often regarded as the primary con-
trol for achieving separation and purification, while crystallization kinetics, and the
mechanisms involved, are often the primary determinant of the physical attributes of
the produced API crystals3,62,87.
2.2.2 Product attributes and performance
The influence of the physical attributes of the solid product of an API on subsequent
downstream processing, e.g. filtration, formulation, and bioavailability, are of outmost
importance for designing the appropriate crystallization processes. Attributes of the
API product of particular concern include8,38,42,43,46,53,84,87:
• Solubility
• Melting point
• Dissolution rate and bioavailability
• Chemical and physical stability
• Powder properties, such as flowability, bulk density, and compressibility
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Different solid forms of an API exhibiting different crystal structures, particle size
distribution (PSD) of the API, the morphology of solid product, and its flow prop-
erties, e.g. suspendability, are important to consider to achieve the above mentioned
attributes of the final API product8,38,42,43,46,53,84,87,88. In this respect, the involved
crystallization processes should be studied in conjunction with subsequent down-
stream processes as depicted in Figure 2.2.
Figure 2.2: A schematic diagram showing the crystallization process in conjunction with
the subsequent downstream processing steps and their effects on solid product attributes3.
Often an API intermediate is produced with properties that are based on considera-
tions regarding chemical and physical stability, flowability, and ease of manufacture.
In contrast, performance in the host system in terms of dissolution rate, bioavailabil-
ity, and chemical and physical stability together with manufacturability, e.g. com-
pressibility, melting point, and bulk density, are of outmost importance for a final
API10,30.
2.2.2.1 Solid forms of an API
Solids of pharmaceutical compounds can have two different solid forms. They can be
either amorphous or crystalline depending on the crystallization conditions. Figure
2.3 shows the different classes and subclasses of solid forms an API can exhibit1,3, 87,88.
Amorphous solids, such as the polymeric pharmaceutical substance sevelamer hy-
drochloride6, can be produced by very rapid crystallization3,62,87. Pharmaceuticals
produced as amorphous solids are primarily made to improve the solubility and dis-
solution rate in the host, but at the expense of chemical and physical stability of
the pharmaceutical49. Besides solid state instability of the amorphous solid, it has
complications with impurity rejection and difficulties in downstream processing, e.g.
filtration, and formulation. Amorphous solids also cause difficulties with the analy-
sis methods usually used for solid phase analysis such as X-Ray Powder Diffraction
(XRPD), microscopy, and Differential Scanning Calorimetry (DSC). It should be em-
phasized that even when a stable crystalline solid is formed it can loose its crystallinity
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Figure 2.3: A schematic diagram showing the different solid forms an API can exhibit.
Note that for multicomponent forms different polymorphs and pseudopolymorphs can also
exist1,3, 87.
forming amorphous solid if it is hygroscopic, i.e. absorbs water, or exposed to heat or
pressure in subsequent drying or comminution, respectively. For instance, crystalline
carbamazepine dihydrate becomes amorphous anhydrate upon dehydration50. There-
fore, attention should be paid to storage conditions and conditions of downstream
processing87,88.
APIs can crystallize in different crystal structures. This phenomenon is referred to
as polymorphism. The different crystal structures are called polymorphs. Polymorphs
crystallizing as mirror-images of each other are referred to as enantiomorphs, e.g.
enantiomers62. Polymorphs exhibit different chemical and physical properties, and
can either be monotropic or enantiotropic as in the case of polymorphs I and III of a re-
verse transcriptase inhibitor87,88. Polymorphs having a monotropic relationship have
only one polymorph as the stable form at all temperatures considered. In contrast, an
enantiotropic relationship between polymorphs implies that the different polymorphs
are stable at different temperatures. In this respect, the polymorph exhibiting the
lowest solubility at the conditions employed is the stable form62. It is therefore es-
sential to control the conditions of crystallization to obtain the desired polymorph.
Then it is necessary to prevent the transformation of the desired polymorph to an-
other polymorph. This transformation is referred to as polymorphic transition3,62,88.
Therefore, the stable polymorph of an API should be identified in the early stages
of pharmaceutical development to avoid the time consuming reevaluation of previous
development results, and in worst case, the recall of the pharmaceutical73.
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Crystalline and amorphous solids can also form pseudopolymorphs, i.e. solvates or
hydrates (the organic solvent is replaced with water), as in the case of dirithyromycin
acetone solvate99 and asparagine monohydrate, respectively. Pseudopolymorphs form
different forms of crystals with distinct chemical and physical properties. The for-
mation occurs when one or more solvent or water molecules are incorporated into
the crystal lattice of the crystalline solid by noncovalent bonds to the API molecules.
Noncovalent bonds comprise hydrogen bonding, pi-stacking, or van der Waals interac-
tions3,62,87,88. Pseudopolymorphs can be either reversible or irreversible. Reversible
pseudopolymorphs can loose solvent or water molecules from the crystal lattice with-
out significant change in the crystallinity of the solid90. In contrast, for irreversible
pseudopolymorphs the removal of solvent or water molecules results in nonsolvated
or anhydrous crystalline or amorphous solid62,87.
Cocrystals are regarded as a special case of pseudopolymorphs where solvent or water
molecules in the crystal lattice are replaced by a nonvolatile species bonded noncova-
lently to the parent crystal lattice of the API crystal1,3, 88. An example is the cocrystal
of ciprofloxacin and norfloxacin89. Cocrystals can also form different polymorphs and
different solvates or hydrates as shown in Figure 2.4.
Figure 2.4: The different multicomponent solid forms of an API and the overlap between
them1.
If the nonvolatile species incorporated are removed, e.g. by exposing the cocrystals
to pressure, the cocrystals can loose its crystallinity and form an amorphous solid.
Amorphous solids can also form amorphized cocrystals with different chemical and
physical properties. If the nonvolatile species is removed, the amorphized cocrystal
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can be converted to a crystalline solid or remains amorphous1,88.
Organic molecules, such as APIs, have often poor water solubility. To improve their
water solubility, salts of APIs are often produced. Thereby, the bioavailability of
the API is also improved. In some cases, however, it is the only way to achieve a
solid product of the desired API or API intermediate, e.g. diastereomeric salt of (S )-
ibuprofen-(S )-lysine87. Salts of APIs are normally produced by reactive crystallization
in which neutralization of the API by an acid or a base occurs87. The acid or base
may be an ionic compound, e.g. sulfate in crixivan sulfate salt87, or another organic
compound, e.g. (R)-mandelic acid in (1S,4S )-sertraline-(R)-mandelic acid36. The
produced salt of an API exhibit different chemical and physical properties. Therefore,
the desired salt and its chemical and physical stability should essentially be considered
early in API development3,87.
2.2.2.2 Particle size and PSD
An important concern in the production of APIs is the particle size and PSD. The
particle size in the pharmaceutical industry is commonly estimated through PSD
measurements by laser diffraction techniques such as Lasentec FBRM R©. The PSD
measurements are used to evaluate the particle size based on the x90, x50, and x10
measures corresponding to the particle size at which the cumulative mass or volume
is 90%, 50%, and 10%, respectively3.
The importance of particle size lies in its impact on the performance of the final
pharmaceutical product because:
• in vitro specifications, e.g. solubility and dissolution rate, can be significantly
affected by particle size. Assuming spherical particles, the solubility increases
for decreasing particle size and vice versa, according to Gibbs-Thomson equa-
tion62. With respect to the dissolution rate, a decrease in particle size increases
the dissolution rate and vice versa. The reason is the lower surface area to
volume ratio52.
• The final pharmaceutical product from formulation, e.g. mixing with excipi-
ents, tabletting, or capsule filling, can be affected by particle size through e.g.
suspendability and compressibility. Furthermore, particle size affects uniformity
of the final pharmaceutical product, i.e. the amount of API in each unit of final
product, and product appearance, such as color and shape3.
Additionally, the PSD of the produced API has great influence on the production cost
due to its effects on the efficiency of downstream unit operations such as filtration
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and drying. Thus, to meet the requirements for an economical API production, the
defined objective regarding the final PSD of an API should be pursued by controlling
all the variables affecting the crystallization process within an acceptable range which
is determined by the chemical and physical nature of the product, solvent used, and
impurities present. In this respect, seeding provides an excellent way for controlling
particle size along with PSD and morphology62,87.
2.2.2.3 Morphology and flow properties
A property of crystals that make them unique and distinct from gaseous or liquid
materials is crystal habit or morphology. Thus, only the appearance of crystals is
reflected by the morphology, and not the internal structure87. In the pharmaceutical
industry, the most commonly used techniques for the elucidation of the morphol-
ogy are optical microscopy or Scanning Electron Microscopy (SEM). The frequently
observed crystal morphologies are shown in Figure 2.53.
Figure 2.5: Crystal morphologies frequently observed in the pharmaceutical industry3.
Essentially, the morphology of the solid product affects flow characteristics of powder
or slurry of the product. The reason is that particles with different morphologies have
different characteristic lengths affecting the PSD of the product. Crystal morphol-
ogy affects the rheological properties of the crystallizing suspension, the efficiency of
downstream processing such as filtration or centrifugation, the bulk density of the
solid, and the flow properties of the solid measured by the Hausner ratio62,74,84,87. In
this respect, acircular, thin blade, and plate-like crystals, with a Hausner ratio greater
than 1.4, poses difficulties in downstream processing resulting in long isolation times,
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agglomeration, crystal breakage or attrition, and poor flowability and solid transport
properties. Columnar, block-like, and pyramidal crystals, with a Hausner ratio less
than 1.2, are in contrast easier to isolate, dry, and handle. The reason is the relatively
low surface area to volume ratio, which in turn affects the solubility and dissolution
rate of the API3. Impurities, solvent used, mixing, and supersaturation levels influ-
ence the final morphology of the product crystals along with the particle size and
PSD. Therefore, the control of these critical crystallization process variables are an
important and integral part of the assurance of target product quality attributes. A
way of controlling crystal morphology is thus the use of seed crystals as a template for
the desired target morphology. However, seeding solely does not ensure the achieve-
ment of the target morphology because growing seed crystals can change morphology
due to supersaturation fluctuations and impurity incorporation3,84,87.
2.3 Solid-liquid phase equilibria of chiral systems
As for any crystallization process, the knowledge to thermodynamics and kinetics,
and their interconnections, is essential for API crystallization, where requirements
for purity, particle size, and morphology are determining for biological activity of the
active compound54,62,88,93. It is well-known that chiral active ingredients are able to
form three different types of solid-liquid phase equilibria41,54,62,93:
1. Conglomerate forming system
2. Racemic compound forming system
3. Pseudoracemate forming systems
Describing the solid-liquid phase behavior of a racemic mixture of two enantiomers
is usually illustrated by a binary melting point phase diagram. In the presence of
an additional phase created by solvent(s), a ternary solubility diagram is useful to
illustrate the solid-liquid phase behavior54,62,93. These systems and their relation
to PC, for which the determination of the thermodynamically stable phase and key
solubility data are essential for design and operation, are described in the following
sections.
2.3.1 Conglomerate forming systems
Solid-liquid phase behavior of conglomerate forming systems include the formation
of a conglomerate, which is an eutectic mixture of pure crystals of the two enan-
tiomers41,54. The fraction of racemic mixtures of organic compounds that exist as
conglomerates is estimated to 5-10%20,54,93. Examples are 4-hydroxy-2-pyrrolidone,
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an important intermediate in the synthesis of many active compounds92, modafinic
acid, an intermediate in the synthesis of modafinil97, and the amino acids threonine20
and asparagine monohydrate86 used in food supplements. The ternary solubility phase
diagram for a nonsolvated conglomerate forming system is shown in Figure 2.6 for
the simplest case of two enantiomers crystallizing from a solution54,62,93.
Figure 2.6: Ternary phase diagram of a simple nonsolvated conglomerate forming sys-
tem62,93. E1 and E2 represent enantiomer 1 and enantiomer 2, respectively. The dashed
and solid lines correspond to the composition dependent solubility curves at one temperature
and at a lower temperature, respectively.
Points A and B correspond to the solubility of E1 and E2, respectively, at one tem-
perature, and points A’ and B’ correspond to the solubility of E1 and E2, respectively,
at a lower temperature. Points C and C’ correspond to the eutectic composition, i.e.
the solubility of the conglomerate, at one temperature and at a lower temperature,
respectively. The 1-phase region consists of undersaturated solution of enantiomers in
solvent. The 2-phase regions E1AC and E1A’C’ consists of solids of pure E1 and satu-
rated solution at one temperature and at a lower temperature, respectively. Similarly
for E2, the 2-phase regions E1BC and E1B’C’ consists of solids of pure E2 and satu-
rated solution at one temperature and at a lower temperature, respectively. Finally,
the 3-phase region consists of a liquid phase racemic mixture of the two enantiomers
and a solid phase existing as a conglomerate of the two pure enantiomers20,62,93.
For solvated or hydrated conglomerate forming systems, where the two pure enan-
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tiomers and the racemate or only the two pure enantiomers form solvate or hydrate
with the solvent, the phase behavior definitely changes. The formation of solvated
solids of pure enantiomers can have significant effect on the chemical stability of
the solid. Furthermore, solvated solids of enantiomers can have significant effects on
downstream processing, such as filtration, and bioavailability93.
Some of the chiroselective separation technologies developed suitable for the sepa-
ration of enantiomers forming conglomerates are PC in batch crystallizers coupled
via crystal-free mother liquor exchange20,21,66, and pilot and commercial scale contin-
uous fluidized-bed crystallizers with sonication28,87. A common prerequisite is that
the solubility of the conglomerate is sufficiently higher than the solubility of pure
enantiomer. In the former, the liquid solutions in the crystallizers, each seeded with
seed crystals of pure enantiomer, are maintained at a nearly racemic composition to
suppress or completely avoid the nucleation of the unwanted enantiomer in the crys-
tallizers. This is achieved by the crystal-free liquid exchange streams coupling the
crystallizers presuming that crystallization kinetics of the enantiomers are identical
in the crystallizers. A drawback is, however, the decrease in the crystallization driv-
ing force due to the consumption of the crystallizing species for crystal growth21,66.
This problem can be solved by manipulating the crystallization temperature profile to
enhance the crystallization driving force, thereby improving process performance21.
A continuous process is however desirable and in this respect the fluidized-bed tech-
nology provides an excellent solution. In the continuous process, seed crystals are
continuously generated by sonication of the crystallizing suspension while racemic
liquid feed solution is continuously supplied. The grown seed crystals are removed
by elutriation and the removed mother liquor is transferred back to the feed solution.
The nucleation of the unwanted enantiomer is suppressed by controlling the supersat-
uration level of the enantiomer. This is performed by controlling the PSD of the seed
crystals in the crystallizing suspensions28,87. Features of stirred vessels crystallizers
and fluidized-bed crystallizers are listed in Appendix A.1.1.
2.3.2 Racemic compound forming systems
Racemic compound forming systems are the most common type of racemic mixtures
corresponding to about 90-95% of chiral API. The formed racemic compound, also
referred to as true racemate, corresponds to a crystalline racemic mixture in which the
two enantiomers are present in a 1:1-ratio in a well-defined arrangement within the
same crystal lattice41,54. Examples are the APIs ketoprofen56 and sertraline7. The
ternary phase diagram of a simple nonsolvated racemic compound forming system is
shown in Figure 2.754,62,93.
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Figure 2.7: Ternary phase diagram for a simple nonsolvated racemic compound forming
system62,93. E1 and E2 represent enantiomer 1 and enantiomer 2, respectively. The dashed
and solid lines correspond to the composition dependent solubility curves at one temperature
and at a lower temperature, respectively.
In the ternary phase diagram, the solubility of the racemic compound corresponds to
the point at the maximum between the two eutectic points, e.g. C and D. Point C
represents the eutectic composition consisting of solids of enantiomer E1 and racemic
compound in equilibrium with a saturated solution enriched with E1. Similarly, D
represents the equilibrium conditions for E2. The regions defining the presence of pure
enantiomers and the width of these regions are defined by the position of the eutectic
points. If the crystallization process is performed with solution composition between
the eutectic points, e.g. C and D, the racemic compound will crystallize as solid. In
the regions to the left and right of the middle region, where the racemic compound
can be formed, an equilibrium occurs between crystals of one of the pure enantiomers
and a saturated solution. Crystallization of the pure enantiomers is achievable in
these regions, but the feasibility of the crystallization process depends strongly on
the position of the eutectic composition points, i.e. the width of the middle region,
and the solubility of the racemic compound, i.e. the position of the point at the
maximum between the eutectic points41,54,55,62.
The main differences between the ternary phase diagram of a conglomerate forming
system and racemic compound forming system are41,54,93:
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• Change in the shape of 1-phase region of unsaturated solution
• Shrinkage of the 2-phase regions, i.e. solid and saturated solution
• An additional 2-phase region where the solid phase of the racemic compound
appears with saturated solution
• Two separated 3-phase regions where the solid phases appear as physical mix-
tures of pure enantiomers and racemic compound and saturated solution
The borders of the different regions in the ternary solubility phase diagram are
strongly dependent on temperature. For evaluation of the feasibility of crystalli-
zation of one pure enantiomer from a racemic compound forming system, the eutectic
enantiomeric excess (ee) plays a major role. This factor is dependent on temperature
and solvent used in the system. Typically, if the initial enantiomeric solution has a
lower initial ee than the eutectic ee, a certain degree of enrichment of the desired
enantiomer in solution is required to facilitate crystallization of this particular enan-
tiomer. This enrichment has to be provided before the actual crystallization and can
be provided by e.g. SMB chromatography. If the initial enantiomeric solution has a
higher initial ee than the eutectic ee, pure enantiomer can be obtained in the solid
phase if enough solvent is added to alter system composition to enter the 2-phase
region54,93.
As in the case of conglomerate forming system with solvate, racemic compound form-
ing system forming solvate exhibit three different ternary phase diagrams, where only
the racemic compound forms a solvate, or only the pure enantiomers forming solvates,
or both the racemic compound and the pure enantiomers form solvates93. As in the
case of solvated or hydrated conglomerates, the presence of solvent molecules in the
enantiopure solids and racemic compound can have significant effects on chemical sta-
bility, bioavailability, and further treatment such as filtration and formulation of the
API62,93. It is also possible that one enantiomer exist as a stable racemic compound
at one temperature and as conglomerate at another temperature, and vice versa as in
the case of crystallization of mandelic acid, or a halogenated derivative thereof, which
is known to be a racemic compound, from an aqueous solution37,68. In such a case, it
is advantageous to perform the crystallization process at a temperature allowing the
formation of conglomerate rather than a racemic compound, if possible93. Otherwise,
for the separation of enantiomers from a racemic compound forming system can be
formed, large scale SMB chromatography and diastereomeric salt crystallization have
been used extensively in the pharmaceutical industry5,39. Other developments for
potential use in large scale separation of enantiomers are liquid-liquid separation by
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chiral extractants76 and chiral selective membranes33.
2.3.3 Pseudoracemate forming systems
A third type of solid-liquid equilibria systems for chiral mixtures is the pseudorace-
mate forming system. Pseudoracemate refers to the formation of a solid solution
between the two enantiomers coexisting in a completely random distribution in the
crystal lattice. This type of solid solution systems is relatively rare and three classical
cases of such systems occur. These are referred to as type I, II, and III depending
on the melting point of the pure enantiomers compared to that of the pseudorace-
mate93.
The difference between a racemic compound, which requires an equal fraction of the
two enantiomers, and a pseudoracemate is that a pseudoracemate is a special case
of continuous series of different chiral solid solutions. From a crystallization point of
view, a slight increase in final enantiomeric excess (ee) can be achieved in the case
of type II, where a maximum melting point exists for the racemate, and III, where
a minimum melting point exists for the racemate. But in the case of type I, where
the enantiomers over the whole composition range melt at the same temperature as
the racemate, no increase in final ee can be achieved. However, because difficulties in
achieving true equilibrium in systems of type II and III, the reproducibility of increase
in final ee in industrial applications is unlikely93.
The formation of solid solutions of enantiomers over the whole range of composition
is rarely observed. However, a more common observation is the formation of con-
glomerate or racemic compounds with partial solid solution formation in a limited
composition range close to the region of pure enantiomer or racemic compound as in
the case of ethanolamine mandelate93,96.
2.4 Crystallization theory
2.4.1 Crystallization driving force: Supersaturation
Crystallization is a rate process which depends on a driving force. The fundamen-
tal driving force for all crystallization processes is supersaturation. Frequently used
expressions of supersaturation are given below3,62:
σ = C − Ceq (2.1)
S =
C
Ceq
(2.2)
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s =
C − Ceq
Ceq
(2.3)
where σ is the supersaturation, S is the supersaturation ratio, and s is the relative
supersaturation. C is the actual concentration of solution and C eq is the saturation
(solubility) concentration3,62. It should be emphasized that the above given defini-
tions are only valid for ideal solutions, i.e. solutions wherein the molecular interac-
tions between solute and solvent(s) are identical to the interactions between solute
molecules and solvent molecules themselves62. Such solutions are unlikely to exist
and to extend the application of the definitions above to nonideal systems, activity
coefficients are often used in the following dimensionless expression62:
µ− µ∗
RT
= ln
γc
γ∗c∗
(2.4)
where µ is the chemical potential, c is the concentration of solute, and γ is the activity
coefficient. The asterix represents the property at saturation62. In this respect, and
especially when solvent mixtures are employed in a solvent-solute system, the solid-
liquid phase behavior can be predicted by a variety of group-contribution methods
such as UNIFAC40,62,77.
2.4.1.1 Crystallization modes
The first step in any crystallization process is the generation of supersaturation to
achieve crystallization. There are commonly four modes used in the pharmaceutical
industry to achieve crystallization in a solution. The modes are employed either
solely or in combination (Table 2.1)3,62,87. Reactive crystallization, commonly known
as precipitation62, can for instance be employed if the solubility concentration of the
solute in a solvent is below 0.01 g/g solvent. If the solubility concentration is above
0.2 g/g solvent and the change of the solubility concentration with temperature is
below 0.005 g/(g solvent ◦C). Otherwise antisolvent or cooling crystallization should
be employed47. To meet the predefined yield requirements of a crystallization process
and to control the physical attributes of the final solid product such as PSD, it could
be advantageous to consider a combination of the listed crystallization modes such
as vacuum crystallization, i.e. combined evaporative and cooling crystallization62, or
combined antisolvent and cooling crystallization63,102.
2.4.2 Metastable region
In order to achieve crystallization, supersaturation greater than unity, i.e. greater
than equilibrium solubility, is required. Figure 2.8 illustrates the different crystalli-
zation phenomena corresponding to the level of supersaturation87.
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Table 2.1: Crystallization modes commonly employed. The influence of solute solubility on the selection of crystallization mode is addressed3.
Crystallization mode Description Solubility behavior
Cooling Solute solubility is reduced to achieve cry-
stallization by cooling the solution from a
high temperature to a low temperature at
constant solvent composition
Solute is soluble in a solvent at high temper-
ature, but below the normal boiling point of
the solvent, and is relatively insoluble at low
temperatures
Antisolvent An antisolvent is added to reduce the solu-
bility of the solute in a solvent in which the
solute is soluble. Crystallization is achieved
by composition change
Yield constraints cannot be achieved by
cooling crystallization at reasonable dilu-
tions. The solubility of the solute in a sol-
vent can be reduced by more than 50%
Reactive Changing the ionic composition or structure
of the solute through reaction can induce
crystallization by change in the solubility be-
havior. The concentration of the product is
changed by reaction to exceed the solubility
limit
Reactants used are often readily soluble in
the solvent with the produced solids by re-
action being completely insoluble
Evaporative Crystallization is induced by increasing the
concentration of the solute in a solvent above
the solubility limit by the evaporation of sol-
vent
Evaporative crystallization is commonly
used in combination with cooling crystalli-
zation to meet yield requirements. Concen-
tration through distillation allows for addi-
tional mass of solute to be recovered
24
Figure 2.8: A hypothetical map between supersaturation and possible crystallization phe-
nomena87. Note that the metastable boundary is only kinetically determined and is depen-
dent on process conditions, such as amount and size of seed crystals or stirring rate. The
region between the metastable boundary and equilibrium solubility is the metastable region.
Between the equilibrium solubility and the metastable boundary, a metastable region
exists. Beyond the metastable boundary, any change to the system will result in a
mixture having a lower Gibbs-free energy than in the initial condition. Within the
metastable region, nuclei from secondary nucleation may form or growth on existing
crystal surface, i.e. seed crystals, may occur. In order to control the crystallization
process and thereby crystal attributes, such as particle size and PSD, it is desirable
to maintain the crystallization process in the metastable region to allow for growth
of already existing crystals previously formed by nucleation or supplied externally as
seed crystals3,87.
The metastable region may be narrower or wider than that illustrated above and
this will have a great influence on the selection of the strategy for operating the
crystallization process. The width of the metastable region is essentially controlled
by the position of the metastable boundary, which is kinetically controlled, while the
equilibrium solubility is a constant thermodynamic property at the given conditions,
e.g. temperature or solvent composition. Thus, the width of the metastable region
may be influenced by3,62,87:
• Cooling rate employed (cooling crystallization)
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• Rate of antisolvent addition (antisolvent crystallization)
• Rate of addition of reactants (reactive crystallization)
• Rate of solvent evaporation (evaporative crystallization)
• Stirring rate
• Amount and size of seeds, if any
• Nature and concentration of impurities
• Storage of solution prior to crystallization
Two methods exist for the measurement of the metastable boundary: 1) Cooling
rate method, and 2) nucleation induction time method3,62,87. The first method is
primarily applicable for cooling crystallization, but can also be used for evaporative
crystallization. The main principle of the method is cooling a solution at very low
cooling rate until particles are detected by the online measurement devices such as
Lasentec FBRM R©. The experiment is repeated several times with faster cooling rates.
For evaporative crystallization, the evaporation rate is varied. In the second method,
supersaturation is initially generated rapidly by cooling, evaporation, reaction, or an-
tisolvent addition. The supersaturated solution is then held isothermally until the
formation of particles is detected by e.g. Lasentec Focused-Beam Reflectance Mea-
surement (FBRM R©) device. The experiment is repeated for different conditions, e.g.
different amount of antisolvent used, different temperatures (cooling and evaporative
crystallization), and different amount of reactants added. The most general method
is the second method because it is applicable for all crystallization modes and gives a
better estimation of the time window available for e.g. addition and growth of seeds
or mixing of antisolvent or reactants with the supersaturated solution3.
2.4.3 Nucleation
As a result of the generation of supersaturation, new crystals may be formed. The
formation of crystal nuclei can be spontaneous and occurs without the presence of
crystalline surfaces. This process is called primary nucleation. This process can either
be homogeneous or heterogeneous61,62,87.
2.4.3.1 Primary homogeneous nucleation
Primary homogeneous nucleation is believed to be based on sequences of collisions and
interactions between molecules in a supersaturated fluid resulting in the association
of molecules to form clusters, which may dissociate or grow, because they may or may
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not achieve thermodynamic stability, i.e. minimum Gibbs-free energy, depending on
their size62,87. If the cluster becomes large enough to have the appearance of a lattice
structure, it becomes an embryo. Further growth results in stable crystalline nucleus
and is basis for crystal growth61,62,87. The rate of primary homogeneous nucleation,
B0, is theoretically given by the following expression61,87:
B0 = A0 exp
[ −16piφ3ν2
3k3BT
3(lnS)2
]
(2.5)
where A0 is the pre-exponential factor containing solute diffusivity, supersaturation,
molecular diameter and volume, equilibrium solute concentration, and Avogadro’s
number. A0 has a theoretical value of 1030 nuclei/(cm3 s). This value generally differ
from observed values due to the unavoidable presence of impurities or low surface
integration rates, which is exhibited by many organic molecules87. The exponential
term reflects the energetics of phase change.
The development of equation (2.5) is based on thermodynamic consideration of the
free energy involved in solid-phase formation and in creation of an arbitrarily spher-
ical crystalline body of a certain size. It is thus observed in equation (2.5) that
if a very high degree of supersaturation is obtained and thereby a supersaturation
rate beyond a critical value of S is achieved, the nucleation rate explosively increases.
However, below a certain optimal temperature the liquid becomes too viscous to allow
nucleation. In contrast, at conditions above that temperature, molecular motion pre-
vents crystal formation. In this respect, an additional thermodynamic term is added
to the exponential term in equation (2.5) to count for these practically important
effects15,62,72.
The limitations in the classical nucleation theory, represented by equation (2.5) lies
in the assumptions made to achieve this expression. Firstly, the assumption that only
one molecule is added to the growing cluster at a time is an extreme simplification.
Certainly, clusters or embryos aggregate and rearrange while growing to critical size.
This building process is in practice also affected by local supersaturation fluctua-
tions87. Secondly, the rate of addition of the molecules to form the solid phase can
exceed the ability of the molecules to orient themselves properly. This is especially
relevant for organic compounds, which create complex crystal lattices connected by
relatively weak forces. The result is a partially or totally amorphous solid, which
can easily be formed87. In industrial crystallizations, the following empirical expres-
sion, relating the primary nucleation rate to the supersaturation, ∆C is commonly
used15,72:
B0 = K0 (S − 1)a (2.6)
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where K0 is the primary nucleation rate constant, and a is the order of the nucleation
process, which is usually between 1 and 2, depending on the physical and hydrody-
namic properties of the crystallizing process15,72.
2.4.3.2 Primary heterogeneous nucleation
In contrast to primary homogeneous nucleation, primary heterogeneous nucleation is
facilitated by the presence of foreign particles or heteronuclei. This presence causes
a reduction in the Gibbs-free energy required for nucleation by the adsorption on
the surface of the foreign particle. Thus, heterogeneous primary nucleation occurs
generally at a lower degree of supersaturation than homogeneous nucleation (Figure
2.9)62,72.
Figure 2.9: Homogeneous and heterogeneous nucleation rate versus supersaturation ra-
tio72.
In fact, the degree of lowering the Gibbs-free energy for nucleation, and thereby su-
persaturation, is dependent on the contact angle of the foreign particle and its surface
energy. Thus, the extent to which the foreign particle mimics the structure of the com-
pound to be crystallized undoubtedly influences the nucleation process62,72,87.
2.4.3.3 Secondary nucleation
The process of secondary nucleation is, in contrast to primary nucleation, not spon-
taneous, but follows primary nucleation by the development of crystals formed by
either primary homogeneous or heterogeneous nucleation. This development results
in uneven growth of crystals on crystal surface of the species considered even at lower
degree of supersaturation compared to primary homogeneous and heterogeneous nu-
cleation. Secondary nucleation can occur through several ways61,62,87:
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• Dust breeding
• Polycrystalline breeding
• Attrition breeding
• Contact nucleation
• Impurity concentration gradient
• Shear nucleation
Thus, secondary nucleation can be induced by vibrations, mixing or the presence of
seeds or impurities. The process of secondary nucleation, although poorly understood,
is important for industrial crystallizations because it enables the control of particle
size and PSD62,72.
An expression of the rate of secondary nucleation, Bsec, is purely established based on
the power law correlation of many experimental data due to the absence of a theory
describing the complex phenomena of secondary nucleation. In this respect, the most
widely used correlation is the following empirical expression62,72,87:
Bsec = ksecM
rP l (∆C)b (2.7)
where kb is the empirical secondary nucleation constant, M is the density of slurry, P
is the agitation rate, and ∆C is the supersaturation. The exponents r, l, and b are
experimentally determined according to operating conditions. Thus, it is observed
that factors that affect the secondary nucleation are the rate of cooling, the rate of
agitation, the presence of impurities, and supersaturation62,72,87.
2.4.4 Crystal growth
Primary and secondary nucleation are followed by crystal growth, which is a dif-
fusion and integration process influenced by the effect of solid surface on which it
occurs62,72,87. Figure 2.10 illustrates the driving forces for crystal growth in solu-
tion72.
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Figure 2.10: Driving forces for crystal growth72. c denotes the concentration of solute in
the bulk solution, ci is the concentration of solute at the crystal surface-solution interface,
and c* is the saturation concentration.
Figure 2.11: Proposed crystal growth mechanisms. (a) illustrates the attachment of a
growth unit into a kink site, (b) illustrates crystal growth arising from surface nucleation,
and (c) the development of growth spiral starting from a screw dislocation15,62,87.
Crystal growth may occur by several mechanisms (Figure 2.11) for which a variety
of theoretical models have been proposed45,62,87. The proposed models describing
crystal growth are15,62,87:
• The Diffusion-Reaction Model
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• Surface Integration Models including Continuous Growth Model, Screw Dislo-
cation Model, and Birth and Spread Model
In most cases more than one mechanism is involved in crystal growth. Hence, these
mechanisms have great influence on the growth rate of crystals. If the mechanisms
occur in parallel, then the mechanism resulting in the faster growth controls the overall
growth rate. If the growth mechanisms occur in series, then the slower mechanism
controls the overall rate of crystal growth15,62.
The process of crystal growth consists of two important kinetic steps62,72:
1. Diffusion of solute ions or molecules through liquid interface from solution to
crystal surface
2. Ordering and integration of solute ions or molecules into the crystal lattice
The driving force in mass transfer, i.e. diffusion, from mother liquor to crystal surface
is given by the concentration driving force, i.e. the difference between the concentra-
tion of the surrounding supersaturated solution and saturation concentration at the
same temperature61,62,72. The second kinetic step of integration can be divided into
a number of stages45:
1. Adsorption of the growth unit (ion or molecule) on the crystal surface
2. Part of the unit’s solvation shell is released
3. The growth unit diffuses into the adsorption layer until it is either incorporated
into the crystal lattice, thereby loosing the remaining of its solvation shell, or
leaves the adsorption layer and returns to the solution
These kinetic processes occur in a consecutive manner and this causes the solu-
tion concentration to adjust itself resulting in an equal rates of the steps at steady
state45,62.
Analogous to similar mass transfer phenomena, the diffusion is improved by the fol-
lowing options45,61,62:
• Increase the degree of supersaturation
• If the resistance of the laminar liquid film surrounding the crystal surface com-
prises a significant part of the total resistance to mass transfer, the increase of
turbulence is essential to reduce the thickness of the laminar liquid film, thereby
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increasing the mass transfer number
• Increase the mass transport area, i.e. area of crystal surface, by increasing the
number of growing crystals
• A combination of the above mentioned options
These options for the improvement of crystal growth should be carefully practiced.
The reason is that fast crystallization (precipitation) could result in many very small
crystal nuclei resulting in impure crystals of undesired morphology and size. For in-
stance, rapid diffusion to each crystal would result in one-dimensional growth giving
needle-like crystals or dendrites. Therefore, it is important to control the relation be-
tween the degree of nucleation-to-crystal growth that determines the product crystal
size and morphology. For instance, if a mass of very small crystals with a wide PSD
is desired, then the dominant kinetic mechanism should be nucleation. In contrast,
if small amounts of large crystals are desired, then the crystal growth mechanism
should be the dominant62. The benefits of a growth-driven crystallization process
are16:
• Larger average crystal size
• Predictable dry solid flow characteristics
• Reduction of aggregation and/or agglomeration
• Control of hydration, solvation, and polymorphism
• Control of PSD
• Decreased sensitivity to mixing
• Improved reproducibility on scale-up
• Easier transformation to continuous operation
Thus, the balance between the nucleation and growth determines the resulting phys-
ical and chemical characteristics of the produced solids and also establishes the basis
for evaluation of whether a crystallization process is successful or not62.
2.4.4.1 Size-dependent growth and growth rate dispersion
In modeling of crystallization processes, it is common to assume that crystal gr-
owth obeys the classical McCabe ∆L law, i.e. size-independent growth, in which the
growth rate is expressed as the linear velocity perpendicular to the growing charac-
teristic dimension or face. According to the Gibbs-Thomson equation, however, there
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is a difference in the solubility of very small particles (below 1 µm) and larger par-
ticles. Consequently, supersaturation becomes a function of particle size. Thus, the
growth of the small particles becomes slower than the larger particles due to a lower
supersaturation of the small particles62,87.
For larger particles (above 1 µm), if the growth controlling mechanism is surface
integration, the particles will become larger, their total surface area increases, and
consequently the probability for the occurrence of dislocations on the surfaces in-
creases due to higher mechanical stresses, collision energy, and impurity inclusion. It
is thus more likely that larger particles grow faster than smaller ones. Similarly, if the
growth rate is diffusion-controlled, larger particles can grow faster than smaller parti-
cles under certain mixing conditions due to higher settling velocity. The dependence
of the growth rate on the size of the growing particles is referred to as size-dependent
growth62,87. In this respect, several empirical growth rate expressions that include
size dependence have been developed70.
Experimental investigations have also shown that even if particles having the same
size and are of the same material are exposed to identical conditions of supersat-
uration, temperature, and mixing, they do not necessarily grow at the same rate.
This phenomenon is known as growth rate dispersion. Two different mechanisms have
been proposed to describe the behavior of growth rate dispersion. The first mech-
anism suggests that there exists a distribution of growth rates among particles in a
population, but each individual particle grows with a constant growth rate. The sec-
ond mechanism proposed suggests that the time-averaged growth rate over a certain
time period is the same for all particles while there exist fluctuations in the growth
rate of each individual particle with time. It should be emphasized that in both cases
growth rate dispersion is dependent on the occurrence of dislocations on the surface
of a particle. The primary cause of these dislocations is the surface integration step
in crystal growth. Changes in the density and locations of dislocations on the surface
of a particle caused by e.g. collisions of particle with impeller or impurity inclusion
can cause large changes in crystal growth rate62,87.
2.5 Conclusions
In this chapter, a concise introduction to the methods currently available for the
production of pure enantiomers was provided. Chiroselective separation technologies
provide a potentially cheaper alternative to other available techniques for the produc-
tion of pure enantiomers. Additionally, a review on the design objectives and criteria
for crystallization processes in the pharmaceutical industry was provided. Solid prod-
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uct attributes are of great importance in the pharmaceutical industry and therefore
crystallization processes involved in the production of an API should be considered
in conjunction to downstream processing and formulation. Moreover, a review on the
solid-liquid phase equilibria of chiral systems was given and in relation to that the
application of chiroselective separation methods were discussed. Finally, the funda-
mentals of crystallization theory, which provide the basis for the work presented in
the subsequent chapters, were highlighted and discussed.
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Chapter 3
Separation of enantiomers by continuous pre-
ferential crystallization:
Experimental realization using a coupled crys-
tallizer configuration
This chapter presents the experimental realization of separation of enantiomers of the
conglomerate forming system of the amino acid asparagine monohydrate in aqueous
solution by preferential crystallization using a lab-scale coupled crystallizer process.
The setup was designed and built by the author of the thesis and comprises the main
objective of the PhD project. The work will be submitted for publication in the
journal Organic Process Research and Development (Authors: Joussef Chaaban, Kim
Dam-Johansen, Tommy Skovby, and Søren Kiil). Modeling of the process presented
in this work and sensitivity analysis to improve process understanding are presented
and discussed in chapter 4.
Abstract
The experimental realization of a continuous preferential crystallization process, con-
sisting of two mixed flow crystallizers coupled via crystal-free liquid exchange streams
and with only the liquid phases operated continuously, is addressed. Experiments in
triplicate, using the conglomerate forming system of dl-asparagine monohydrate (dl-
AsnH2O) in water, were conducted and the achievement of nearly racemic composition
of the liquid phase in the crystallizers was verified. An experiment was also carried
out using seed crystals of a smaller average particle size than used in the reference
experiments. Successful enantioseparation by crystal growth, with the repeatability
being within ±10% deviation, was obtained. However, slow crystal growth, due to a
low surface integration rate, led to a negligible consumption of the desired enantiomer
in the feed solution added resulting in low productivities. Productivities, yields, and
purities of solid products were influenced by the morphological differences in the seed
crystals. Due to irregularly shaped seed crystals, increase in the productivities and
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yields were achieved in the l-Tank. Lower purities of solid products from the l-Tank
compared to solid products from the d-Tank were obtained. This could be due to
surface nucleation of d-AsnH2O, ascribed to the surface structure of the seeds of l-
AsnH2O supplied. Improvements in productivity, yield, and purity in the l-Tank, for
the same process duration, were realized using seed crystals of lower average particle
size having a smoother surface structure. The main advantages compared to other
separation processes are low capital cost, high crystal purity and yield, ease of upscal-
ing, increased safety, and reduced environmental impact due to reduction in amount
of solvent used. The application is currently limited to conglomerate forming systems,
but the separation concept may open new possibilities for process improvements re-
garding enantioseparation of racemic compound forming systems as well.
3.1 Introduction
Continuous pharmaceutical production and separation processes in minireactors are
receiving increasing attention as a mean of efficient and safe manufacturing12,60. Con-
tinuous crystallization also has a great potential in this respect. A substantial number
of active ingredients in the pharmaceutical, agrochemical, food, and cosmetic indus-
tries are racemic mixtures, i.e. conglomerates and racemic compounds. Usually,
only one enantiomer is biologically effective and the other enantiomer can be con-
sidered as an impurity comprising 50% of the mixture. Human and environmental
side effects are in many cases attributed to the presence of counter enantiomers. A
clear evidence of the potential consequences of administering racemic drugs is e.g.
the dramatic incident of the pharmaceutical thalidomide in the last century, which
caused fetal abnormalities, such as severely underdeveloped limbs9,48. During the last
decade, the commercialization of chiral active ingredients attracted great attention,
which has resulted in new guidelines for the commercialization of chiral ingredients
by the FDA, the Japanese authorities, and the European Community13,80,98. Strict
regulatory requirements and increasing public demand for the production of chiral
active ingredients in optically pure form have sparked intensive research devoted to
the development of reliable and cost-efficient production processes. In this context,
two options are available: 1) Enantioselective synthesis (chemical or enzymatic asym-
metric synthesis) or 2) Enantioselective separation of racemic mixtures.
As a result of intensified efforts put into the development of enantioselective syn-
thesis, remarkable progress has been achieved, chemically as well as enzymatic13,14.
However, an obstacle to the wide commercial application is the cost of such selective
synthesis processes. Among other reasons, the use of expensive chemical auxiliaries
and reagents as well as enzymes must be considered. Therefore, separation of enan-
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tiomers from racemic mixtures comprises an attractive alternative for the production
of optically pure enantiomers13.
The technique most utilized commercially is chiral chromatography with its wide se-
lection of chiral stationary phases. This allows the separation of many racemates26,27,82.
A version of chiral chromatography successfully applied in industrial scale is contin-
uous countercurrent SMB chromatography enabling an increase in productivity and
realizing the goal of achieving optically pure enantiomers34. Nevertheless, highly ex-
pensive chiral stationary phases and a dilute separation product have initiated the
search for and development of alternative technologies which, among others, include 1)
diastereomeric (or classical) resolution5,22,41, 2) chiral membranes32,33,100, 3) dynamic
resolution14,57,94,95, 4) liquid-liquid extraction75,76,85,101, and 5) preferential crystalli-
zation14,19–21,54,66,67,91. Preferential crystallization, in particular, has attracted great
attention, the reason being that the majority of chiral pharmaceutical, agrochemical,
food, and cosmetic products, and their intermediates are produced as highly pure
solids.
3.1.1 Coupled-Batch Preferential Crystallization
A thoroughly studied preferential crystallization process is the Coupled-Batch Prefe-
rential Crystallization (CB-PC) process19–21,66. It consists of two batch crystallizers
coupled via crystal-free mother liquor exchange streams between the crystallizers.
The process can be operated either isothermally throughout the duration of separa-
tion21,66 or with a transient decrease in crystallization temperature21. Both opera-
tions are performed with external supply of enantiopure seeds to facilitate selective
crystal growth. Both operation modes for the CB-PC process have proven to be
feasible for the simultaneous separation of enantiomers by crystallization20,21,66 with
improved productivity and yield compared to preferential crystallization in a single
batch crystallizer. Because of the crystal-free liquid exchange streams, the delay or
even the suppression of the nucleation of excess counter enantiomer is possible due
to the nearly racemic composition of the mother liquors. However, a characteristic
drawback is the decrease in the crystallization driving force, i.e. supersaturation of
desired enantiomer, with time in the crystallizing solutions.
The CB-PC process is applicable for conglomerate forming systems21,66 and racemic
compound forming systems as well20. In case of conglomerate forming systems, the
enantiomers are separated simultaneously (one in each crystallizer) by seeding. En-
richment of initial racemic solution is not necessary. An essential requirement allowing
for separation is a sufficiently higher solubility of the racemate compared to that of
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the pure enantiomers. For a racemic compound forming system the process is fea-
sible only if 1) sufficient enrichment of the desired enantiomer beyond the eutectic
composition is present in the initial racemic solution, and 2) the solubility of the
racemic compound is sufficiently higher than that of pure enantiomers41,67. In this
case, the simultaneous separation of the racemic compound and the desired enan-
tiomer in excess can be performed. A loss in the yield of pure solid product of the
desired enantiomer is unavoidable in this process due to the consumption of that
enantiomer in the formation of solid racemic compound.
A detailed theoretical study followed by experimental investigation of the parameters
influencing the enantioseparation performance of the CB-PC was performed by Elsner
et al.19,21. The study was conducted on the conglomerate forming system of the amino
acid threonine using water as solvent. The study highlighted that an increase in
productivity can be achieved by manipulating critical process parameters such as flow
rate of crystal-free liquid exchange between crystallizers, initial enantiomeric excess
in solutions, mass of seeds supplied, time for initiating liquid exchange (switching
time), process duration time, and crystallization temperature.
3.1.2 Coupled Continuous Preferential Crystallization
In the present study, the continuous preferential crystallization apparatus called
Coupled-Continuous Preferential Crystallization (CC-PC) process is investigated. This
newly developed process is based on the thoroughly investigated CB-PC apparatus
developed by Elsner et al.20,21, and a proof-of-concept investigation of a continuous
isothermal version of the process is conducted. The objectives are to assess the po-
tential achievement of simultaneous separation of the enantiomers by crystal growth
and the achievement of a nearly racemic composition of the liquid phase in each crys-
tallizer. Due to the nearly racemic composition of the mother liquor, the crystal-free
liquid exchange could ensure the suppression of crystallization of the counter enan-
tiomer. The stages and decisions made during the development of the CC-PC process
are provided in Appendix A.
The newly developed continuous process is evaluated with respect to productivity,
yield, and purity of the solid product produced. To evaluate the robustness of the
process, experiments in triplicates with almost identical experimental conditions were
conducted. Furthermore, to investigate the flexibility of the process, an experiment
where seed particles with smaller size were used was also conducted.
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3.1.3 Chemical model system
The investigation is performed as a case study of enantioseparation of the enan-
tiomers of the amino acid asparagine monohydrate from an aqueous racemic mixture
by preferential crystallization. The selection of the asparagine monohydrate system
as model compound for the investigation in this study was based mainly upon two
reasons:
1. Aqueous solution of the compound belongs to the conglomerate forming sys-
tems86
2. Solubility data and data for crystallization kinetics are available in the litera-
ture66
The solubility of the asparagine monohydrate compound in water decreases with de-
creasing temperature66. This facilitates the application of cooling crystallization as
separation method in the continuous preferential crystallization process considered.
Enantioseparation of the enantiomers of the selected model compound in the isother-
mal CB-PC process was also investigated by Petrusˇevska-Seebach et. al66. It was
concluded that the crystallization process is controlled predominantly by surface in-
tegration at the given experimental conditions. In general, surface integration rate
exhibited by many organic molecules is known to be rather low87 leading to a slow
consumption of the enantiomer from the liquid phase. It was also found that the gr-
owth rate of the desired enantiomer is dependent on the concentration of the counter
enantiomer which can inhibit the growth of the desired enantiomer66. The low rate of
crystal growth means that the consumption of the desired enantiomer from the con-
tinuously added feed solution in the CC-PC process considered in this study is, for any
practical uses, expected to be negligible. Therefore, the purpose of this work is not
to demonstrate a quantitative separation of the two monohydrate enantiomers in the
feed streams, but, as an initial step, to show that it is possible to grow only one of the
enantiomers in each of the two crystallizers. Thus, the estimated productivities of the
solid product produced are expected to be low. However, it is believed that process
parameters influencing the growth rate of the seed crystals, such as crystallization
temperatures, can be manipulated so that feasible separation of the enantiomers of
quantitative scale can be realized.
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3.2 Experimental section
3.2.1 Materials
The chiral compounds used as enantiopure seeds in the present study were d-(+)-
Asparagine monohydrate (d-AsnH2O) (≥99%) and l-(-)-Asparagine monohydrate
(l-AsnH2O) (≥99%) purchased from Sigma-Aldrich (Copenhagen, Denmark). dl-
(±)-Asparagine monohydrate (dl-AsnH2O) (≥99%)) was also obtained from Sigma-
Aldrich (Copenhagen, Denmark) and dissolved in demineralized water (solvent) and
used as racemic feed for the experiments.
3.2.2 Experimental setup and procedures
3.2.2.1 Continuous Preferential Crystallization (CC-PC) process
The schematic diagram of the experimental setup is shown in Figure 3.1 and a picture
of the setup is shown in Figure 3.2.
Figure 3.1: Schematic diagram of the CC-PC process for the preferential crystallization
experiments. TF symbolizes the temperature in the feed tank, TF1 is the temperature of
feed entering the d-Tank, T1 is the temperature in the d-Tank, T2 is the temperature in
the l-Tank, TE1 is the temperature of mother liquor eﬄuent from the d-Tank, T1-2 is the
temperature of exchange stream from the d-Tank to the l-Tank and T2-1 is the temperature
of exchange stream from the l-Tank to the d-Tank. Blue and red filled circles symbolize
growing enantiopure seeds of d-AsnH2O and l-AsnH2O in the d- and l-Tank, respectively.
The grey boxes in the d- and l-Tank represent filters for mother liquor exchange.
The CC-PC process in Figure 3.1 is a modification of the CB-PC. The modification
consists of the addition of two feed streams consisting of undersaturated racemic
solution, one to each crystallizer, and two purge streams from the crystal-free liquid
exchange to maintain constant volumes in the crystallizers. It should be emphasized
that the process is operated continuously with respect to the liquid phase only.
40
Figure 3.2: Photograph of experimental setup for the preferential crystallization experi-
ments. The small insert (lower left corner) shows the instrumentation in the crystallization
vessels. Six individual pumps are necessary to run the setup in a continuous mode.
Each of the crystallizers (d-Tank and l-Tank) consisted of jacketed round-bottom
glass vessels of 250 mL in total volume with 75 mm ID flange and lid with five necks.
The stirrer used in each crystallizer was a 45 mm ringed propeller-type impeller (Hei-
dolph PR 32 Ringed Propeller, Schwabach, Germany) mounted on a motor (IKA
Eurostar Digital, Staufen, Germany). Two separate thermostated circulation water
baths (LAUDA Alpha RA 8 for the D-Tank and LAUDA Ecoline Star Edition RE
104 for the L-Tank, Lauda-Königshofen, Germany) were used for cooling the crys-
tallizers. The liquid solutions from and into the crystallizers were transported by
six separate peristaltic pumps (Longer Pump LP-BT-100-1F, pump head YZ1515x,
Baoding Longer Precision Pump Co. Ltd., Hebei, China). A detailed instruction
manual for the CC-PC process is provided in Appendix B.
3.2.2.2 Preparation of undersaturated racemic feed solution
The racemic feed solution was prepared by dissolving 100 g of solid dl-AsnH2O in 1.90
kg of demineralized water in a jacketed cylindrical glass vessel with total volume of
2.5 liters (Feed tank). An in-house made stirrer shaft fitted with a half-moon impeller
of PTFE mounted on a motor (IKA Eurostar Power Control-Visc, Staufen, Germany)
was placed in the center of the feed vessel. The feed slurry was heated up to about
31 ◦C by a thermostated circulation water bath (LAUDA M3, Lauda-Königshofen,
Germany) and maintained for 1 hour for complete dissolution. The solution was
maintained at that temperature throughout the duration of the experiment. The
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temperature of feed solution was recorded via the Vernier Software package Logger
Lite 1.6.1 using the thermocouple sensor connected to Go! Link interface (Vernier
Software and Technology LLC, Beaverton, OR, USA).
3.2.2.3 Continuous Preferential Crystallization (CC-PC) experiments
The first experiments were performed with almost identical experimental conditions
according to Table 3.1. An additional experiment was conducted with the experimen-
tal conditions given in Table 3.1, but using enantiopure seeds with a smaller average
particle size (i.e. a sieve fraction of 150-250 µm).
Table 3.1: Operational conditions for experiments conducted in triplicates.
Parameter Value Unit
Feed tank
Feed temperature 304 K
Concentration 5 wt% dl-AsnH2O
Total mass of feed solution 2000 gram
Stirring rate 250 rpm
Heating rate 14 K/h
d-Tank and l-Tank
Inlet feed temperature 300 K
Saturation temperature 296 K
Crystallization temperature 292 K
Effective volume 220 mL
Residence time of liquid phase 15 min
Inlet feed flow rate 7.3333 mL/min
Liquid exchange flow rate 7.3333 mL/min
Eﬄuent flow rate 14.6667 mL/min
Mass of seeds 0.4648 gram
Sieve fraction of seeds 250-355 µm
Cooling rate 14 K/h
Stirring rate 250 rpm
Initially, 220 mL of undersaturated racemic solution from the feed vessel was trans-
ferred into each crystallizer by two separate peristaltic feed pumps (Longer Pump
LP-BT-100-1F, YZ1515x, Baoding Longer Precision Pump Co. Ltd., Hebei, China).
Stirring of solutions was initiated and maintained at about 250 rpm. A liquid sample
of about 4 mL was withdrawn from the feed solution for oﬄine polarimetric analysis
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and density determination. The racemic solutions in the crystallizers were then cooled
with constant cooling rate about 14 K/h to a crystallization temperature of about
19 ◦C and maintained throughout the duration of the experiments. The tempera-
tures were recorded via the Vernier Software package Logger Lite 1.6.1 using Al-Cr
thermocouples type K (0.1 K in resolution) connected to thermocouple sensors which
in turn were connected to Go!Link interface (Vernier Software and Technology LLC,
Beaverton, OR, USA).
The experiments were initiated by starting the peristaltic pumps at a flow rate of
7.333 mL/min. The liquid phase was separated from the solids by in-situ sintered
metal filters with pore size of 10 µm (IDEX Health and Science, Wertheim-Mondfeld,
Germany) fitted in each crystallizer. When the temperature of the solutions in the
crystallizers was stabilized, dry homochiral seeds of pure enantiomer were externally
supplied to each crystallizer. The mass of seeds was collected from a certain sieve
fraction and analyzed oﬄine for the particle size distribution with laser diffraction
particle size analyzer (Malvern Mastersizer 2000, Malvern Instruments Ltd.). Liquid
samples of about 4 mL were withdrawn from the respective purge stream from each
crystallizer every 15 minutes after seeding. The samples were analyzed oﬄine for
optical rotation at about 23 ◦C and 589 nm in 1 mL glass cell (PerkinElmer 341
Polarimeter, PerkinElmer Life and Analytical Sciences, Shelton, CT, USA) with a
reproducibility of ±0.002◦. Additionally, the liquid density of the liquid samples was
measured oﬄine at about 23 ◦C using Density Meter DMA 35 (Anton Paar GmbH,
Graz, Austria) with a reproducibility of ±0.0005 g/mL.
After each experiment, the pumps and the heating and cooling water baths were
turned off and the slurries were filtered using ashless cellulose filter paper with 7.0 cm
in diameter and pore size of 3 µm placed on a Büchner funnel with vacuum suction.
The filtered solids were washed with 50 mL ice cold ethanol to remove mother liquor
adhering to the crystal surface. A short time delay occurred between the filtration
tasks. The solids were dried for 24 hours in a ventilated cupboard and weighed for
yield and productivity estimation. The solids were also analyzed for optical purity
using oﬄine polarimetry and STA consisting of DSC and TGA (STA 409, NETZSCH-
Gerätebau GmbH, Selb, Germany) using Pt/Rh crucibles with lids. The STA analysis
was conducted at a heating rate of 5 K/min and up to 300 ◦C with purge gas flow of
100 mL N2/min. Furthermore, samples of the seeds and harvested solids were coated
with gold particles and analyzed by SEM imaging at Center for Nanoscopy (CEN) in
the Technical University of Denmark (DTU).
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3.3 Process Metrics
To quantify the efficiency of the present preferential crystallization process, produc-
tivity, yield, and purity of the solid product have been considered. Additionally, the
liquid phase concentration (mass fraction) change during the crystallization experi-
ments has been assessed to observe the performance of the process.
3.3.1 Analysis
3.3.1.1 Concentration of enantiomer in the liquid phase
The concentration (mass fraction) profiles for each enantiomer in the mother liquor in
each crystallizer during the crystallization process are calculated by a combination of
the polarimetric analysis and the density analysis of samples of the mother liquor18.
The polarimetric analysis determines the difference in the concentrations of d-Asn
and l-Asn in the mother liquor according to the calibration curve obtained for dif-
ferent aqueous solutions with known concentrations of each enantiomer. The density
analysis determines the total concentration of enantiomers in the mother liquor by
using the calibration curve of liquid density for known concentrations in a series of
aqueous solutions. The detailed calibration procedure and data for polarimetry and
densitometry analyses are provided in Appendix C.1 and C.2, respectively.
3.3.1.2 Supersaturation ratio
The crystallization driving force, i.e. supersaturation, in terms of the supersaturation
ratio of the desired enantiomer in each crystallizer is also estimated. The supersat-
uration ratio of the desired enantiomer is defined as the ratio between the mass
fraction of the desired enantiomer and the equilibrium mass fraction of the desired
enantiomer. The equilibrium mass fraction is in turn a function of the crystalliza-
tion temperature and the concentration of the counter enantiomer in the crystallizing
suspensions21,66.
3.3.1.3 Productivity and yield
The productivity is defined as the product of the optical purity of the solid product
and the ratio between the mass of solid product produced and the mass of the desired
enantiomer in feed solution fed into the crystallizing suspension per unit time. The
mass of the solid product produced is estimated as the difference between the mass
of dry solids harvested and the initial mass of the supplied seeds. The mass of the
desired enantiomer in the feed solution is estimated by the product of the density of
the feed solution, the volumetric flow rate of the feed inlet and the mass fraction of
the desired enantiomer in the feed solution.
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The solid product yield is in turn defined as the product of the optical purity and the
ratio between the mass of the solid product produced and the initial mass of seeds
supplied.
3.3.1.4 Optical purity
The optical purity of the solid product was determined quantitatively by polarimetry.
Solid samples were dissolved in water and the solutions were analyzed for optical
rotation and compared to the reference solutions of the pure enantiomer estimated
from a linear fit of the calibration curve. The optical purity was then calculated as the
ratio between the actual observed optical rotation of a solution of the solid product
with a certain concentration and the expected observed optical rotation of a solution
of the pure enantiomer with the same concentration. The procedure and calibration
data are provided in Appendix C.3.
3.4 Results and Discussion
Results of the crystallization process, namely crystallization temperature and optical
rotation of the liquid phase are now presented and discussed. Estimations of the liquid
phase compositions, supersaturation ratios, and growth rates of crystals are also given
and discussed. Moreover, the results obtained of the solid phase analysis in terms of
purity, productivity, and yield of solid products produced are evaluated.
3.4.1 Crystallization temperature and observed optical rota-
tion
Crystallization temperatures in the d- and l-Tank and the observed optical rotation
of the mother liquors are shown in Figure 3.3 for all three initial experiments.
Minor fluctuations in the crystallizer conditions are due to heat transfer limitations,
the efficiency of mixing in the crystallizers, and the placement of the thermocouple.
Nevertheless, under isothermal conditions the process performed with a reasonable
repeatability.
The reason for the selection of 19 ◦C as crystallization temperature in the present
investigation is that a crystallization temperature lower than the surrounding air tem-
perature enables natural heating of the liquid exchange streams and thereby avoid
the nucleation of the counter enantiomer in the tubing between the crystallizers. The
liquid exchange temperature achieved was about 23 ◦C, which is the saturation tem-
perature of the pure enantiomer66. Operating at crystallization temperature higher
than the temperature of the surroundings requires a heating system to avoid cooling
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Figure 3.3: Temperatures and observed optical rotations of the mother liquors in the
d- and l-Tank during preferential crystallization experiments. Error bars represent the
standard deviation. Where error bars cannot be seen, a standard deviation of zero was
found. The racemate has an optical rotation of zero. At time equal zero, enantiopure seeds
are introduced. The experimental conditions are provided in Table 3.1.
of the liquid exchange streams. Due to limited space, such a heating system was
problematic to implement.
The observed optical rotations over time indicate that the composition of the mother
liquor is nearly racemic because of values very close to zero.
3.4.2 Liquid phase concentration profiles of enantiomers
The estimated liquid phase concentrations of d-Asn and l-Asn in each tank as a func-
tion of time, calculated from the polarimetric and the liquid density measurements,
are shown in Figure 3.4.
As shown above by the observed optical rotation, the liquid phase composition is
nearly racemic and this is due to the crystal-free liquid exchange streams between
the two crystallizers. Furthermore, as shown in Figure 3.4 a nearly constant con-
centration of the preferred enantiomer in each crystallizer is achieved and that the
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Figure 3.4: Liquid phase concentrations of enantiomers in each tank as a function of time.
Error bars represent the standard deviation. At time equal zero, enantiopure seeds are
introduced.
concentration of enantiomers is the same as the concentration in the feed solution.
Because of the slow rate of surface integration, negligibly low consumption of the
desired enantiomer in each crystallizer occurs. It is thus expected that the crystalli-
zation driving force, i.e. supersaturation, and thereby the rate of crystal growth, is
constant for the desired enantiomer in each crystallizer and can be determined only
by knowing the concentration of the enantiomers in the feed solution.
3.4.3 Supersaturation and crystal growth
The estimated supersaturation ratio of the preferred enantiomer in each crystallizer
is given in Figure 3.5.
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Figure 3.5: Transient development in the supersaturation ratio for the preferred enantiomer
in each tank. At time equal zero, enantiopure seeds are introduced.
Indeed the crystallization driving force of the preferred enantiomer is almost constant
in the respective crystallizers. Obviously, there exists a slight difference in the su-
persaturation driving force of the crystallizing enantiomer which could be explained
by the difference in the morphology and the size of the enantiopure seed crystals
supplied21,69 and the minor fluctuations in the temperature of the crystallizing solu-
tions.
An inherent consequence of the above mentioned constant driving force is a constant
crystal growth rate of the enantiopure seeds in each tank throughout the duration
of the crystallization experiments. This is desirable because of the possibility for
improving the control of the purity and the particle size of the growing crystals.
3.4.4 Analysis of the solid product
A summary of the results of the analysis of the solid product produced in terms of
productivity, yield, and purity for the triplicate experiments (Exp 1-3) conducted and
the additional experiment (Exp 4) are listed in Table 3.2. Some statistics are given in
Table 4.1. With respect to the size and the mass of the seed crystals used in this study
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Table 3.2: Summary of the results of the productivity, yield, and purity of solid product produced in experiments Exp 1-3 in both d-Tank and
l-Tank and the additional experiment (Exp 4). Note the units.
Experiment Exp 1 Exp 2 Exp 3 Exp 4
Tank d l d l d l d l
Sieve fraction of seeds [µm] 250-355 250-355 250-355 250-355 250-355 250-355 150-250 150-250
Purity [%]∗ 100.0 93.4 100.0 92.2 100.0 93.9 100.0 100.0
Productivity [×10−4 g/(g min)]† 0.97 1.71 1.24 1.57 1.39 1.80 1.82 2.31
Yield [%]‡ 31.2 54.5 39.0 50.8 43.2 57.0 57.7 76.8
Fraction of solids produced [%]§ 23.8 36.8 28.1 35.5 30.2 37.2 36.6 43.4
∗ The optical purity is defined as the ratio between the actual observed optical rotation of a solution of the solid product with a certain concentration and the
expected observed optical rotation of a solution of the pure enantiomer with the same concentration.
† The productivity is defined as the product of the optical purity of the solid product and the ratio between the mass of solid product produced at the end of
experiment and the mass of the desired enantiomer in feed solution fed into the crystallizing suspension per unit time.
‡ The solid product yield is defined as the product of the optical purity and the ratio between the mass of the solid product produced and the initial mass of
seeds supplied.
§ The fraction of solids produced is defined as the ratio of the mass of solids produced by growth of seed crystals to the total mass of solids harvested (seeds
and solids produced) at the end of the experiment.
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(see Table 3.1), the selection was mainly based upon the amount of the seed crystals
of each enantiomer available for performing three identical experiments, taking into
account the increase in the risk of agglomeration and secondary nucleation caused by
attrition and breakage when using a large amount of seed crystals.
Table 3.3: Summary of some statistical results of the productivity, yield, and purity for
experiments Exp 1-3 in the d- and l-Tank. Note the units.
Tank d l
Purity [%] 100.0±0.0 93.9±2.0
Productivity [×10−4 g/(g min)] 1.20±0.21 1.69±0.12
Yield [%] 37.8±6.1 54.1±3.1
Fraction of solids produced [%] 27.4±3.3 36.5±0.9
SEM photomicrographs in Figure 3.6 show the difference in the growth of the seed
crystals in both the d- and l-Tank for the experiments Exp 1 and 3.
3.4.5 Productivity and yield
As shown in Table 3.2, the productivity and yield of solid product are low due to
the slow crystal growth controlled by low surface integration rates. However, slightly
higher values are obtained for the product from the l-Tank, in which l-AsnH2O
seed crystals were grown, compared to the d-Tank. This could be explained by the
difference in the morphology and the size of enantiopure seed crystals acquired21,69.
The enantiopure seed crystals of l-AsnH2O have a more random structure with many
irregularities compared to seeds of d-AsnH2O. These irregularities could be a result of
attrition and abrasion in the manufacturing process and the sieve analysis performed
prior to introduction to the crystallizing solution in the l-Tank. The stirring of the
crystallizing suspensions does not cause any attrition or breakage of the enantiopure
seed crystals introduced during the experiments performed. The rougher and irregular
morphology of the seed crystals of l-AsnH2O (Figure 3.6 (b)) allows for rapid and
more random crystal growth (Figure 3.6 (d) and (f)) compared to the more systematic
growth of seed crystals of d-AsnH2O (Figure 3.6 (a), (c), and (e)). The reason is the
higher number of nearest neighboring molecules accompanied with the irregular grow
sites such as kink sites on the seed crystals of l-AsnH2O, which promote rapid crystal
growth62.
The PSDs of the enantiopure seeds used in the experiments are shown in Figure 3.7.
The PSDs are plotted as dFv/dlog(dp) versus log dp in order to normalize the area
under the differential curve to 1 which make the PSDs comparable2. The seed crystals
50
Figure 3.6: SEM photomicrographs of the seeds of d-AsnH2O ((a)) and l-AsnH2O ((b))
and the final solid products showing the growth of the seed crystals of d-AsnH2O in the
d-Tank for experiments Exp 1 and 3 ((c) and (e)) and the growth of the seed crystals of
l-AsnH2O in the l-Tank for experiments Exp 1 and 3 ((d) and (f)). Note the scale of the
images.
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Figure 3.7: Normalized frequency functions of the PSDs for the enantiopure seeds of d-
and l-AsnH2O supplied in experiments Exp 1-3 (sieve fraction 250-355 µm) and Exp 4 (sieve
fraction 150-250 µm). Note the logarithmic scale on the abscissa.
of l-AsnH2O in both sieve fractions have a more narrow PSD with larger average
particle size compared to the seeds of d-AsnH2O. This could possibly be due to the
manufacturing of the respective seeds and the subsequent sieve fraction analysis. The
result is more uniform and larger seeds of l-AsnH2O. This means a larger surface
area available for the crystal growth of l-AsnH2O, which could contribute to the
higher yield and slightly higher productivity achieved in the l-AsnH2O in Exp 1-3.
Additionally, the seeds used in Exp 4 have a smaller average particle size compared
to the larger sieve fraction used in Exp 1-3 (Table 3.2). Thus, the higher yield and
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productivity in this case could be due to the larger surface area available for crystal
growth in the crystallizing solutions.
In the present study, the duration of the crystallization experiments of 90 minutes
was limited by the volume of the feed solution and the mean residence time of the
liquid phase in the crystallizers. A mean residence time of the liquid phase of 15
minutes was chosen to ensure that the flow rate of the crystal-free liquid exchange is
sufficiently high to obtain a racemic composition in the mother liquor in both crystal-
lizers, because identical crystallization kinetics of the monohydrate enantiomers are
assumed. The supersaturation ratio of the preferred enantiomer in each crystallizer
could be maintained constant (Figure 3.5) thereby obtaining a constant growth rate.
In this context, a longer duration could be realized by a longer mean residence time of
the liquid phase in order to improve the utilization of the mass of enantiomers in the
feed solution thereby improving the productivities and the yields of the solid product
in each crystallizer.
In Table 3.2 it is shown that the mass of seed crystals supplied comprises the major
fraction of the mass of solids harvested at the end of each experiment. Increasing
the mean residence time of the liquid phase could increase the fraction of the solids
produced of the total amount of the harvested solids.
3.4.6 Optical purity
The optical purity estimated is lower than the desired 100% for the solid product from
the l-Tank as listed in Table 3.2. The reason for the purity drop in the l-Tank could
be explained by the surface structure and size of the seed crystals at which surface
nucleation of the counter enantiomer could occur69. The rougher surface morphology
of the seed crystals of l-AsnH2O and the larger surface area available for growth of the
seeds of l-AsnH2O in the l-Tank could result in a relatively higher growth rate of the
seeds of l-AsnH2O (Figure 3.5) and thereby the observed purity drop in the l-Tank69.
The randomly oriented particles observed on the irregular locations on the surface of
the grown seed crystals of l-AsnH2O (Figure 3.6 (b), (d) and (f)) suggest the surface
nucleation of the counter enantiomer d-AsnH2O in the l-Tank. In contrast, due to the
more uniform and smoother surface structure of the smaller seed crystals of l-AsnH2O
supplied to the l-Tank in Exp 4, 100% purity was achieved. This fact could explain
the effect of the surface morphology of the seed crystals supplied on the purity of the
solid product achieved in the preferential crystallization experiments21,69. However,
it should be emphasized that in general the purity drop in preferential crystallization
is unavoidable due to the changes of the surface structure of the seed crystals during
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the crystallization process. The purity drop can be delayed by controlling the surface
morphology of the seed crystals and the process duration21,69.
To qualitatively assess whether the nucleation of the counter enantiomer d-AsnH2O
on the surface of the seed crystals of l-AsnH2O in the l-Tank occurred or not, STA
measurements were conducted. The thermograms from the STA measurements of
the solid products from Exp 1 are provided in Appendix D. The STA measurements
showed that the decomposition of d- and l-AsnH2O occurs simultaneously at about
215 ◦C. Therefore, it was not possible to distinguish between the racemate and the
pure enantiomer. However, a difference in the stage of the dehydration of crystal water
occurred, but it was not possible to confirm the presence of the counter enantiomer
d-AsnH2O. The reason is that the difference in the surface structure, crystallinity,
crystal defects due to grinding, aging etc. of the crystals in both pure form and the
solid products from the crystallization experiments allow for different dehydration
kinetics29,31.
3.4.7 Unutilized enantiomer in purge
From a simple steady-state total mass balance for both enantiomers for a control
volume of the CC-PC process, the fraction of unutilized enantiomer in the purge can
be estimated. It was found that the growth rate of the desired enantiomer is very
low at the given experimental conditions and therefore practically no consumption
of the enantiomer in the feed occurs in the crystallizer. As mentioned, this is due to
the nature of the controlling mechanism for crystal growth comprising slow surface
integration of the asparagine monohydrate molecules onto the surfaces of the supplied
seed crystals. Furthermore, rarely do all crystal faces have the same growth rate87
and therefore growth rate differences between the crystal faces of the growing seed
crystals could slow down the overall growth kinetics. Additionally, the inhibitory
effect of the presence of the counter enantiomer66, which is also supplied by the liquid
feed solution, could also contribute to lower the rate of surface integration.
To increase the separation potential of this particular chemical system, a modification
of the crystal surfaces of the seed crystals could alter the surface integration rates and
thereby enhancement of the crystal growth can potentially be realized21. Additionally,
a prohibitive long residence time (days), high crystallization temperature (evaporation
of water), or large amount of seed crystals (risk for agglomeration) would be required.
Therefore, it seems more beneficial to recycle the purge streams and to continuously
add seed crystals and remove solid product. In this respect, enantiopure seed crystals
of could be produced in a separate MSMPR crystallizer or by a technique called
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the impinging jet42. This approach could result in higher productivity and yield
due to the larger surface area of the continuously supplied seed crystals available for
growth. This fully continuous process, however, requires a substantial extension and
modification of the present setup and will be explored in a future investigation.
For other conglomerate forming chemical systems, with higher rates of crystallization,
the setup has great promise as a continuous separation unit.
3.5 Conclusions
In the present work, an experimental realization of the newly suggested continuous
preferential crystallization process has been performed using the conglomerate form-
ing system dl-asparagine monohydrate in water. It can be concluded that enantiosep-
aration by the continuous process developed is achievable and that the experiments
performed are repeatable. This confirms that the process is robust.
It has been proven that a nearly racemic composition is achieved throughout the du-
ration of the experiments taking into account the effects of morphological differences
in the initially supplied seed crystals. Furthermore, separate growth of the supplied
seed crystals of the desired enantiomer in each crystallizer was verified.
It can be concluded that reasonable productivities, yields, and purities are achieved,
taking into account the short process duration of 90 minutes and the morphological
differences in the enantiopure seeds supplied. The lower purity achieved for the solid
product from the l-Tank is ascribed to the surface nucleation of counter enantiomer
d-AsnH2O due to the morphology of the enantiopure seeds of l-AsnH2O. An increase
in the productivity, yield and purity can be achieved in the l-Tank for the same
duration time of 90 minutes only by using smaller particle size of enantiopure seeds
of both enantiomers with a smoother surface structure of the l-AsnH2O crystals.
The present continuous process has potential for further development into a fully
continuous process to increase the efficiency of enantioseparation for conglomerate
forming systems having slow growth rates controlled by surface integration. Further
work is therefore required to develop and implement proper solid feeding systems for
the continuous supply of enantiopure seeds, efficient downstream units necessary for
the continuous harvest of solid product, and effective recycle systems for the recycle
of the purge streams.
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Chapter 4
Separation of enantiomers by continuous pre-
ferential crystallization:
Mathematical modeling of a coupled crystal-
lizer configuration
In this chapter, a theoretical investigation of the lab-scale CC-PC process experi-
mentally investigated in chapter 3 is presented. A dynamic one-dimensional model
to describe the overall behavior of the CC-PC process was established, and model
validation against experimental data was conducted. Sensitivity analysis to improve
process understanding are presented and discussed together with the validity of the
assumptions made. The work will be submitted for publication in the journal Organic
Process Research and Development (Authors: Joussef Chaaban, Kim Dam-Johansen,
Tommy Skovby, and Søren Kiil). The program developed to solve the model discussed
was written in MATLAB R2009b, and consists of three separate m-files.
Abstract
A mathematical model describing the continuous separation of enantiomers by simul-
taneous preferential crystallization in a coupled crystallizer configuration is developed.
The model was validated against experimental data for a chemical model compound,
the conglomerate forming system of asparagine monohydrate in water. The kinetic
parameters required were taken from available literature sources and simulations com-
pared to experimental data. Simulations were found to be in good agreement with
experimental data. Additional model simulations suggest that the separation process
can be improved by increasing the mean residence time of the liquid phase in the crys-
tallizers, the crystallization temperature, and the mass of seeds supplied. Reducing
the size of seed crystals will also lead to a better separation. The model can be used
to simulate the performance of the continuous crystallization process for a racemic
compound forming system. The racemic compound and the pure enantiomer can be
separated simultaneously in each crystallizer having sufficient enrichment of the pure
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enantiomer in the feed solution. The model can also be extended to represent a fully
continuous separation process taking into account the continuous supply of enantiop-
ure seed crystals and liquid feed solution and the continuous removal of solid product
and mother liquor.
4.1 Introduction
Racemic mixtures, i.e. conglomerates and racemic compounds, comprise a substantial
fraction of chiral active ingredients in the pharmaceutical, agrochemical, food, and
cosmetic industries13,79. Usually, the desired biological activity and physiological
effect of the enantiomers are ascribed to only one of the two enantiomers. Thus, 50%
of a racemic mixture can be considered as an impurity thereby providing the active
enantiomer with undesirable side effects9,48.
Strict regulatory requirements for the production of chiral active ingredients in opti-
cally pure form have resulted in strong efforts being put into the development of enan-
tioselective separation technologies13,80. The major fraction of chiral compounds and
their intermediates must be produced as highly pure solids, and therefore preferential
crystallization, in particular, has attracted great attention and is successfully applied
for the separation of enantiomers from conglomerate forming systems14,54,67,91.
An interesting development in preferential crystallization technologies is the Coupled-
Batch Preferential Crystallization (CB-PC) process19,21,66. This process consists of
two batch crystallizers in which the simultaneous crystallization of each enantiomer
occurs in a separate crystallizer. The crystallizers are physically coupled via crystal-
free liquid exchange streams, thereby maintaining a nearly racemic composition of
the mother liquors in the crystallizers. A critical parameter is the flow rate of the
exchange streams which is strongly dependent on the crystallization kinetics of the
compounds and must be carefully selected. In the case of enantiomers, the crystalli-
zation kinetics of the two molecules can be assumed identical. Therefore, to ensure a
nearly racemic composition in the mother liquors and thereby avoid crystallization of
the undesired enantiomer, the exchange flow rates should be set as high as practically
possible19.
A thorough modeling and simulation study, followed by experimental validation of
some parameters influencing the performance of the CB-PC process, using the con-
glomerate forming system of the amino acid threonine in water was performed by
Elsner et al.19,21. This study showed that productivity can be improved by manipu-
lating critical process parameters such as initial enantiomeric excess in crystallizing
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solutions, flow rate of crystal-free liquid exchange between crystallizers, switching
time for initiating liquid exchange, mass of seeds supplied, crystallization tempera-
ture profile (isothermal or polythermal), and process duration19,21. Due to the slow
surface integration rate of the preferred enantiomer on the seed crystals, the authors
could demonstrate that simultaneous crystal growth of the preferred enantiomers in
each crystallizer could successfully be carried out even though the extent of separa-
tion, and thereby the productivities, were negligible21.
4.1.1 Continuous Coupled Preferential Crystallization
A further step in the development of preferential crystallization processes is the newly
developed continuous coupled preferential crystallization (CC-PC) process11. The
continuous setup is a modification of the coupled batch process. In this extended
configuration, two feed streams, consisting of undersaturated racemic solution, one to
each crystallizer, and two purge streams, taken from the crystal-free liquid exchange
streams, to maintain constant volumes in the crystallizers are employed. The process
is continuous with respect to the liquid phase and, at least in this first investigation,
batch for the solid phase11. In this respect, steady-state in the liquid phase in each
crystallizer can be achieved when the growth rate becomes very close to the rate of
accumulation of the preferred enantiomer.
The CC-PC process is applicable for conglomerate forming systems, i.e. a physical
mixture of equal amount of solid enantiomers, where the enantiomers are separated
simultaneously (one in each crystallizer) by seeding. Enrichment of initial racemic
solution, which would be required for a racemic compound (’true’ racemate), is not
necessary. An essential requirement, allowing for separation of the enantiomers, is
a sufficiently higher solubility of the racemate compared to that of the pure enan-
tiomers.
An experimental realization of the CC-PC process for the separation of asparagine
monohydrate enantiomers, d-asparagine monohydrate (d-AsnH2O) and l-asparagine
monohydrate (l-AsnH2O), using seeded cooling crystallization at isothermal condi-
tions, was performed in Chaaban et al.11. In that work, it was found that the CC-PC
process was suitable for enantioseparation without the undesired nucleation of the
counter enantiomer. The crystallization driving force, i.e. supersaturation, could be
maintained at a constant value throughout the process duration, ensuring constant
growth rate of seed crystals and thereby improved productivity, yield, and purity of
the final solid product.
In the present study, a transient mathematical model of the CC-PC process is set up
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and solved. The objective is to investigate the influence of critical process parameters
on the performance of the CC-PC process. Parameters considered are productivity,
solid product yield (based on mass of enantiomer present in the feed solution), yield
of solid product (based on mass of enantiopure seeds supplied), and the yield of
crystal size, i.e. additional size of the growing seed crystals gained by crystal growth.
Moreover, the optimal operation conditions are suggested. Simulations are validated
against experimental data of the conglomerate forming system of the amino acid
asparagine monohydrate in water as solvent11.
4.2 Description of the continuous setup
The CC-PC process considered is shown schematically in Figure 4.1.
Figure 4.1: Schematic illustration of the CC-PC process for the separation of enantiomers
using the conglomerate forming system of asparagine monohydrate. TF symbolizes the
temperature in the feed tank, T1 is the crystallization temperature in the d-Tank, T2
is the crystallization temperature in l-Tank, Blue and red filled circles symbolize growing
enantiopure seeds of d-asparagine monohydrate (d-AsnH2O) and l-asparagine monohydrate
(l-AsnH2O) in the d- and l-Tank, respectively. The filters (grey boxes) in the d- and l-Tank
are used to retain solids.
The preferential crystallization of the asparagine monohydrate enantiomers begins
with the cooling of the aqueous racemic solutions present in each crystallizer to bring
them into the metastable zone. The racemic feed solution of the conglomerate mono-
hydrate enantiomers dissolved in water is supplied continuously to the crystallizers
at a higher temperature. When the crystallization temperature is reached in the
crystallizers, enantiopure seeds of the monohydrate enantiomers are supplied to each
crystallizer. Thus, crystal growth of the d- and l-AsnH2O seeds occurs in the d- and
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d-Tank, respectively, at isothermal conditions with identical crystallization tempera-
tures in both crystallizers (i.e. T1 = T2). The crystal-free liquid exchange streams
between the crystallizers are initiated and mother liquor is transferred via a filter
to the opposite crystallizer to obtain a nearly racemic composition in the mother
liquors. To maintain a constant suspension volume in each crystallizer, mother liquor
is withdrawn from the liquid exchange streams from the crystallizers and transferred
to the purge tanks.
4.3 Mathematical modeling
In this section, the assumptions underlying the mathematical model are first pre-
sented. Then follows the development of the mathematical model.
• The crystallizers are considered ideally mixed.
• The operation of the two crystallizers is isothermal.
• Residence times and volumes of the liquid phase in the crystallizers are identical.
• No crystals are withdrawn or fed to the crystallizers. Only initial seeding is
used.
• Nucleation of enantiomers, crystal breakage, attrition, and agglomeration are
neglected. Only growth on the initially supplied seed crystals takes place.
• Secondary nucleation of the seeded enantiomer, caused by the presence of the
seed crystals in the crystallizing suspension, is neglected in accordance with
Petrusˇevska-Seebach et al.66.
• Crystal growth inhibition by the presence of the counter enantiomer is neglected.
• Crystallization kinetics, i.e. nucleation and growth kinetics, of the enantiomers
are supposed to be identical.
• The overall growth rate of the seed crystals is independent of size66 and mor-
phology of the seeds and thereby time.
• The overall growth rate is controlled by surface integration kinetics as suggested
by Petrusˇevska-Seebach et al.66.
• The size-independent crystal growth is assumed to be governed by McCabe ∆L
law70.
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The validity of the above assumptions, and some additional ones to be made during
the model development below, is assessed after model validation of the CC-PC pro-
cess with experimental data has taken place. The mathematical model can now be
developed by considering each crystallizer as a control volume.
4.3.1 Model development
4.3.1.1 Crystal population balance
During the crystallization process, only growth of the enantiopure seeds occurs in
each crystallizer. The crystal population balance equation (PBE) for the preferred
enantiomer in each crystallizer becomes70:
∂n
(p)
i (t, L)
∂t
= −G(p)i (t)
∂
∂L
n
(p)
i (t, L) , i ∈ {1, 2} (4.1)
with the boundary condition:
n
(p)
i (t, L = 0) = 0 (4.2)
The initial condition is:
n
(p)
i (t = 0, L) = n
(p)
seeds,i (L) (4.3)
n
(p)
seeds,i (L) is the initial number distribution of the seed crystals, which is directly
linked to the mass of enantiopure seeds of the preferred enantiomer supplied into the
crystallizer per unit volume of suspension:
m
(p)
seeds,i = kvρS
∫ ∞
L=0
L3n
(p)
seeds,i (L) dL (4.4)
4.3.1.2 Crystal growth kinetics
The linear overall growth rate, G(p)i , can be described by a power-law growth rate
model expressing the relation between supersaturation ratio of the preferred enan-
tiomer and crystal growth62:
G
(p)
i (t) = kg,i (Ti)
(
S
(p)
i (t)− 1
)α
, i ∈ {1, 2} (4.5)
The temperature-dependent rate constant for the surface integration controlled crys-
tal growth, kg,i, can be expressed by an Arrhenius equation62:
kg,i (Ti) = k0,i exp−Ea,g
RTi
(4.6)
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4.3.1.3 Supersaturation ratio
The supersaturation ratio of the preferred, p, enantiomer as well as the counter, c,
enantiomer, S(k)i , in each crystallizer can be expressed as62:
S
(k)
i (t) =
wki (t)
wkeq,i (t)
, k ∈ {p, c} (4.7)
where w(k)i is the mass fraction of enantiomer k and w
(k)
eq,i is the solubility mass fraction
of enantiomer k at the crystallization temperature.
4.3.1.4 Concentration of enantiomers
The mass fraction of the enantiomers in each crystallizer, w(k)i , is expressed as:
wki (t) =
m
(k)
i (t)∑
(k)m
(k)
i (t) +m
sol
i
, k ∈ {p, c} (4.8)
where m(k)i is the mass of dissolved enantiomer k and msoli is the mass of solvent at
the crystallization temperature.
4.3.1.5 Liquid phase mass balance for the preferred enantiomer
The liquid phase mass balance of the preferred enantiomer includes the consumption
from the continuous phase leading to deposition on the surfaces of the enantiopure
seed crystals resulting in crystal growth and the mass flow rates of the inlet and outlet
streams:
dm(p)i (t)
dt
= m˙
(p)
F,i + m˙
(p)
j−i (t)− m˙(p)E,i (t)− m˙(p)g,i (t) , i ∈ {1, 2} 6= j ∈ {1, 2} (4.9)
where m(p)i is the mass of enantiomer p in crystallizer i, m˙
(p)
F,i is the mass flow rate
of the feed inlet into the crystallizer, m˙(p)j−i is the crystal-free liquid exchange from
crystallizer j to crystallizer i and m˙(p)E,i is the crystal-free eﬄuent mass flow rate from
the crystallizer. It should be emphasized that the liquid mass flow rates are expressed
as the product of the volumetric flow rate of solution, the density of the solution at
the actual temperature and concentration, and the mass fraction of the preferred
enantiomer in the solution.
The rate of the mass of solids produced by crystal growth, m˙(p)g,i (t), is given by70:
m˙
(p)
g,i (t) = 3ρSkvG
(p)
i (t)A
(p)
i (t)Vi (4.10)
Equation (4.10) is derived based on the assumption that the overall growth rate is
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linear, i.e. the growth rate is the same along the same characteristic dimension of all
crystals, and a size-independent growth rate62,70.
Regarding the liquid phase mass balance for the preferred enantiomer, the initial
condition in the crystallizers is the initial mass of the preferred enantiomer in solu-
tion:
m
(p)
i (t = 0) = m
(p)
0,i (4.11)
4.3.1.6 Liquid phase mass balance for the counter enantiomer
Since it is assumed that neither nucleation nor growth of the counter enantiomer
occurs, the liquid phase component mass balance of the counter enantiomer in each
crystallizer includes only the terms relating the mass flow rates of the inlet and outlet
flows:
dm(c)i (t)
dt
= m˙
(c)
F,i + m˙
(c)
j−i (t)− m˙(c)E,i (t) , i ∈ {1, 2} 6= j ∈ {1, 2} (4.12)
where i 6= j.
The initial condition for the mass balance in (4.12) is given by the initial mass of the
counter enantiomer in solution:
m
(c)
i (t = 0) = m
(c)
0,i (4.13)
4.3.1.7 Feed flow rates
In the above mentioned mass balances, the feed mass flow rate of enantiomer into
each crystallizer is given as a function of the fraction of the feed solution entering the
crystallizer. For i = 1:
m˙
(k)
F,1 = δm˙
(k)
F (4.14)
and for i = 2:
m˙
(k)
F,2 = (1− δ) m˙(k)F (4.15)
It should be emphasized that the flow rate of the racemic feed solution is assumed
constant and therefore is only a function of the temperature of the feed.
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4.3.1.8 Crystal-free liquid exchange flow rate
The mass flow rate of the crystal-free liquid exchange between the crystallizers is
given as:
m˙
(k)
j−i (t) = m˙
(k)
E,j (t)− m˙(k)P,j (t) (4.16)
where i 6= j. It should be noted that the volumetric flow rate of the purge streams is
equal to the volumetric flow rate of the feed solution entering the respective crystal-
lizer. This is based on the assumption that changes in the volume of the suspension
in the crystallizer, due to the crystallization reaction, are negligible.
4.3.1.9 Eﬄuent flow rate
The eﬄuent mass flow rate of enantiomer from the crystallizers is given as a function
of the concentration of enantiomer in the liquid phase in each crystallizer:
m˙
(k)
E,i (t) =
Vi
τi
ρL,i (Ti, wi)w
(k)i (t) (4.17)
4.3.2 Process metrics
4.3.2.1 Separation efficiency: U -value
To assess the efficiency of the CC-PC process, the ratio between the total concentra-
tion of the preferred enantiomer in the purge streams and the total concentration of
the preferred enantiomer in the feed solution entering the crystallizers, calculated by
a steady-state mass balance, is considered at time t. The ratio is denoted the U -value
and is expressed as:
U − value (t) = w
(p)
i (t) + w
(p)
j (t)
w
(p)
F,i + w
(p)
F,j
× 100%, i ∈ {1, 2} 6= j ∈ {1, 2} (4.18)
4.3.2.2 Yield based on feed solution
The yield, based on the feed solution, provides a measure of the amount of enantiomer
supplied from the liquid feed solution which is produced as solid material deposited
on the seed crystals supplied in each crystallizer. The yield is given as the ratio
between the accumulated mass of the solid product produced at the end of the process
duration, tf , and the total mass of the enantiomer fed into the crystallizer:
Y
(p)
L,i (tf ) =
m
(p)
g,i
m
(p)
F,i
× 100% (4.19)
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4.3.2.3 Productivity and yield based on seeds
The productivity from the simulations of the preferred enantiomer in each crystallizer
at the end of the process duration is estimated as the ratio between the accumulated
mass of the solid product produced and the product of the total mass of enantiomer
fed into the crystallizer and the duration of the process, tf :
Pr(p)i (tf ) =
m
(p)
g,i
m
(p)
F,itf
(4.20)
Similarly, the yield of the solid product of the preferred enantiomer produced in each
crystallizer at the end of the duration of the process, tf , is defined as the ratio between
the accumulated mass of solid product produced and the mass of the enantiopure seeds
initially supplied to the crystallizer:
Y
(p)
S,i (tf ) =
m
(p)
g,i
m
(p)
seeds,i
× 100% (4.21)
4.3.2.4 Crystal size yield
The simulations of the CC-PC process are also evaluated by the gain in the average
size of the solid product. This is defined as the ratio between the average size of
the final solid product and the sum of the average size of the initially supplied seed
crystals and the average size of the final solid product produced at the end of the
process duration, tf :
Y
(p)
i (tf ) =
L
(p)
av,i
L
(p)
av,i + L
(p)
seeds,i
× 100% (4.22)
4.4 Numerical solution procedure
The coupled partial differential equation system and the liquid phase mass balances
are solved using the method of moments (MOM) according to Randolph and Larson70.
This transformation method of the PBE is useful to obtain average quantities of the
particle size distribution of the final solid product. The reason for the selection of
the method of moments is the lack of knowledge of the Particle Size Distribution
(PSD) of the harvested solid product due to the insufficient quantity of the solid
product harvested at the end of each experiment11. Furthermore, in most industrial
applications the representation of the PSD is sufficiently obtained by some average
or total quantities70.
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Using integration by parts, the following general expression is obtained for the mo-
ments of the number density function of the crystal population of the preferred enan-
tiomer in the crystallizing suspension70:
dN (p)x,i (t)
dt
= xN
(p)
x−1,i (t)G
(p)
i (t) (4.23)
where the moments are expressed as70:
N
(p)
x,i (t) =
∫ ∞
L=0
Lxn
(p)
i (t, L) dL (4.24)
The first four moments of the population balance, i.e. x ∈ {0, 1, 2, 3} , for the
preferred enantiomer in each crystallizer are derived:
dN (p)0,i (t)
dt
= 0 (4.25)
dN (p)1,i (t)
dt
= N
(p)
0,i (t)G
(p)
i (t) (4.26)
dN (p)2,i (t)
dt
= 2N
(p)
1,i (t)G
(p)
i (t) (4.27)
dN (p)3,i (t)
dt
= 3N
(p)
2,i (t)G
(p)
i (t) (4.28)
The derivation of the moments is provided in Appendix E. The first four moments
of the PBE result in coupled ordinary differential equations (ODEs) together with
the liquid phase mass balances. The systems of the ODEs are solved using the built-
in ode45 function in MATLAB (The Mathworks Inc., Natick, USA). The necessary
MATLAB scripts are provided in Appendix F. The model is capable of describing
the transient change in the concentrations of the enantiomers in the mother liquor in
each crystallizer. Furthermore, the transient change in the moments representing the
particle size distribution of the crystal population of the preferred enantiomer in each
crystallizer is also obtained from the model. The purpose of the model is to provide
a suitable tool for the estimation of critical process parameters to enable the sepa-
ration of conglomerate forming enantiomers by the CC-PC process without the loss
in productivity and yield due to crystallization of the counter enantiomer. Moreover,
the model can be used to elucidate effects of changes in the crystallization kinetics
on the progress of the separation process to be used for optimization studies.
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4.5 Estimation of physical and chemical parameters
A number of chemical and physical parameters for the asparagine monohydrate enan-
tiomers and data for the crystallization kinetics of the conglomerate forming system
of asparagine monohydrate in water are required in the model. Some of these were es-
timated by Petrusˇevska-Seebach et al.66. The parameters are listed in Table 4.2.
4.5.1 Physical constants
The solid density was taken from Haynes35 and the volume shape factor and the
area shape factor were taken from Myerson62 based on the observation by SEM of
the enantiopure seed crystals and the solid product harvested at the end of each
experiment11.
4.5.2 Solubility concentration of enantiomer
The equilibrium mass fraction, describing the solubility of l-AsnH2O in water at
crystallization temperature, wl-Asneq,i , is experimentally determined and is expressed
as a function of the concentration of the counter enantiomer d-Asn, wd-Asni , in the
crystallizer66:
wl-Asneq,i (t) = 0.0092 exp 0.0443 (Ti − 273.15) + 0.030482wd-Asni (t) (4.29)
where i ∈ {1, 2}. Equation (4.29) is assumed to be valid also for d-AsnH2O in
water.
4.5.3 Density of the liquid phase
The density of the liquid phase in the crystallizers, ρL,i, can be expressed by the
following empirical correlation66:
ρL,i (Ti, wi) =
1
0.9999 + 4.911× 10−6 (Ti − 273.15)2
+ 0.3572wi (t) (4.30)
Note that equation (4.30) takes into account the dependence of the liquid density on
the temperature of the solution and the total concentration of the enantiomers in the
solution.
4.5.4 Parameters for growth kinetics
The pre-exponential factor included in the Arrhenius expression for the overall growth
rate constant, k0,i, is estimated by fitting the model to the progress curves of the
concentration of the dissolved enantiomers in the mother liquor obtained from the
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three experiments for continuous preferential crystallization11.
The activation energy for crystal growth and the order of crystal growth used are
estimated by Petrusˇevska-Seebach et. al66. The values obtained imply that the mech-
anism for the control of crystal growth is predominantly surface integration61.
The remaining parameters were taken from the experimental conditions for the exper-
imental realization of the CC-PC process11. These parameters are adjustable and are
investigated in the sensitivity analysis subsequent to model validation in the present
study.
4.6 Results and discussion
4.6.1 Model validation using the data of Chaaban et al.11
The validation of the dynamic model for the continuous preferential crystallization
of the asparagine monohydrate enantiomers, denoted d-AsnH2O and l-AsnH2O, is
performed using the experimental data from the liquid and solid phase analyses of
triplicate experiments carried out and presented in Chaaban et al.11. Initially, the
input parameters listed in Table 4.2 are used. The validity of some of these parameters
is also investigated subsequent to validation of the model.
4.6.1.1 Productivity and yield
A summary of the simulation and experimental results of the productivity and the
accumulated yield of the solid product obtained are listed in Table 4.1.
Table 4.1: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, and the yield in crystal size from the
d- and l-Tank obtained by the simulation and experimental data11, YS and Y. Note the
units. Standard deviations for the experimental results are also given.
Experimental Simulation
Tank d l d l
U -value [%] 100.0±1.8 100.4±2.1 100.2 100.0
YL [%] 1.08±0.19 1.52±0.11 1.08 1.52
Pr [×10−4 g/(g min)] 1.20±2.10 1.69±0.12 1.17 1.65
YS [%] 37.79±6.12 54.08±3.07 37.79 54.09
Y [%]∗ N/A N/A 51.35 51.85
∗ Not experimentally determined due to insufficient sample size for PSD measurements.
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Table 4.2: Physical and chemical parameter values required for the mathematical model.
Parameters Symbol Value Unit
Physical constants
Density of AsnH2O crystal35† ρS 1533 kg/m3
Volume shape factor kv 2 -
Area shape factor ka 10 -
Universal gas constant R 8.3145×10−3 kJ/(mol K)
Process variables
Crystallization temperature‡ Tcryst 19 ◦C
Liquid volume in crystallizers V 220 mL
Mean residence time of liquid phase in crystallizers τ 15 min
Fraction of feed solution inlet δ 0.5 -
Mass of seeds of preferred enantiomer in d-Tank m(p)seeds,1 0.4642 g
Mass of seeds of preferred enantiomer in l-Tank m(p)seeds,2 0.4641 g
Initial sieve fraction of seeds in crystallizers - 250-355 µm
Feed inlet temperature TF 27 ◦C
Conc. of d-Asn in feed solution into d-Tank§ wd-AsnF,1 2.4282 wt%
Conc. of l-Asn in feed solution into d-Tank¶ wl-AsnF,1 2.4607 wt%
(continued)
† Average of solid density of d- and d-AsnH2O at 15 ◦C35.
‡ Crystallization temperature in both crystallizers, i.e. Tcryst = T1 = T2.
§ Average concentrations in the feed solution estimated by polarimetric analysis of feed samples for the three experiments performed11.
¶ Average concentrations in the feed solution estimated by polarimetric analysis of feed samples for the three experiments performed11.
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Table 4.2 – (Continued)
Parameters Symbol Value Unit
Conc. of d-Asn in feed solution into l-Tank‖ wd-AsnF,2 2.4282 wt%
Conc. of l-Asn in feed solution into l-Tank∗∗ wl-AsnF,2 2.4607 wt%
Process duration tf 90 min
Parameters for growth kinetics
Pre-exponential factor for growth rate of d-AsnH2O k0,1 19.50 m/s
Pre-exponential factor for growth rate of l-AsnH2O k0,2 23.78 m/s
Activation energy for crystal growth66 Ea,g 49.1 kJ/mol
Order of crystal growth66 α 1 -
‖ Average concentrations in the feed solution estimated by polarimetric analysis of feed samples for the three experiments performed11.
∗∗ Average concentrations in the feed solution estimated by polarimetric analysis of feed samples for the three experiments performed11.
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The values of the process outputs obtained from the simulation are in good agreement
with the experimental results. The pre-exponential factors, k0,1 and k0,2, used for
estimation of the growth rates of the enantiomer monohydrates, were adjusted to
fit simultaneously simulations of the productivity, yield of solids produced, and the
transient liquid phase concentration curves for the enantiomers. The values of the
pre-exponential factors are given in Table 4.2.
Using equation (4.6), the growth rate constant, kg,i (Ti), can be estimated. In the
present study, the growth rate constant is calculated to 0.325×10−7 m/s in the d-
Tank and 0.396×10−7 m/s in the l-Tank, both at 19 ◦C. A very small difference
between the growth rate constants was found. This difference may be ascribed to the
difference in the surface structure, the size of the growing seed crystals, and the type
of crystallization process, which are all lumped into the pre-exponential factor.
The pre-exponential factor for crystal growth of l-AsnH2O was estimated to 67.53
m/s at 30 ◦C by Petrusˇevska-Seebach et. al66. Using this value, the calculation
of the growth rate of l-AsnH2O at the crystallization temperature of 19 ◦C gives
1.12×10−7 m/s, which is about 65 % higher than the value obtained in the present
study. This may be ascribed to the difference in the surface structure and initial
size of the seed crystals used. The sensitivity of the model to changes in the pre-
exponential factors and the crystallization temperature is investigated and presented
later in this study.
4.6.1.2 Concentration of enantiomers
In Figure 4.2, a comparison of simulations and experimental data for the mass frac-
tions of d- and l-Asn in the d- and l-Tank are shown. The comparison shows a
reasonable good agreement for the mass fractions of dissolved enantiomers in the
crystallizing suspensions. Simulations also show that the composition in the mother
liquors is nearly racemic.
Simulations in Figure 4.2 also suggest that the concentration of the counter enan-
tiomer increases slightly, but this effect is within the standard deviation of the exper-
imental data. The concentration of the preferred enantiomer in the d- and l-Tank is
maintained nearly constant and is within the standard deviation of the experimental
data. Steady-state concentrations of the preferred enantiomer and the counter enan-
tiomer in the liquid phase in each crystallizer are obtained after about 60 minutes
corresponding to four residence times.
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Figure 4.2: Comparison of model simulations (solid lines) with experimental data for
the mass fractions of d- and l-Asn in the d-Tank (left) and the l-Tank (right) (symbols).
Error bars for experimental data are also shown. At time equals zero seeding is performed.
Conditions are the same as in Table 4.2.
4.6.1.3 Supersaturation and crystal growth
Comparison of experimental data and simulations of the supersaturation ratios of the
crystallizing enantiomer of d-Asn in the d-Tank and l-Asn in the l-Tank and the
mass growth rate of the preferred enantiomer are shown in Figure 4.3.
Simulations of the supersaturation ratio of the preferred enantiomer in each crystal-
lizer are in reasonable agreement with the experimental data. Moreover, the tendency
in the progress of the simulation is identical to that of the mass fraction of the pre-
ferred enantiomer in each crystallizer shown in Figure 4.3. This is a consequence
of the dependency of the supersaturation ratio on the actual concentration of the
preferred enantiomer.
In Figure 4.3, a comparison of model simulations with experimental data for the
mass growth rates of the preferred enantiomer in each crystallizer shows reasonable
agreement between the experimentally estimated growth rates and simulations. It is
also seen that the mass growth rate of d-AsnH2O estimated by simulations in the
d-Tank is lower when compared to the growth rate of l-AsnH2O in the l-Tank. The
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Figure 4.3: Comparison of model simulations (solid lines) with experimental data for the
supersaturation ratios and the mass growth rates of the preferred enantiomer in the d-Tank
(top) and the l-Tank (bottom) (symbols). Error bars for experimental data are also shown.
At time equals zero seeding is performed. Conditions are the same as given in Table 4.2.
reasons for this difference are the different growth rate constants and the different
overall surface area of the initially supplied seed crystals.
4.6.2 Sensitivity analysis
A sensitivity analysis is performed to investigate the effect of the different process
variables and kinetic constants on the overall process performance, thereby searching
for the most optimal conditions for the separation of asparagine monohydrate enan-
tiomers by the CC-PC process. It should be emphasized that the simulations are
performed assuming that the crystallizers are operated at identical conditions and
only one parameter is changed at a time while all the remaining parameters are kept
the same as given in Table 4.2 or as indicated in the text. Steady-state mass balance
check of the simulation outputs was performed, where ever it is possible, to ensure
the predictability of the model.
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4.6.2.1 Mean residence time of the liquid phase
The mean residence time of the liquid phase in the crystallizers is varied between 15
(base case) and 60 minutes. The concentration of the enantiomers in the liquid phase
for the simulations is given in Figure 4.4.
Figure 4.4: Model simulations of the concentration of enantiomers in the d-Tank (left)
and the l-Tank (right) for the mean residence time of the liquid phase, τ , between 15 (base
case) and 60 minutes. The remaining process parameters are the same as given in Table 4.2.
At time equals zero seeding is performed. Note the difference in the scale of the abscissa.
For a mean residence time of the liquid phase of 15 minutes, the concentration of
the preferred enantiomer increases indicating an accumulation of the enantiomer in
the liquid phase caused by slow surface integration compared to the rate of supply
of the preferred enantiomer into the crystallizers. For l-Asn in the l-Tank, the
concentration decreases slightly in the beginning, but increases again. This may be
due to the initial rapid growth of l-AsnH2O seed crystals due to the initially higher
supersaturation of l-Asn. At higher mean residence times, the concentration of the
preferred enantiomer decreases more rapidly. This decrease is more pronounced in
the first 50 minutes and begins to level out. The rapid decrease indicates an increase
in the consumption of the preferred enantiomer in the crystallizing suspension due
to sufficient time for the enantiomer species to integrate into the surface of the seed
crystals and thereby improve the separation performance of the process.
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Correspondingly, the concentration of the counter enantiomer is higher than the pre-
ferred enantiomer and decreases as the mean residence time in the liquid phase in-
creases. This is due to the decrease of the concentration of the counter enantiomer
in the opposite crystallizer in which this counter enantiomer is consumed for crystal
growth of the seed crystals. This is exactly the desired effect of the coupled crystal-
lizer configuration. Overall, however, the concentrations do not vary much with the
residence time.
To evaluate the performance of the process, a summary of the estimated process
metrics are listed in Table 4.3.
Table 4.3: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y,
from the d- and l-Tank obtained by the simulations for changing the mean residence time,
τ , between 15 (base case) and 60 minutes. Note the units.
15 min 30 min 45 min 60 min
Tank d l d l d l d l
tf [min] 90 90 180 180 270 270 360 360
U -value [%] 100.2 100.0 99.71 99.31 99.24 98.66 98.80 98.06
YL [%] 1.08 1.52 2.18 3.10 3.27 4.61 4.2 5.97
Pr [×10−4 g/(g min)] 1.17 1.65 1.19 1.68 1.18 1.67 1.21 1.69
YS [%] 37.79 54.09 76.73 110.4 114.8 164.2 150.7 212.9
Y [%] 51.35 51.85 52.49 53.35 53.46 54.56 54.29 55.54
From Table 4.3 it can be seen that the overall separation performance of the CC-PC
process is improved compared to the base case at τ = 15 min. This improvement can
be ascribed to the fact the duration of the process becomes longer which gives more
time for the crystallizing species to integrate into the surface of the seed crystals
thereby resulting in increased yields. The U -value, however, has changed slightly
due to a very slow consumption ascribed to the slow surface integration on the seed
crystals. In contrast, the productivity decreases slightly, which is an inherent effect
of the longer duration of the process.
4.6.2.2 Excess of enantiomer in feed solution
Sometimes preferential crystallization processes for the separation of enantiomers are
carried out with an initial enantiomeric excess of the preferred enantiomer. The
achievement of the desired enantiomeric excess (ee) leads to additional cost for which
a higher productivity should compensate. In Figure 4.5, enantiomeric excess of the
d-Asn is considered and the enantiomeric excess is varied between zero and 6% for
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the same duration as the base case, i.e. 90 minutes. It should be emphasized that
the concentration of enantiomers in the feed solution is changed to 2.5 wt% of d- and
l-Asn compared to the values given in Table 4.2, i.e. the base case corresponding to
eeD = 0, to obtain a clearer picture of the effects of the enantiomeric excess.
Figure 4.5: Model simulations of the concentration of enantiomers in the d-Tank (left) and
the l-Tank (right) for the enantiomeric excess of d-Asn, eeD, of 0 (base case) to 6%. The
concentration of the enantiomer in the feed solution is changed to 2.5 wt%. The remaining
process parameters are the same as given in Table 4.2. At time equals zero seeding is
performed. Note the difference in the scale of the abscissa.
The increase in the enantiomeric excess of the d-Asn has a negligible effect on the
liquid phase composition in both crystallizers. However, a slight decrease in the
concentration of d-Asn is observed due to the slow surface integration on the seed
crystals and is independent on the enantiomeric excess. The concentration of l-
Asn is decreasing in the l-Tank, in which it is consumed for crystals growth, and
is increasing in the d-Tank as expected. The change in the concentration of l-Asn
in the liquid phase in each crystallizer is, however, very small as indicated by the
very small scaling of the abscissa in Figure 4.5. Increasing the enantiomeric excess of
d-Asn in the liquid phase increases the solubility concentration of the l-Asn as given
in equation (4.29). The supersaturation ratio, i.e. the crystallization driving force,
decreases for the increase in the ee of d-Asn. Therefore, the concentration of l-Asn in
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the crystallizers increases. Additionally, the increase in the ee of d-Asn also increases
the density of the feed solution as given in equation (4.30) when the feed temperature
and total concentration of the enantiomers are considered. This results in a higher
mass flow rate of the enantiomers in to and out of the crystallizers. Note that the
liquid phase concentration of d-Asn in the d- and l-Tank reaches constant value
after about two residence times, i.e. after about 30 minutes of operation. In contrast,
the concentration of l-Asn in the d-Tank reaches constant value after about four
residence times, i.e. after about 60 minutes of operation. This effect can be explained
by the mentioned dependence of the solubility of l-AsnH2O on the concentration of
d-Asn in the liquid phase.
Table 4.4: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y,
from the d- and l-Tank obtained by the simulations for an enantiomeric excess of d-Asn,
eeD, between zero (base case) and 6%. Note the units.
0% 2% 4% 6%
Tank d l d l d l d l
U -value [%] 100.1 100.0 99.9 100.0 99.7 100.1 99.5 100.1
YL [%] 1.42 1.75 1.92 1.73 2.45 1.71 3.01 1.69
Pr [×10−4 g/(g min)] 1.55 1.91 2.09 1.88 2.67 1.86 3.27 1.84
YS [%] 51.54 63.49 72.45 62.78 96.21 62.04 122.88 61.28
Y [%] 51.80 52.15 52.40 52.13 53.00 52.11 53.61 52.09
As a consequence of the declining crystallization driving force of l-Asn, the separation
performance of the process regarding l-AsnH2O is declining for increasing ee of d-
Asn in the feed solution, as observed in Table 4.4. In contrast, increasing the ee
of d-Asn improves the separation performance of the process with respect to d-
AsnH2O as expected. However, the efficiency of the process is only slightly improved.
This could again be explained by the slow surface integration on the surface of the
seed crystals. It should also be addressed that the model does not account for the
inhibiting effect of d-Asn on the growth of the l-AsnH2O seed crystals as suggested by
Petrusˇevska-Seebach et. al66. In this case, the declining effect on the crystallization
of l-AsnH2O would be more pronounced. Similarly, changing the enantiomeric excess
of the opposite enantiomer, i.e. l-Asn, would result in the same tendencies.
4.6.2.3 Crystallization temperature and subcooling
The liquid density of the crystallizing solutions, the solubility of the enantiomers, and
thereby the metastable zone width, and the growth rate constant are all dependent
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on the crystallization temperature. However, the influence of the crystallization tem-
perature is more significant for the supersaturation ratio, which is dependent on the
solubility of the enantiomer, and the growth rate constant, which in turn influences
the overall growth rate. In order to elucidate the effect of increasing the crystalliza-
tion temperature, a simulation is carried out for a crystallization temperature of 30
◦C with the saturation concentration of the enantiomers in the racemic feed solution
at 38 ◦C66 (∆T = 8 ◦C) and is compared to the base case having a crystallization
temperature of 19 ◦C and saturation temperature of 23 ◦C (∆T = 4 ◦C). The process
duration is the same as in the base case, i.e. 90 minutes.
Figure 4.6: Model simulations of the supersaturation ratio of the preferred enantiomer in
the d-Tank (top) and the l-Tank (bottom) for a crystallization temperature, Tcryst, of 19
◦C (base case) and 30 ◦C. The remaining process parameters are the same as given in Table
4.2. At time equals zero seeding is performed.
The supersaturation ratio of the preferred enantiomer in each crystallizer increases
with increasing crystallization temperature as shown in Figure 4.6. The reason for
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this is the significant influence of the crystallization temperature on the solubility of
the enantiomers and thereby the metastable zone width, which becomes larger when
the temperature increases66. Additionally, the crystallization driving force decreases
during the operation at the higher crystallization temperature while it remains con-
stant for the base case temperature. The reason is the higher overall growth rate
influenced by the temperature-dependent growth rate constant.
Table 4.5: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y,
from the d- and l-Tank obtained by the simulations for different crystallization temperature,
Tcryst, of 19 ◦C (base case) and 30 ◦C. Note the units.
19 ◦C 30 ◦C
Tank d l d l
∆T [◦C] 4 4 8 8
kg [×10−8 m/s] 3.25 3.96 6.76 8.25
U -value [%] 100.2 100.0 99.0 98.2
YL [%] 1.08 1.52 7.20 9.35
Pr [×10−4 g/(g min)] 1.17 1.65 7.82 10.2
YS [%] 37.79 54.09 519.3 674.7
Y [%] 51.35 51.85 58.96 60.30
As seen in Table 4.5, the performance of the process improves significantly with
respect to the process metrics considered, except the U -value. The improvement in
the yields and the productivity can be explained by the increase in the mass of the
enantiomers present in the feed solution entering the crystallizers, the increase in
the crystallization driving force of the preferred enantiomer, and the increase in the
growth rate constant to more than the double. The very small change in the U -value
can be ascribed to the low rate of the dominating mechanism for crystal growth, i.e.
surface integration.
4.6.2.4 Fraction of the feed solution inlet
The change in the fraction of feed solution entering the crystallizers is also simulated to
elucidate its influence on the outcome of the CC-PC process considered. The change
in the feed fraction changes the mass of the enantiomers entering the crystallizers,
which in turn affects the performance of the process. In this respect, the feed fraction δ
is varied between 0.5 and 0.6. In Figure 4.7, the supersaturation ratio of the preferred
enantiomer in each crystallizer is depicted.
79
Figure 4.7: Model simulations of the supersaturation ratio of the preferred enantiomer
in the d-Tank (top) and the l-Tank (bottom) for the fraction of feed solution entering the
crystallizers, δ, between 0.5 (base case) and 0.6. The remaining process parameters are the
same as given in Table 4.2. At time equals zero seeding is performed. The solubility is
indicated at supersaturation ratio of unity. Note the difference in the scale of the abscissa.
Increasing the feed fraction allow for the supply of a higher amount of the preferred
enantiomer into the respective crystallizer and the withdrawal of higher amount of
enantiomers to maintain a constant volume of the crystallizing suspension. The sim-
ulations depicted in Figure 4.7 show that an increase in the feed fraction increases
the concentration of d- and l-Asn in the d-Tank resulting in a higher crystallization
driving force for the d-Asn. On the other hand, less feed is supplied to the l-Tank in
which l-AsnH2O is crystallizing. The decrease below the solubility of l-Asn in the
l-Tank for a feed fraction of 0.6 is caused by the increase of the concentration of the
counter enantiomer d-Asn, which in turn increases the solubility of the l-AsnH2O
in the l-Tank according to equation (4.29). This is due to the transfer of a higher
amount of d-Asn than l-Asn in the exchange stream from the d-Tank to the l-Tank.
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The increase in the solubility destabilizes the solid-liquid system in the l-Tank, and
thereby the dissolution of the supplied seed crystals of l-AsnH2O occurs to stabilize
the system. Similarly, increasing the feed fraction of feed solution into the l-Tank
would result in the same tendencies. Additionally, liquid phase steady-state con-
centrations of the preferred and the counter enantiomer are achieved after about 45
minutes of operation corresponding to three residence times.
Table 4.6: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y,
from the d- and l-Tank obtained by the simulations for the change in the feed fraction into
the d-Tank, δ, between 0.5 and 0.6. Note the units.
0.5 0.55 0.6
Tank d l d l d l
U -value [%] 100.2 100.0 99.1 99.9 96.9 98.7
YL [%] 1.08 1.52 1.66 0.545 2.05 -0.651
Pr [×10−4 g/(g min)] 1.17 1.65 1.80 0.592 2.23 -0.707
YS [%] 37.79 54.09 64.04 17.49 86.37 -18.56
Y [%] 51.35 51.85 52.09 50.79 52.70 49.53
Table 4.6 shows the obtained measures for the performance of the process. It is seen
that an improvement is achieved for the separation of the d-AsnH2O enantiomer from
the d-Tank. This is indicated by the increase in the yields and the productivity. A
slight decrease in the U -value is achieved showing an increase in the consumption of
the preferred enantiomer due to crystal growth. Table 4.6 also shows that the increase
of the fraction of feed entering the d-Tank has a negative effect on the performance
of the process regarding the crystallization of the l-AsnH2O enantiomer in the l-
Tank. This is indicated by the negative values and the significant decrease in the
yields and the productivity. This is likely to be because of the destabilization of
the solid-liquid system. The U -value, however, indicates that more of the preferred
enantiomer in the l-Tank is consumed, but is not consumed for crystal growth as the
other measures indicate. The reason for the decrease in the U -value for the l-Tank
is the fact that during the crystallization process the crystallizing suspension in the
l-Tank is completely converted to a liquid solution with a higher concentration of the
counter enantiomer d-Asn compared to the concentration of l-Asn, which becomes
less than the concentration in the feed solution. Therefore, the concentration of l-
Asn in the purge stream from the l-Tank becomes less than the concentration in the
feed solution entering the l-Tank.
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4.6.2.5 Mass of seeds and average size of seeds
Increasing the mass of seeds or decreasing the average size of the seeds supplied to
each crystallizer should increase the production rate of solid product by crystal growth
of the desired enantiomer due to larger surface area available for growth as indicated
in equation (4.10). In this respect, the mass of the seeds supplied at the same average
size is increased from 0.5 g (base case) to 5 g. Note that the mass of seeds for the base
case are changed from the values given in Table 4.2 in order to obtain a clearer picture
of the effect of change in the mass of seeds. Figure 4.8 shows the simulations of the
concentration of enantiomers in the d- and l-Tank and Table 4.7 lists the obtained
values of the measures of the performance of the process.
Figure 4.8: Model simulations of the concentration of enantiomers in the d-Tank (left)
and the l-Tank (right) for the mass of seeds, mseed, between 0.5 g (base case) and 5 g.
The remaining process parameters are the same as given in Table 4.2. At time equals zero
seeding is performed. Note the difference in the scale of the abscissa.
Figure 4.8 shows that increasing the mass of the enantiopure seed crystals supplied
results in a decrease in the concentration of the preferred enantiomer in the crys-
tallizing suspensions. This is due to the increased consumption for the deposition
on the surface of the seed crystals due to the larger surface area available for crystal
growth as expected. The decrease in the liquid phase concentration also decreases the
crystallization driving force. Steady-state conditions for both the preferred and the
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counter enantiomer in the liquid phase in each crystallizer are achieved after about
60 minutes corresponding to four residence times.
Table 4.7: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y,
from the d- and l-Tank obtained by the simulations for the change in the mass of seeds,
mseed, between 0.5 g and 5 g. Note the units.
0.5 g 1 g 3 g 5 g
Tank d l d l d l d l
N2 [m2]†† 4.90 4.90 9.80 9.80 29.41 29.41 49.01 49.01
U -value [%] 100.2 99.9 99.7 99.3 98.4 97.7 97.5 96.7
YL [%] 1.15 1.62 2.13 2.95 4.93 6.44 6.68 8.46
Pr [×10−4 g/(g min)] 1.25 1.76 2.32 3.20 5.36 7.01 7.26 9.19
YS [%] 37.58 53.69 34.82 48.74 26.84 35.54 21.82 27.98
Y [%] 51.34 51.84 51.27 51.73 51.06 51.39 50.90 51.16
As expected, the initial total surface area of the seed crystals supplied increases with
increase in the mass of the seeds. As seen in Table 4.7, the performance of the
process is improved with respect to the U -value, the yield based on the feed and
the productivity. This indicates that the measures relating the production of solids
relative to the amount of enantiomer in the feed solution are improved. Thus, the
separation efficiency is improved. However, increasing the mass of seeds decreases
the measures relating the production of solids due to crystal growth and the initially
present seeds, i.e. yield of solid product based on the amount of seed supplied and
the crystal size yield based on the initial size of the seed crystals. The reason for
this decrease is the fact that crystal growth and thereby the production of solid is
distributed on a larger number of seeds with the same average size.
Model simulations of the concentration of enantiomers in the d- and l-Tank for the
different sieve fractions of the seeds, i.e. 250-355 µm (base case), 200-250 µm, and
150-200 µm, are depicted in Figure 4.9. The enantiopure seeds of both enantiomers
are assumed uniform.
†† Total initial surface per m3 suspension.
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Figure 4.9: Model simulations of the concentration of enantiomers in the d-Tank (left)
and the l-Tank (right) for the different sieve fractions of the seeds, SFseed, of 250-355 µm
(base case), 200-250 µm, and 150-200 µm. The remaining process parameters are the same
as given in Table 4.2. At time equals zero seeding is performed. Note the difference in the
scale of the abscissa.
As shown in Figure 4.9, the decrease in the average size of the enantiopure seed crys-
tals supplied decreases the concentration of the preferred enantiomer in the liquid
phase. This is due to the enhanced production of solid product due to crystal growth
caused by the larger surface area available for crystal growth compared to the base
case having larger size of seeds. Note that the initially larger decrease in the concen-
tration ofL-Asn in the l-Tank compared to the concentration of d-Asn in the d-Tank
may be caused by the higher growth rate of the seeds of l-AsnH2O in the l-Tank.
Note that steady-state concentration of the counter enantiomer in the liquid phase
for the smaller size of seed crystals of the preferred enantiomer in each crystallizer is
achieved earlier than when larger seed crystals are used.
84
Table 4.8: Summary of the results of the U -value, yield based on feed solution, YL, pro-
ductivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y,
from the d- and l-Tank obtained by the simulations for the different sieve fractions of the
seeds, SFseed, of 250-355 µm (base case), 200-250 µm, and 150-200 µm. Note the units.
250-355 µm 200-250 µm 150-200 µm
Tank d l d l d l
N2 [m2]‡‡ 4.90 4.90 6.59 6.59 7.87 7.86
U -value [%] 100.2 99.9 100.0 99.7 99.8 99.4
YL [%] 1.15 1.62 1.56 2.20 2.01 2.84
Pr [×10−4 g/(g min)] 1.25 1.76 1.69 2.39 2.18 3.09
YS [%] 37.58 53.69 50.79 72.77 65.50 93.93
Y [%] 51.34 51.84 51.75 52.39 52.18 52.95
As seen in Table 4.8, the increase in the initial total surface area of the seed crystals
supplied is not as significant as it is for the increase in the mass of seeds given in Table
4.7. Thus, the extent of the improvement of the performance of the CC-PC process
is larger for the change in the mass of seeds supplied compared to the decrease in the
average size of the seeds crystals. The decrease in the average size of the seed crystals
provides a larger surface area for crystal growth thus increasing the production rate of
the solid product. This is indicated by the increase in the yields and the productivity
as shown in Table 4.8. In this respect, to obtain a smaller size of the seed crystals
milling is necessary. This operation adds cost to the process and therefore should
be compensated for by the increase in the productivity. A combination of the two
parameters, i.e. the mass of the seeds and the size of the seeds, could be the optimal
approach to improve the performance of the process significantly. Thus, to realize
this approach the conversion of the CC-PC process to a fully continuous process is
desirable.
4.6.2.6 Pre-exponential factor for growth rate
The change in the pre-exponential factor for the growth rate of the desired enantiomer
affects the growth rate of the desired enantiomer significantly. The pre-exponential
factor could count for the physical attributes of the seed crystals, i.e. morphology
and surface structure of the seed crystals, and also counts for the growth rate of
the different faces of the crystals. The following simulations are performed using
two values for the pre-exponential factor, i.e. 25 m/s (base case) and 50 m/s. It
should be emphasized that the base case value is the same for both crystallizing
enantiomers.
‡‡ Total initial surface per m3 suspension.
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Figure 4.10: Model simulations of the concentration of enantiomers in the d-Tank (left)
and the l-Tank (right) for the different values of the pre-exponential factor for the growth
rate, k0, i.e. 25 m/s (base case) and 50 m/s. The remaining process parameters are the
same as given in Table 4.2. At time equals zero seeding is performed. Note the difference
in the scale of the abscissa.
As shown in Figure 4.10, the increase in the pre-exponential factor decreases the
concentration of the preferred enantiomer in the crystallizing suspensions. The reason
is the enhanced rate of the overall crystal growth as expressed in equation (4.5) and
(4.6) and thereby the increasing surface area of the growing seed crystals available for
growth. Only the concentration of the counter enantiomer increases until steady-state
in the liquid phase of this enantiomer is achieved.
Table 4.9: Summary of the results of the U -value, yield based on feed solution, YL, produc-
tivity, Pr, the accumulated yield of solid products, YS , and the yield in crystal size, Y, from
the d- and l-Tank obtained by the simulations for the different values of the pre-exponential
factor for the growth rate, k0, of 25 m/s (base case) and 50 m/s. Note the units.
25 m/s 50 m/s
Tank d l d l
kg [×10−8 m/s] 4.16 4.16 8.33 8.33
U -value [%] 100.1 100.0 99.4 99.2
YL [%] 1.39 1.60 2.80 3.26
(continued)
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Table 4.9 – (Continued)
Tank d l d l
Pr [×10−4 g/(g min)] 1.51 1.74 3.04 3.54
YS [%] 48.74 56.99 98.33 116.2
Y [%] 51.69 51.94 53.06 53.49
As shown in Table 4.9, the growth rate constant for the overall growth rate doubles
when the pre-exponential factor doubles as expected. Due to the enhanced growth
of the seed crystals, the performance of the process with respect to yields and the
productivity is improved, except the U -value. The change in the pre-exponential
factor could be achieved by a pretreatment of the seed crystals with a suitable solvent
to allow for the change in the surface structure of the seed crystals and to activate
the surfaces by providing a larger number of grow sites to obtain an acceleration
of the surface integration of the preferred enantiomer into the surface of the seed
crystals. The combination of such a pretreatment and the mass and size of seed
crystals supplied would possibly provide the conditions of the supplied seed crystals
necessary for enhanced crystal growth and process performance.
4.7 Validation of model assumptions
For model development, some simplifying assumptions were made. In this section,
the most important ones are readdressed.
Primary homogeneous and heterogeneous nucleation of the preferred and the counter
enantiomer in each crystallizer were neglected. This seems to be a reasonable assump-
tion because the changes in the concentrations of the enantiomers in each crystallizer
at the process conditions considered are small resulting in concentrations below the
supersolubility limit. The reason is the low rate of crystal growth by surface integra-
tion as suggested by Petrusˇevska-Seebach et al.66.
Secondary nucleation of the seeded enantiomer was neglected. This is also reasonable
under the process conditions considered, where the solid fraction in the crystallizing
suspensions is below 5%, and is in accordance with the investigation carried out by
Petrusˇevska-Seebach et al.66.
The presence of d-Asn in the liquid phase could result in crystal growth inhibition
of the l-AsnH2O in the l-Tank. This effect was neglected in the model development.
This effect should be taken into account because it can have significant effect on the
supersaturation, i.e. crystallization driving force, of the preferred enantiomer in the
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liquid phase66.
The overall growth rate of the seeded enantiomer in each crystallizer is assumed to
be size-independent. This a reasonable assumption because the experimental inves-
tigation carried out by Petrusˇevska-Seebach et al.66 shows that no growth anomalies
such as growth rate dispersion and/or size-dependent growth were observed in the
case of asparagine monohydrate. During the present model validation against exper-
imental data, however, the difference in the pre-exponential factor for crystal growth
of the monohydrate enantiomers is obviously due to growth anomalies caused by
the different surface structure of the seed crystals initially supplied according to the
observations in the experimental investigation carried out by Chaaban et al.11.
4.8 Conclusions
A mathematical model describing the CC-PC process for the continuous separation
of enantiomers by preferential crystallization in a coupled crystallizer configuration
under isothermal conditions was developed. Only the phenomenon of crystal growth
of the preferred enantiomer in each crystallizer was included. Experimental data
available were used for validation of the model and to estimate the important kinetic
parameters relevant for crystal growth. Simulations for different process variables
were performed to assess the predictability of the model, at least from a theoretical
point of view, using the conglomerate forming system of asparagine monohydrate as
model compound.
It was shown that the increase in the mean residence time of the liquid phase, the
increase in the crystallization temperature, the increase in the mass of seeds, and
the reduction of the size of the seed crystals all contribute positively to the overall
process performance. The sensitivity of the model to theses parameters suggests
that the conversion of the CC-PC process to a fully continuous process could be
advantageous.
An important next step is to validate the predictability of the model by experimental
data obtained for the change in the investigated process variables. Another equally
important step is to extend the model to count for the nucleation, agglomeration,
and crystal breakage phenomena, which could occur in the CC-PC process. The
model developed in the present study could also be extended to cover the behavior
of the CC-PC process using a racemic compound forming system. Finally, the model
could be further modified to represent a fully continuous separation process including
downstream processing units and continuous supply of seed crystals.
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Chapter 5
Conclusions and suggestions for future work
In this chapter, summaries of the results of the work presented in the preceding
chapters are provided. Suggestions for future continuation of the work will be pre-
sented.
5.1 Conclusions
Litterature survey – The strict regulatory requirements and the increasing public de-
mand for the production of enantipure drugs have drawn great attention towards
exisiting and new routes for the production of pure enantiomers to be utilized in
the production of chiral active pharmaceutical ingredients (APIs). Crystallization is
extensively used in the pharmaceutical industry for separation and purification pur-
poses and for the control of solid product attributes, such as polymorphism, particle
size, and particle size distribution (PSD). In this respect, Preferential Crystallization
(PC), as a chiroselective separation technique, is an attractive approach for the sep-
aration of pure chiral APIs. However, the applicability is limited to conglomerate
forming systems or racemic compound forming systems with sufficient enrichment of
the desired enantiomer. Therefore, the selection of solvent, the crystallization mode
to be employed, and the type and attributes of the solid product to be produced are of
great importance and should be considered early in product and process development
stages in conjunction with the prior synthesis steps and the subsequent downstream
processing units.
Experimental realization of the Continuous Coupled PC (CC-PC) process – It is desir-
able for the pharmaceutical industry to convert from the conventional batch operation
to the more attractive continuous operation. The potential of continuous operation
for the preferential crystallization of enantiomers was investigated in the CC-PC pro-
cess, in which only the liquid phase was operated continuously. The CC-PC process is
considered a first step towards a fully continuous preferential crystallization process.
The objectives of the study was to assess the achievement of the separate simul-
taneous crystal growth of enantiomers on existing enantiopure seed crystals in each
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crystallizer, and the achievement of nearly racemic composition in the mother liquors.
Experiments in triplicates were conducted to assess the robustness of the developed
process. The chiral chemical compound used was asparagine monohydrate in water,
which belongs to the conglomerate forming systems. An additional experiment was
conducted to assess the performance of the process by changing the initial size of the
seeds. It was found that the experiments were repeatable and the process was con-
sidered robust. Simultaneous separation of the enantiomers in each crystallizer was
achieved and a nearly racemic composition of the mother liquors was maintained.
Reasonable productivities, yields, and purities were achieved. However, the purity
of l-asparagine monohydrate (l-AsnH2O) decreased due to surface nucleation of the
counter enantiomer d-asparagine monohydrate (d-AsnH2O). The productivities, and
yields increased slightly as a result of using smaller seed particles, and the purity
for the l-AsnH2O increased due to the initially smoother surface morphology of the
enantiopure seed crystals supplied. Moreover, from a steady-state mass balance the
separation efficiency evaluated based on the quantity of unutilized enantiomer in the
purge streams was found to be negligibly small indicating that almost no separation
has occurred. This was ascribed to the very low growth rate caused by the slow sur-
face integration on seed crystals and the possible growth inhibition by the presence
of the counter enantiomer.
Modeling and simulations of the CC-PC process – As a tool to predict the performance
of the newly developed CC-PC process, a one-dimensional model was developed. The
model was developed based on the crystal population balance equation (PBE) for
each population of crystals in each crystallizer, assuming that only crystal growth
occurs, combined with a liquid phase mass balance for each component in each crys-
tallizer. No source terms were included in the PBE. The PBE was transformed using
the method of moments and combined with the mass balances to obtain a set of cou-
pled ordinary differential equations (ODEs) for each component. Firstly, the model
outputs were validated against the average experimental data obtained from the trip-
licate experiments previously conducted. It was found that the model outputs were
in good agreement with the experimental data. Secondly, the predictability of the
model was investigated through a sensitivity analysis to assess the most influential
parameters on process performance. The analysis showed that the increase in the
mean residence time of the liquid phase, the increase in crystallization temperature,
the increase in mass of seeds, and the reduction of size of seeds initially supplied
contribute positively to the overall process performance. However, the separation
efficiency, indicated by the U-value, evaluated based on the quantity of unutilized
enantiomer in the purge streams was found to be negligibly small, i.e. between zero
and 3% at best, indicating that almost no separation has occurred. The reason is the
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very low growth rate caused by the slow surface integration on seed crystals at the
given operating conditions. It can thus be concluded that the conversion to a fully
continuous process could be advantageous to improve the separation efficiency in case
crystal growth kinetics can be improved by e.g. using another solvent. It could also
turn out that the studied CC-PC process can only be industrially useful in case the
nature of growth kinetics of the chemical system allows for sufficiently rapid surface
integration or that the kinetics is controlled primarily by solute diffusion.
5.2 Suggestions for future work
Extension of the applicability of the CC-PC process – As previously mentioned, the
applicability of the present CC-PC process is limited to the separation of enantiomers
from a conglomerate forming system. It would be advantageous to address the flexibil-
ity of the CC-PC process in terms of the applicability for other conglomerate forming
systems. Furthermore, a study on the polythermal operation instead of isothermal
operation to increase the understanding of the performance of the CC-PC process is
suggested. Additionally, studies on the applicability of the CC-PC process for the
separation of enantiomers from a racemic compound forming system are desirable. In
this respect, the study of the applicability of the CC-PC process for diastereomeric
salt crystallization could give further insight into the potential of the process.
Conversion to a fully continuous process – The newly developed CC-PC process has
the potential of further development into a fully continuous preferential crystalliza-
tion process to improve the separation efficiency. The conversion to a fully continuous
preferential crystallization process requires the integration of untis for the continuous
supply of seed crystals or other means of generation of seed crystals, e.g. sonication.
Additionally, solid product removal units have to be integrated as well in order to re-
move growing solids continuously thereby enabling the control of the supersaturation
level and the PSD of solid product.
Modeling and model validation – The developed one-dimensional model was used for
conducting a sensitivity analysis to achieve an understanding of the complexity of
the CC-PC process. The drawback is though that the model does not include terms
describing the secondary nucleation of the preferred enantiomer, primary nucleation
of the counter enantiomer, inhibition of crystal growth of the preferred enantiomer by
the presence of counter enantiomer, size-dependent growth rate, agglomeration and
crystal breakage/attrition phenomena, the effect of morphology change during crystal
growth on supersaturation level. Moreover, validation of the simulations conducted
against experimental data for the variations in process parameters is suggested to
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assess the predictability of the model. The model could also be extended to describe
the preferential crystallization process for the separation of enantiomers from racemic
compound forming systems. Finally, it is also suggested that the model is extended
to describe the fully continuous process including downstream processing units and
solid feed units, if any.
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Abbreviations
Al-Cr Aluminium-Chromium alloy
API Active Pharmaceutical Ingredient
Asn Asparagine
AsnH2O Asparagine monohydrate
PC Preferential Crystallization
CB-PC Coupled Batch Preferential Crystallization
CC-PC Coupled Continuous Preferential Crystallization
CEN Center for Electron Nanoscopy
CHEC Center for Harmful Emission Control
COGs Cost Of Goods
CSTR Continuously-Stirred Tank Reactor
DSC Differential Scanning Calorimetry
DTU Technical University of Denmark
EMA European Medicine Agency
Exp Experiment
FDA Food and Drug Administration
PSD Particle Size Distribution
XRPD X-Ray Powder Diffraction
DSC Differential Scanning Calorimetry
FBRM Focused-Beam Reflectance Measurement
MATLAB MAtrix LABoratory
MOM Method Of Moments
MSMPR Mixed Suspension-Mixed Product Removal
ODE Ordinary Differential Equation
PAT Process Analytical Technology
PBE Crystal Population Balance Equation
PTFE PolyTetraFluorEten (Teflon R©)
Pt/Rh Platinum/Rhodium alloy
R&D Research and Development
SEM Scanning Electron Microscopy
SMB Simulated Moving-Bed
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STA Simultaneous Thermogravimetric Analysis
TGA Thermogravimetric Analysis
UNIFAC UNIversal quasichemical Functional-group Activity Coefficients
USA United States of America
US$ US Dollar
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Nomenclature
Variables
Symbol Description Unit
A Total surface area m2
a Order of nucleation process –
A0 Pre-exponential factor for homogeneous nucle-
ation rate
No./(m3 s)
B0 Homogeneous nucleation rate No./(m3 s)
Bsec Secondary nucleation rate No./(m3 s)
C Concentration kg/m3
c Counter enantiomer –
Ea Activation energy for crystal growth by surface
integration
kJ/mol
G Linear growth rate m/s
K0 Primary nucleation rate constant No./(m3 s)
k Growth rate constant m/s
k0 Pre-exponential factor for growth rate constant m/s
ka Area shape factor –
kB Boltzmann’s constant kJ/K
ksec Empirical secondary nucleation constant Empirical
kv Volume shape factor –
L Characteristic dimension of crystals m
M Slurry density kg/m3
m Mass of species kg
m˙ Mass flow rate of species kg/s
N Moment of population balance /(m3 suspension)
n Number density function No./(m3 suspension)
P Stirring rate rpm
p Preferred enantiomer –
Pr Productivity kg/(kg s)
R Universal gas constant kJ/(mol K)
S Supersaturation ratio –
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s Relative supersaturation –
SF Sieve fraction µm
T Temperature K
t Time s
V Volume in crystallizer m3
w Mass fraction of species –
x10 Particle size at which the cumulative mass or vol-
ume is 10%
–
x50 Particle size at which the cumulative mass or vol-
ume is 50%
–
x90 Particle size at which the cumulative mass or vol-
ume is 90%
–
Y Yield –
Greek letters
Symbol Description Unit
α Order of crystal growth –
δ Fraction of feed solution into one crystallizer –
γ Activity coefficient –
µ Chemical potential kJ/mol
ν Molecular volume m3/mol
φ Surface tension kJ/m2
ρ Density kg/m3
σ Supersaturation –
τ Mean residence time of liquid phase s
Subscripts
Symbol Description
cryst Crystallization
E Eﬄuent of liquid phase from crystallizer
eq Equilibrium
F Feed
f Final
g Growth
i Crystallizer 1 or 2 (D- or L-Tank)
j Crystallizer 1 or 2 (D- or L-Tank)
L Liquid phase
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P Purge
S Solid
x Index for moments of population balance
Superscripts
Symbol Description
b Empirical exponent for supersaturation (Sec-
ondary nucleation)
c Counter enantiomer
k Counter enantiomer or preferred enantiomer
l Empirical exponent for stirring rate (Secondary
nucleation)
p Preferred enantiomer
r Empirical exponent for slurry density (Secondary
nucleation)
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Appendix A
Process Development: Stages and Decisions
A.1 Process system selection
The Ph.D. project was initially concerning the design and development of a contin-
uous crystallization process for the separation of enantiomers of APIs from a racemic
compound forming system provided by H. Lundbeck A/S. The objective was to re-
place the expensive countercurrent SMB chromatography and/or the diastereomeric
salt crystallization process thereby ultimately improving process economy.
After numerous discussions, it turned out that it is thermodynamically impossible to
separate the enantiomers by the frequently used seeded cooling preferential crysta-
llization unless a thermodynamically unstable conglomerate is formed in the desired
range of operating conditions. The search for solvent(s) and temperature(s) at which
such a conglomerate can be formed and stabilized for the provided racemic compound
forming system was considered time-consuming and out of the scope of the present
Ph.D. project.
It was then decided to consider other alternatives to the racemic compound forming
system and a conglomerate forming system was provided by H. Lundbeck A/S. On the
basis of that the focus of the further work in the Ph.D. project was directed to the
design, establish, and experimentally investigate a new preferential crystallization
process. The next step was to generate different design alternatives and to decide
which to select for further investigation based on the following considerations:
• Flexibility and versatility
• Cheap in operation and maintenance
• Easy to implement, operate, and upscale
• Minimum use of mechanical parts
• Implementation of PAT tools for PSD control
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A number of designs was generated, but due to limited time, it was decided to mod-
ify the already studied coupled-batch preferential crystallization (CB-PC) process
developed by Elsner et al.20. The modification should consist of the conversion to a
fully continuous PC process. Different considerations for the implementation of solid
feeding units and systems for continuous filtration at lab-scale were presented and
discussed. Even though the designs could possibly be implemented in commercial
scale, it was difficult to find alternatives for downstream processing units such as
continuous filtration at lab-scale. All in all, it was found to be a complex process
network to handle in a single Ph.D. project due to time limitation. Therefore, it was
decided to systematically study the conversion from the batch PC to the continuous
PC.
The systematic study of the conversion consisted of building a PC process in which
the liquid phase was operated continuously and the solid phase remained in batch.
Some of the solid phase harvested could be used as heel seeds for a subsequent repeat
of the PC process. The result was the newly developed coupled continuous PC (CC-
PC) process. The CC-PC process was experimentally realized and investigated as a
proof-of-concept. The investigation should answer two main questions:
1. Does simultaneous crystal growth of enantiopure seed crystals of the the pre-
ferred enantiomer in each crystallizer occur?
2. Is it possible to achieve a nearly racemic composition, i.e. nearly 50:50 compo-
sition, of the mother liquor in each crystallizer and maintain a constant driving
force throughout the process duration?
To answer these questions and to assess the robustness of the CC-PC process, ex-
periment in triplicates were conducted. The results of this work were considered
potential scientific material for publication and it was decided that a manuscript
should be produced for publication. However, the CC-PC process was only proven
using a conglomerate forming system. Future work should focus on the flexibility of
the process.
A theoretical investigation through model establishment and solution and sensitivity
analysis was desirable to improve process understanding of the complex CC-PC pro-
cess for the separation of enantiomers of conglomerate forming systems. Furthermore,
suggestions for process improvements were also highlighted. This work was also suc-
cessfully conducted and the outcome was considered valuable scientific material for
publication. A second manuscript was therefore produced.
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A.1.1 Fluidized bed vs. Stirred vessel
Continuous fluidized bed technology is to a limited extent commercially used for the
production of pure enantiomers. Merck & Co. has already a continuous fluidized bed
process for the separation of an API salt intermediate implemented at commercial
scale. However, the predominant system in the pharmaceutical industry is the stirred
vessel, either batch ore semi batch. The versatility of the fluidized-bed technique is
limited to particular purposes because of specific requirements to mixing properties
and flexibility. Some of the important features of fluidized bed crystallizers and stirred
vessel crystallizers are listed in Table A.1.
Table A.1: Features of fluidized bed crystallizers and stirred vessel crystallizers87.
Function Fluidized bed Stirred vessel
Continuous
and/or batch
Continuous Both
Cooling Excellent Good
Evaporative NA Good
Antisolvent NA Good
Reactive NA Good
Type of mixer Fluidization Variety of impellers
Macromixing Excellent Poor to Good
Mesomixing NA Poor to Good
Micromixing NA Poor to Good
Supersaturation
range
Low Wide
Control of super-
saturation
Excellent at low supersat-
uration
Achievable
Nucleation Minimum Wide range
Crystal growth Maximum Wide range
Seeding Massive Wide range
Scale up Good with good seed Can be difficult
In general and as shown in Table A.1, stirred vessels are more versatile and flexible
regarding the different crystallization modes applicable. Furthermore, specific require-
ments to mixing behavior and seeds should be met in order to operate a successful
fluidized bed crystallization process. Particularly, the availability of the required seed
amount and quality are of importance to the applicability of fluidized bed crystalliza-
tions in the pharmaceutical industry. This is due to the effects on product quality
attributes and process performance. Additionally, the operating window regarding
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the supersaturation range is also of great importance in order to allow for a con-
trolled crystallization process and to meet the metastability window, i.e. metastable
zone width, for the particular solute-solvent system.
A.2 Chemical system selection
The chemical system was selected based on the following criteria:
• Since the CC-PC process is a modification of the CB-PC process, which has
limited applicability to conglomerate forming systems, the solute-solvent sys-
tem should belong to the conglomerate forming systems, e.g. asparagine mono-
hydrate or threonine.
• To avoid complicated ATEX approval of the CC-PC process for the given solvent
volumes used and due to impractical implementation of reflux systems for the
CC-PC process, aqueous solutions are desirable.
• Solubility of pure enantiomer is lower than that of conglomerate to enable the
separation of pure enantiomers from a racemic mixture.
• Solubility should increase with increasing temperature to facilitate cooling cry-
stallization.
• Width of the metastable region should be sufficiently wide to allow for seeding
and thereby crystal growth.
• Data for crystallization kinetics and solubility data are available in literature
due to time limitation to generate the required data.
• Cheap and safe for ease of handling, i.e. safety approval not necessary.
The chemical system selected based on the given criteria was the conglomerate form-
ing system of the amino acid asparagine monohydrate in water (solvent). The neces-
sary solubility data and data for crystallization kinetics are available in Thiemann86
and Petrusˇevska-Seebach et al.66.
A.3 Equipment and auxiliary selection
A.3.1 Pump selection
The selection of the pumps to be used in the establishment of the CC-PC process was
based on the following criteria:
• Cheap, flexible, and multipurpose.
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• Fluid not in contact with mechanical parts of the pump. The reason is to avoid
excessive evaporation of solvent and thereby undesired nucleation. Furthermore,
crystal breakage/attrition during slurry transport should be avoided.
• Suitable for slurry transport.
• Ease of maintenance, setup, and operation.
• Operation at a wide range of flow rates/pressures.
In this respect, it was decided to select a positive displacement pump which is suitable
for slurry transport in case the further development of the CC-PC process to fully
continuous process is conducted. Therefore, and based on the given criteria above,
peristaltic pumps with both dispensing and flow options were selected. All six pumps
were identical and of the type Longer Pump LP-BT-100-1F with YZ1515x (single
tube with three rollers, flow rate uncertainty ±2%) pump head from the manufacturer
Baoding Longer Precision Pump Co. Ltd., Hebei, China. Three rollers were sufficient
for continuous flow without excessive pulsation. The pump head is easy to setup and
handle. All the pumps were calibrated before use to ensure the desired flow rate.
A.3.2 Tubings and fittings
The selection of the tubings for the setup of the CC-PC process was mainly based on
the following criteria:
• Dimensions for the required flow rate. Note that it is recommended that the
desired flow rate is within 20-80% of the maximum flow rate for the tubing.
• Chemical and heat resistance.
• Hardness and lifetime.
• Smoothness of inner surface to avoid excessive friction resistance and deposition
of solids.
The tubes selected based on the given criteria above were Silicone peroxide tubes
from VWR. The dimensions were 1.6 mm in inner diameter and a wall thickness of
1.6 mm. The tubes were inserted in other silicone tubes with large inner diameter (9
mm) in order to make the tubings more rigid to handle and to decrease cooling of the
fluid transferred in the smaller tubings if operation of the CC-PC system at higher
temperatures is desired. Some fittings ordered from Mikrolab A/S were used for tube
connections and thermocouple installations. The dimensions and chemical resistance
of the fittings were taken into account.
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A.3.3 Impeller selection for mixing
The selection of the impeller type for mixing purpose was made based on the following
criteria:
• Provide axial mixing pattern to facilitate both improved micromixing but also
suspendability (macromixing) of the crystals.
• Avoidance of crystal breakage/attrition. Reduced tip speed (shear) to avoid
secondary nucleation and to allow the control of PSD of the final product.
• Chemical resistance (stainless steel or PTFE).
• Dimensions fitted to crystallizer dimensions.
The impeller selected was a 45 mm stainless steel (both impeller and shaft) propeller
type impeller with guided ring to reduce the shear of crystals. The stirrer (shaft and
impeller) was purchased from Heidolph Instruments, Schwabach, Germany.
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B.1 Introduction
Crystallization is a frequently applied method in many industries to produce pure
solids from a solution. On a very large scale, inorganic salts, e.g. NaCl, are crystallized
from a supersaturated solution, but also simple and complex organic compounds, e.g.
sugar and ketoprofen, respectively, and complex proteins, e.g. insulin, are crystallized
during manufacturing.
In the pharmaceutical industry, crystallization is used for two objectives: 1) Sepa-
ration and purification, and 2) control of critical attributes of the product. In this
respect, crystallization is used for the separation of chiral compounds from a racemic
mixture. For this purpose, crystallization can be performed by seeding to allow for
the production of highly pure crystals of the wanted chiral compound. This process
is commonly known as preferential crystallization (PC). Seeding is often also used to
control the final particle size, particle size distribution (PSD), and morphology of the
final product.
Separation of chiral compounds from a racemic mixture is commonly conducted in
batch mode. To increase process yield and improve control of product attributes,
continuous operation is desirable. To investigate the performance of a continuous PC
process, a process in which only the liquid phase is continuously operated and the solid
phase is in batch. The process is called coupled continuous PC (CC-PC) process. This
is regarded as a first step towards fully continuous PC process. This manual provides
an step-by-step guide for the operation of the CC-PC process with an example using
the chiral asparagine monohydrate in water as the racemic mixture.
B.2 Objective(s)
The purpose of the experiment is to investigate the separation of enantiomers of as-
paragine monohydrate (AsnH2O) from an aqueous racemic mixture by seeded cooling
crystallization in the CC-PC process. The achievement of a nearly racemic composi-
tion of the mother liquor and the achievement of crystal growth of the seed crystals
with the desired enantiomers are studied. Quantitative analyses are performed to
evaluate the performance of the separation process and product quality in terms of
optical purity.
B.3 Equipment and setup
The setup is a lab-scale setup designed and built in lab 103 at the Center for Harmful
Emission Control (CHEC) at Department of Chemical and Biochemical Engineering
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(KT) at the Technical University of Denmark (DTU). The main components are the
feed tank, feed pumps, crystallizers (d- and l-Tank), mother liquor exchange pumps,
and purge pumps. The CC-PC process is shown in a photograph in Figure B.1. Note
the small insert which shows the main instrumentation parts in each crystallizer.
Figure B.1: Photograph of experimental setup for the preferential crystallization experi-
ments. The small insert (lower left corner) shows the instrumentation in the crystallization
vessels. Six individual pumps are necessary to run the setup in a continuous mode.
The process is also depicted in a schematic diagram in Figure B.2. The crystallizers,
C1 and C2, consist of two rounded-bottom glass vessels of a total volume of 250 mL
each with heating/cooling jacket and they comprise the central part of the setup. In
the crystallizers, the separation of enantiomers by crystal growth of the pure seed
crystals supplied takes place. The effective volume is 220 mL of solution.
B.3.1 Crystallization units
The crystallizers are mounted on a ring holder by assembling the bottom part, which is
the crystallizer itself, and the top part, which is a 75 mm lid with five necks/openings
(Figure B.3).
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Figure B.2: Schematic diagram of the CC-PC process for the preferential crystallization
experiments. TF symbolizes the temperature in the feed tank, TF1 is the temperature of
feed entering the d-Tank, T1 is the temperature in the d-Tank (C1), T2 is the temperature
in the l-Tank (C2), TE1 is the temperature of mother liquor eﬄuent from the d-Tank,
T1-2 is the temperature of exchange stream from the d-Tank to the l-Tank and T2-1 is
the temperature of exchange stream from the l-Tank to the d-Tank. Blue and red filled
circles symbolize growing enantiopure seeds of d-AsnH2O and l-AsnH2O in the d- and l-
Tank, respectively. The grey boxes in the d- and l-Tank represent filters for mother liquor
exchange.
Figure B.3: Assembling the parts of the crystallization units.
The screws, four for each unit, are fastened and the stirrer is lowered so the impeller
is about 1/3 apart from the bottom of the crystallizer. Make sure that the stirrer
does not touch the sides of the neck and the bottom of crystallizer. Insert the dif-
ferent connections, i.e. thermocouples Temp1 and Temp2 (each inside steel tubes),
tubes etc., into each opening on the lid as shown in Figure B.3. Make sure that the
thermocouple does not touch the impeller and the inside wall of the crystallizer and
is placed just above the impeller. Also make sure that the tubes are not in contact
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with the wall of crystallizer and impeller.
Figure B.4: Components in the crystallization units.
Inside each crystallizer, three components are implemented: 1) Stirrer with 45 mm
propeller impeller with guided ring, 2) thermocouple inserted into a steel tube contain-
ing liquid silicone to improve heat transfer, and 3) a stainless steel sintered metal filter
with pore size of 10 µm (IDEX Health and Science, Wertheim-Mondfeld, Germany).
The propeller impeller with guided ring is more gentle on crystals due to reduced tip
speed. The stirrer speed can be adjusted by turning the knob on the motor (M1 and
M2). The filter is used to retain solids in the crystallizing suspensions.
The crystal-free mother liquor is exchanged between the crystallizers by two pumps
(C1-C2 and C2-C1) (Longer Pump LP-BT-100-1F, YZ1515x, Baoding Longer Preci-
sion Pump Co. Ltd., Hebei, China) with an uncertainty in flow rate of ±2%. The
temperature of the transferred mother liquor is recorded at three positions: 1) At the
suction side of the pump C1-C2 (TEX-1) using the software of Texas Instruments
thermosensor (grey box analog to digital converter), 2) at the inlet to crystallizer C1
(Temp4), and 3) at the inlet to crystallizer C2 (Temp6). Moreover, the temperature
of the feed into crystallizer C1 (Temp3) is also monitored. Temperatures Temp1-6
are all connected to the Logger Lite 1.6.1 software interface.
B.3.2 Cooling system
The cooling is performed by using demineralized water as coolant with a constant
cooling rate of 14 K/h. Alternatively, other coolants such as ethylene glycol can be
used. Each crystallizer has a cooling unit (HEX(C1) and HEX(C2)) connected to
it by Silicone tubes with appropriate length and an inner diameter of 19 mm. The
tubes are connected from the discharge of the cooling unit marked ’OUT’ and to the
bottom opening of the crystallizer. The tube connected to the inlet of the cooling unit
marked ’IN’ is connected to the top opening of the crystallizer (Figure B.5).
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Figure B.5: Cooling unit and the connected tubes.
The cooling unit is turned on and off by the ’ON/OFF’ button on the control board
on the top of the cooling unit (Figure B.6).
Figure B.6: Control board on cooling unit.
Figure B.7: Computer screen showing the interface of Logger Lite 1.6.1 software for tem-
perature logging through the GO!Link thermocouple connection sensor.
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Note that the two cooling units are different in coolant capacity and control modes. To
decrease or increase the coolant temperature use the respective buttons on the control
board on each cooling unit. Note that there is no automatic control of temperature
in crystallizer. The control of temperature is performed manually by observing the
temperature (Temp1 and Temp2) on the computer screen through the Vernier Soft-
ware package Logger Lite 1.6.1 using the thermocouple sensor connected to Go! Link
interface (Vernier Software and Technology LLC, Beaverton, OR, USA) (Figure B.7).
The temperature is logged automatically.
B.3.3 Feed system
The feed system is shown in Figure B.8.
Figure B.8: Feed system.
The feed tank (FEED) is a cylindrical glass vessel of a maximum volume of about
2.5 L. It has a 75 mm flange and a lid with three necks/openings is connected to
it by a fastening clamb. In the openings, a thermocouple marked Temp5 (inside a
glass tube) and the stirrer are inserted. An in-house made stirrer shaft fitted with
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a half-moon impeller of PTFE mounted on a motor (MF) (IKA Eurostar Power
Control-Visc, Staufen, Germany) is placed in the center of the feed vessel. The last
opening is kept closed by a plastic/glass plug to avoid impurities to enter the feed
solution and to avoid faster cooling of the solution. The heating is conducted by
Figure B.9: Heating unit for feed system.
the connected heating unit (HEX(F)) (LAUDA M3, Lauda-Königshofen, Germany)
and the temperature is controlled manually by observing the solution temperature
on the connected computer screen (Temp5). The temperature is adjusted through
the control board of the heating unit. The temperature is monitored via the Vernier
Software package Logger Lite 1.6.1 using the thermocouple sensor connected to Go!
Link interface (Vernier Software and Technology LLC, Beaverton, OR, USA). Note
that the unit is only used for heating, so it has no cooling unit installed. The feed
solution is transferred to the crystallizers through the pumps F1 and F2 (Longer
Pump LP-BT-100-1F, YZ1515x, Baoding Longer Precision Pump Co. Ltd., Hebei,
China) with an uncertainty in flow rate of ±2%.
B.3.4 Purge system
The purge system for the CC-PC process is shown in Figure B.10. The purge system
consists of two pumps (P1 and P2) (Longer Pump LP-BT-100-1F, YZ1515x, Baoding
Longer Precision Pump Co. Ltd., Hebei, China) with an uncertainty in flow rate
of ±2%, two purge collection tanks of 1 L each (Purge 1 and Purge 2), and two
sample valves. The purpose of the purge system is to withdraw mother liquor from
the crystallizers to maintain a nearly constant volume of the crystallizing suspensions.
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Figure B.10: Purge system.
The solutions collected in the purge collection tanks can, if needed, be reused as feed
for additional experiments together with fresh feed solution.
B.3.5 Analysis equipment
B.3.5.1 Liquid phase analysis: Polarimetry
To determine the concentration of the enantiomers in the mother liquor, a polarimeter
is used to determine the observed optical rotation in the solution. The polarimeter
(PerkinElmer 341 Polarimeter, PerkinElmer Life and Analytical Sciences, Shelton,
CT, USA) can be accessed in the Department of Chemistry at DTU (building 201,
Organic synthesis). The polarimeter used is shown in Figure B.11.
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Figure B.11: The polarimeter and the accompanied 1 mL cell used.
The polarimeter is turned on by the ’ON/OFF’ button at the top. The polarimeter is
left for about 10 minutes to heat up the Na-lamp to full strength. The used spectrum
line is the Sodium D-line of a wavelength of 589 nm. The measurement temperature
of the polarimeter is set by default to 20 ◦C and the measurement reproducibility is
±0.002◦.
B.3.5.2 Liquid phase analysis: Densitometry
The density measurement is conducted to determine the total concentration of the
solution. The liquid density is measured using a Density Meter DMA 35 (Anton
Paar GmbH, Graz, Austria) shown in Figure B.12 with a reproducibility of ±0.0005
g/mL.
Figure B.12: The densitometer with 1 mL sampling cell.
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The sample solution is pumped through the sample tube by pressing the sampling
button and slowly releasing it. The sample then enters the 1 mL sample cell and the
measurements is conducted. Note that no air bubbles are allowed to enter the sample
cell while measuring. The presence will cause error in measurement. The sample
temperature is also measured. Alternatively, if small volume of sample is required, a
syringe filled with more than 1 mL sample is pumped into the syringe inlet and the
density and sample temperature are recorded.
B.3.5.3 Solid phase imaging: Scanning Electron Microscopy (SEM)
The equipment used for SEM imaging of the dry seed crystals and the produced
crystals is a Quanta 200 ESEM FEG scanning electron microscope. The equipment is
located at the Center for Nanoscopy at DTU. Booking with the responsible technician
for an introduction to the equipment is necessary prior to the use of the equipment.
The SEM equipment is shown in Figure B.13.
The samples to be analyzed are first of all placed on the respective sample holders.
These consist of circular stainless steel holders of about 2 cm in diameter and are
covered with double-gluing carbon sheets. After adding a small amount of sample,
the samples are coated with gold particles in a specialized coating apparatus. This is
to allow for clear imaging and to avoid heating of the sample which destroys it.
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Figure B.13: The SEM microscope at CEN, DTU.
B.4 Experimental procedure
Before starting any practical work spend some time to inspect the equipment and
identify the main components and utilities. Use the flow diagram in Figure 3.1 for
assistance. Also get yourself familiar with the control board of the cooling and heating
units and how to navigate around in the computer interface. Fill out the safety data
sheet (APV) for dl-, d-, and l-asparagine monohydrate.
B.4.1 Precautions
There are some precautions to count for before starting the experiments:
• The temperature in the vessels is not automatically controlled. Manual control
by adjustment of temperature of cooling/heating units is necessary.
• The pumps used are peristaltic (positive displacement) pumps with an uncer-
tainty in flow rate of ±2%. Before turning on the feed pumps F1 and F2 make
sure that the outlet valve in the bottom of the feed tank is released.
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• The pumps can operate with bidirectional flow. Make sure that the pump is
set to pump the desired direction according to pump instruction manual.
• The tubes in the pump heads should rest on the rollers and should not be
elongated.
• Make also sure that the tubes are not bend so that transport of solution is
hindered.
• Make sure that air bubbles present in the tubes are removed.
• The impellers should turn unhindered and should not touch the walls of the
vessels.
• Tubes should not fold around the impeller and should not touch the walls of
the crystallizers.
• Thermocouples should not touch the impeller and should be placed about 1/3
of the solution height from the bottom of the vessel.
• Thermocouple sensors should be placed away from any heating source. Heating
can influence the voltage measured in the sensor.
• Sampling valves are closed and are only opened when sampling is conducted.
B.4.2 Materials
The chiral compounds to use as enantiopure seeds are d-(+)-Asparagine monohydrate
(d-AsnH2O) (≥99%) and l-(-)-Asparagine monohydrate (l-AsnH2O) (≥99%) can be
purchased from Sigma-Aldrich (Copenhagen, Denmark). dl-(±)-Asparagine mono-
hydrate (dl-AsnH2O) (≥99%)) can also obtained from Sigma-Aldrich (Copenhagen,
Denmark). Demineralized water is used as solvent.
B.4.3 Seed preparation: Sieve analysis and Particle size dis-
tribution (PSD)
B.4.3.1 Sieve analysis
To prepare the enantiopure seeds of d- and l-AsnH2O, a sieve analysis was conducted
on each compound. The sieve size used are 106 µm, 125 µm, 150 µm, 250 µm,
355 µm, and 500µm. Prior to use, each sieve is cleaned according to the following
procedure:
1. Treat each sieve with ultrasound in clean demineralized for about 10 minutes
to remove deposits from previous use.
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2. Remove additional deposits by scrapping them off the sieve.
3. Wash the sieve with demineralized water.
4. Spray the sieve with 96% EtOH and dry by flushing with air.
5. Place the sieves for complete drying.
When the sieves are dried completely, they are weighed and the weight is recorded.
Then the sieves are placed in descending order from top to bottom in the Vibratory
Sieve Shaker AS 300 control (located in the oven lab, CHEC, DTU). Before adding
the lid, the mass of solid AsnH2O to be sieved is poured on the top sieve. The lid
is then mounted. The sieve shaker is turned on and is set according to the following
settings:
• Amplitude = 150 mm/’g’
• Sieving time = 10 min
Subsequently, the sieves with solids are weighed and the weight is recorded. The sieved
solids from each sieve are then transferred to small glass flasks marked with the sieve
number. Note if any agglomerates appear and transfer them separately.
B.4.3.2 PSD measurement
The mass of seeds is collected from a certain sieve fraction and analyzed oﬄine for the
PSD with laser diffraction particle size analyzer (Malvern Mastersizer 2000, Malvern
Instruments Ltd.). The eluent used is EtOH and the amount of sample size is about
1 g (a full 0.5 mL Eppendorf tube). Before sample measurement, a specification sheet
should be filled and handed in to the responsible technician.
B.4.4 Preparation of undersaturated racemic feed solution
The racemic feed solution is prepared according to the following procedure:
1. Add 1.90 kg of demineralized water in the feed tank (FEED).
2. Turn on the stirrer motor (MF) and set to 270 rpm.
3. Heat the water to about 31 ◦C through HEX(F) (setpoint: 30 ◦C).
4. Remove the plug from the opening and put the paper funnel (made by user).
Make sure that all the solids are supplied.
5. Add 100 g (one flask) of solid dl-AsnH2O into the heated water.
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6. Maintain the temperature of the slurry at 31 ◦C for about one hour for complete
dissolution. The temperature of feed solution is maintained at that temperature
throughout the duration of the experiment.
After complete dissolution, a single sample of the feed solution of ca. 4 mL (in vial
with lid) is withdrawn by releasing the outlet valve of the feed tank and turning
on pump F1. After sampling, the pump F1 is turned off and the outlet valve is
closed.
B.4.5 Preferential crystallization experiments
The preferential crystallization experiments using the CC-PC process are conducted
according to the following experimental procedure:
1. Start the computer and start the Logger Lite 1.6.1 interface and the Texas
Instrument software.
2. Adjust the time for data logging and the increment for temperature recording.
Save the files. Note that only the temperature TEX-1 is recorded by the Texas
Instrument software.
3. Turn on the cooling units HEX(C1) and HEX(C2) connected to the crystallizers
C1 and C2.
4. Set the setpoint of the cooling units to 22.3 ◦C. The crystallizers are thereby
heated to about 22 ◦C.
5. Transfer 220 mL feed solution to C1 and C2 by the dispensing function of the
pumps F1 and F2, respectively, according to the pump instruction manual.
6. Weigh about 0.4648 g of enantiopure seed crystals of each enantiomer of the
desired sieve fraction. Collect in 0.5 mL Eppendorf tubes.
7. Add 50 mL 96% EtOH in each cap bottle and bring to cool in refrigerator.
8. When the solution is transferred turn on the stirrers M1 and M2 at a speed of
250 rpm.
9. Return to flow rate mode on the pump according to the pump instruction
manual.
10. Adjust the flow rate to 7.3333 mL/min on pump F1 and F2. The flow rate
corresponds to a predefined residence time of the liquid phase of 15 min in each
crystallizer.
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11. Start data logging. Note the time.
12. Set the setpoint of the cooling units to a temperature so that the crystallizers
are cooled to about 19 ◦C.
13. Start the pumps according to the sequence: C1-C2, C2-C1, F1, F2, P1, and P2.
Note the time.
14. Adjust the cooling units to obtain a temperature in the crystallizers of about
19 ◦C.
15. When a temperature of about 19 ◦C is reached, observe if crystallization occurs
or not.
16. Withdraw one liquid sample of about 4 mL (in vial with lid) from each crystal-
lizer.
17. Supply the predefined mass of enantiopure seeds into each crystallizer. This is
done be removing the thermocouples and inserting paper funnels into the open-
ings of the crystallizers and emptying the Eppendorf tubes into the crystallizers.
Note the time for seeding.
18. Immediately withdraw a liquid sample from each crystallizer simultaneously
through the purge streams and mark the sample vial. Remember to close the
sampling valves after each sampling.
19. Observe for volume change in the crystallizers and maintain the crystallization
temperature in the crystallizers. Also maintain the feed temperature.
20. At every residence time (15 min) withdraw a liquid sample simultaneously from
each crystallizers. Remember to close the sampling valves after each sampling.
21. Prepare for solid harvest by filtration using ashless cellulose filter paper with 7.0
cm in diameter and pore size of 3 µm placed on a Büchner funnel with vacuum
suction. Note the mass of the dry filter and the filter holder.
After a process duration of about 90 minutes, the termination of the experiment is
conducted through the following procedure:
1. Adjust the temperature of the cooling units to 19 ◦C.
2. Stop the data logging and note the time.
3. Stop the feed pumps F1 and F2.
4. Stop the purge pumps P1 and P2.
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5. Stop the exchange pumps C1-C2 and C2-C1.
6. Stop the cooling unit for crystallizer C1 and dismantle the tubings connected
to the crystallizer from the cooling unit. Remember to dismantle the top tube
first.
7. Dismantle the crystallizer glass vessel from the ring holder by screwing off the
screws around the crystallizer.
8. Start the vacuum pump and add the slurry on the filter, which is wetted by
96% EtOH.
9. Wash the harvested solids with 50 mL ice cold 96% EtOH.
10. Stop the vacuum pump and put the solids to dry under ventilation overnight
(about 24 hours).
11. Repeat points 6–10 for the second crystallizer, C2.
After the solids are dried, the mass of solid produced is estimated by a simple mass
analysis. The results are used for further evaluation of the performance of the sepa-
ration process in terms of the U-value, solid product yield, productivity, and optical
purity.
B.5 Process metrics
B.5.1 Liquid phase concentration of enantiomers
The concentration, in mass fraction, of each enantiomer in the liquid phase (mother
liquor) is estimated using a combination of the measurements of optical rotation of
the liquid solution and liquid phase density. The expressions used are:
wdi (t) =
1
2
(
ρL (t)− ρW
kd
+
αobs,L
kP
)
(B.1)
wli (t) =
1
2
(
ρL (t)− ρW
kd
− αobs,L
kP
)
(B.2)
For explanation of the symbols used please see the Nomenclature. The necessary
calibration data and curves are given in Appendix C.
B.5.2 Separation efficiency: U -value
To assess the efficiency of the CC-PC process, the ratio between the total concen-
tration of the preferred enantiomer in the purge streams and the total concentration
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of the preferred enantiomer in the feed solution entering the crystallizers, calculated
by a steady-state mass balance, is considered at final time. The ratio is denoted the
U -value and is expressed as:
U − value = w
(p)
i + w
(p)
j
w
(p)
F,i + w
(p)
F,j
× 100%, i ∈ {1, 2} 6= j ∈ {1, 2} (B.3)
where 1 refers to crystallizer C1 and 2 refers to crystallizer C2.
B.5.2.1 Productivity and yield based on seeds
The productivity from the simulations of the preferred enantiomer in each crystallizer
at the end of the process duration is estimated as the ratio between the accumulated
mass of the solid product produced and the product of the total mass of enantiomer
fed into the crystallizer and the duration of the process, tf :
Pr(p)i =
m
(p)
produced,i
m
(p)
F,itf
(B.4)
Similarly, the yield of the solid product of the preferred enantiomer produced in each
crystallizer at the end of the duration of the process, tf , is defined as the ratio between
the accumulated mass of solid product produced and the mass of the enantiopure seeds
initially supplied to the crystallizer:
Y
(p)
S,i =
m
(p)
produced,i
m
(p)
seeds,i
× 100% (B.5)
B.5.2.2 Optical purity of solid product
The optical purity of the solid product is determined quantitatively by polarimetry
using the observed optical rotation of a pure reference of the preferred enantiomer in
solution with the same concentration as the solid product from each crystallizer in
solution. The optical purity is thus calculated by the following expression:
Pu(p)S,i =
α
(p)
obs,i
α
(p)
ref,i
× 100% (B.6)
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B.5.3 Final remarks
At the end of each experiment, remember to flush the tubes with demineralized water
and wash the crystallizers and the feed tank from any residual solution or solids. Use
always demineralized water. Do not leave the setup while running and make sure that
the fume hood is closed during operation. All the pumps should be calibrated before
use. The thermocouples were calibrated according to the thermocouple for TEX-
1 calibrated at Risøe, Termometri section. All the thermocouples were inserted in
demineralized water and left overnight for equilibration. Afterwards the temperatures
of the thermocouples, besides the one for TEX-1 measurement, are set according to
the thermocouple calibrated at Risøe. Documentation for the calibration is enclosed
with this manual.
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Nomenclature
Variables
Symbol Description Unit
c Counter enantiomer –
kd Calibration constant for liquid phase density kg/m3
kP Calibration constant for optical rotation ◦
m Mass of species kg
Pr Productivity kg/(kg s)
Pu Optical purity –
t Time s
w Mass fraction of species –
Y Yield of solid product –
Greek letters
Symbol Description Unit
ρ Density kg/m3
Subscripts
Symbol Description
F Feed
f Final
i Crystallizer 1 or 2
j Crystallizer 1 or 2
L Liquid phase
obs Observed
produced Produced solids
ref Reference
S Solid
seeds Seeds
W Water
Superscripts
Symbol Description
d d-isomer
l l-isomer
p Preferred enantiomer
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Appendix C
Calibration Curves
C.1 Calibration procedure for estimation of concen-
tration difference by polarimetry
For the observed optical rotation dependence on the difference in the mass fractions
of d-Asn and l-Asn in aqueous solutions, the observed optical rotation of several
aqueous solutions of mixtures of d-Asn and l-Asn (wd-Asn = 0, 0.24, 0.49, 0.97,
1.46, 1.73, 2.00 wt% with wl-Asn = 2.00, 1.76, 1.51, 1.02, 0.53, 0.27, 0 wt%) was
measured by oﬄine polarimetry at 20 ◦C and 589 nm (sodium D-line) in 1 mL glass
cell (PerkinElmer 341 Polarimeter, PerkinElmer Life and Analytical Sciences, Shelton,
CT, USA). The polarimeter was zeroed by demineralized water. 1 mL from each
solution was transferred to the glass cell by a 2.5 mL syringe with needle. After each
measurement, the glass cell was washed three times with demineralized water. The
obtained data are depicted in Figure C.1.
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Figure C.1: Calibration curve and linear fit for the mass fraction difference between d-Asn
and l-Asn in aqueous solution as function of the observed optical rotation.
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C.2 Calibration procedure for estimation of total con-
centration by densitometry
For the liquid density dependence on the total concentration of d-Asn and l-Asn in
aqueous solutions, the liquid density of several aqueous solutions of mixtures with
varying total concentration of d-Asn and l-Asn (wd-Asn = wl-Asn = 2.16, 2.20, 2.24,
2.29, 2.35 wt%) was measured by oﬄine densitometry at about 23 ◦C (±0.1 ◦C) using
Density Meter DMA 35 (Anton Paar GmbH, Graz, Austria). First of all, a sample of
demineralized water was measured using a 2.5 mL syringe without needle to transfer
the liquid sample to the densitometer. The temperature and density of sample were
recorded. Similarly, liquid solution samples with the above mentioned concentrations
were analyzed. After each measurement, the densitometer was washed three times
with demineralized water. The data obtained are depicted in Figure C.2.
Figure C.2: Calibration curve and linear fit for the liquid density as function of the total
concentration of enantiomers in aqueous solutions.
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C.3 Calibration procedure for optical purity estima-
tion by polarimetry
For the observed optical rotation dependence on the mass fraction of pure l-Asn in
aqueous solutions, the observed optical rotation of several aqueous solutions of l-Asn
(wl-Asn = 0, 0.27, 0.53, 1.02, 1.51, 1.76, 2.00 wt%) was measured by oﬄine polarimetry
at 20 ◦C and 589 nm (sodium D-line) in 1 mL glass cell (PerkinElmer 341 Polarimeter,
PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). The polarimeter was
zeroed by demineralized water. 1 mL from each solution was transferred to the glass
cell by a 2.5 mL syringe with needle. After each measurement, the glass cell was
washed three times with demineralized water. The obtained data are depicted in
Figure C.3.
Figure C.3: Calibration curve and linear fit for the mass fraction of l-AsnH2O in aqueous
solution as function of the observed optical rotation.
C-4
Appendix D
STA Measurements
D.1 Purity assessment by STA measurements
DSC and TGA thermograms for purity assessment of the purity of the solid products
produced from the d-Tank in Exp 1 after washing with ice cold 96% EtOH and
subsequent drying for 24 hours in fume hood are shown in Figure D.1 (a) and (b).
Similarly, the thermograms for the solid products from the l-Tank in Exp 1 are shown
in Figure D.2 (c) and (d).
Figure D.1: DSC and TGA thermograms for the solid product from the d-Tank in Exp 1
((a) and (b), respectively).
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Figure D.2: DSC and TGA thermograms for the solid product from the l-Tank in Exp 1
((b) and (d), respectively).
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Appendix E
PBE Transformation by MOM
E.1 Transformation of the Population Balance Equa-
tion (PBE) by the Method Of Moments (MOM)
The PBE, assuming the growth rate of the preferred enantiomer, p, in crystallizer i,
G
(p)
i , is size-independent, is given as:
∂n
(p)
i (t, L)
∂t
= −G(p)i (t)
∂
∂L
n
(p)
i (t, L) , i ∈ {1, 2} (E.1)
Multiplying by Lx on both sides of the PBE and rearranging gives:
Lx
∂n
(p)
i (t, L)
∂t
+G
(p)
i (t)L
x ∂
∂L
n
(p)
i (t, L) = 0 (E.2)
Integrating on both sides:∫ ∞
L=0
Lx
∂n
(p)
i (t, L)
∂t
dL+G(p)i (t)
∫ ∞
L=0
Lx
∂
∂L
n
(p)
i (t, L) dL = 0 (E.3)
Rewriting:
∂
∂t
∫ ∞
L=0
Lxn
(p)
i (t, L) dL+G
(p)
i (t)
∫ ∞
L=0
Lx
∂
∂L
n
(p)
i (t, L) dL = 0 (E.4)
In general the moments, Nx, where x = 0,1,2,3, of the number distribution functions
are defined as follows:
N
(p)
x,i (t) =
∫ ∞
L=0
Lxn
(p)
i (t, L) dL (E.5)
Inserting equation (E.5) into equation (E.4) and conducting integration by parts
gives:
dN (p)x,i (t)
dt
+G
(p)
i (t)
([
Lxn
(p)
i (t, L)
]∞
0
−
∫ ∞
0
xLx−1n(p)i (t, L) dL
)
= 0 (E.6)
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Integrating the integral (the third term on the right hand side) gives:
dN (p)x,i (t)
dt
+G
(p)
i (t)
([
Lxn
(p)
i (t, L)
]∞
0
− xN (p)x−1,i (t)
)
= 0 (E.7)
Inserting the limits in the second term on the right hand side gives:
dN (p)x,i (t)
dt
+G
(p)
i (t)
([
∞xn(p)i (t,∞)− 0xn(p)i (t, 0)
]
− xN (p)x−1,i (t)
)
= 0 (E.8)
Since it is assumed that n(p)i (t, L =∞) = 0 and n(p)i (t, L = 0) = 0, the change of
the moments of the number distribution function with time are given by rearranging
equation (4.8) to obtain the following general expression:
dN (p)x,i (t)
dt
= xN
(p)
x−1,i (t)G
(p)
i (t) (E.9)
E-2
Appendix F
MATLAB Codes
F-1
